Radiation biodosimetry systems

ABSTRACT

Disclosed herein are compositions and methods for accurately estimating the absorbed dose of radiation indicated by a subject based on the expression pattern of a panel of radiation-modulated (RM) genes at various time points following exposure of the subject to ionizing radiation.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 16/532,138, filed Aug. 9, 2019, which is a divisional of U.S. patent application Ser. No. 14/823,433, filed on Aug. 11, 2015 and now issued as U.S. Pat. No. 10,435,747, and claims the benefit of U.S. Provisional Application No. 62/038,969, filed Aug. 19, 2014, the disclosures of which are hereby incorporated by reference in their entirety for all purposes.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with government support under HHSO100201000008C awarded by Biomedical Advanced Research and Development Authority. The government has certain rights in the invention.

REFERENCE TO A SEQUENCE LISTING SUBMITTED VIA EFS-WEB

The content of the ASCII text file of the sequence listing named “112624_00614_ST25.txt” which is 108 kb in size was created on Nov. 10, 2015 and electronically submitted via EFS-Web herewith the application is incorporated herein by reference in its entirety.

BACKGROUND

Radiation exposure is one of the most serious hazards of the modern era. The health consequences to individuals and populations exposed to radiological incidents, accidental or otherwise, can range from negligible to fatal depending on the amount of radiation that is absorbed by an individual. Yet, it is often difficult or impossible to quickly determine the absorbed dose of radiation for an individual or population after a radiological event and thereby determine an appropriate course of treatment. This is particularly critical when large numbers of individuals are potentially affected by radiation exposure and must be quickly “triaged” to prioritize treatment strategies. Thus, there is a great need for systems that quickly estimate, post-hoc, the absorbed dose of radiation by an individual resulting from an ionizing radiation exposure incident.

BRIEF SUMMARY OF THE INVENTION

Disclosed herein are compositions and methods for accurately estimating the absorbed dose of radiation suffered by a subject based on the expression pattern in RNA obtained from peripheral blood of a panel of radiation-modulated (RM) genes at various time points following exposure of the subject to ionizing radiation.

Accordingly in one aspect provided herein is a radiation biodosimetry assay system, comprising a plurality of nucleic acid amplification reactions comprising (i) mRNA or cDNA from a human subject suspected of (but not necessarily) suffering from radiation exposure; (ii) primer pairs capable of hybridizing under stringent conditions to mRNAs or cDNAs comprising the nucleotide sequences referred to in Table 4 or the complementary sequences thereof, wherein each primer pair hybridizes to a different one of the mRNAs or cDNAs; and (iii) a thermostable enzyme suitable for amplification of target amplicon sequences from the mRNAs or cDNAs. A mathematical algorithm that converts gene expression results to estimated absorbed dose of radiation.

In some embodiments the one or more nucleic acid amplification reactions further comprise detectably labeled TAQMAN® probes capable of hybridizing under stringent conditions to the mRNAs or cDNAs. In some embodiments the thermostable enzyme is a thermostable polymerase.

In some embodiments the mRNA is from a subject that was exposed to radiation about 4-hours to about seven days prior to the time at which a biological sample comprising the mRNA was obtained.

In another aspect provided herein is a radiation biomarker assay kit, comprising a nucleic acid probe set consisting essentially of nucleic acid probes that hybridize specifically with nucleic acid targets comprising at least one of the nucleotide sequences referred to in SEQ ID NOs: 1-39 or the complementary sequences thereof. In some embodiments the probe set comprises no more than 100 probes. In some embodiments the probe set consists of the nucleic acid probes that hybridize specifically with the nucleic acid targets.

In some embodiments the nucleic acid probe set comprises primer pairs and TAQMAN probes suitable for qPCR analysis of mRNAs or cDNAs comprising at least one of the nucleotide sequences referred to in SEQ ID NOS: 1-39 or the complementary sequences thereof. In some embodiments the nucleic acid probes are provided in a multi-well plate. In some embodiments, where the nucleic acid probes are provided in a multi-well plate, at least two nucleic acid probes that hybridize to at least two different nucleic acid targets are in the same wells of the multi-well plate.

In some embodiments the kit also includes radiation exposure positive and negative control mRNA samples or cDNAs thereof. In another aspect provided herein is a method for assessing a dose of ionizing radiation absorbed by a subject, comprising (i) determining the mRNA expression levels of mRNAs comprising at least one of the nucleotide sequences referred to in SEQ ID NOs: 1-39 in a biological sample, comprising mRNA from the subject, to obtain an expression profile; and (ii) transforming the gene expression profile and when available, the duration of time from exposure to sample collection, into a measure of absorbed dose of radiation for the subject based on a mathematical algorithm. In one embodiment, the algorithm utilizes multiple random forest regression trees to estimate absorbed dose and confidence limits and then a top-level logic layer to combine outputs into a single estimated absorbed dose with confidence limits.

In some embodiments the method further includes treating the subject based on the estimated absorbed dose of radiation determined in step (ii).

In some embodiments the absorbed dose of ionizing radiation is determined within about seven days of subject exposure to ionizing radiation.

In some embodiments the method also includes a step of obtaining the biological sample from the subject prior to step (i).

In a further aspect provided herein is a method for radiation treatment triage of a subject in need thereof comprising (i) determining the mRNA expression levels of mRNAs comprising the nucleotide sequences referred to in at least one of SEQ ID NOs: 1-39 (or any other sequence identifier included herein, in any combination) in a biological sample comprising leukocyte mRNA from the subject to obtain a gene expression profile; and (ii) providing a suitable treatment for radiation exposure to the subject based on the expression levels of the genes.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, and patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will be better understood and features, aspects and advantages other than those set forth above will become apparent when consideration is given to the following detailed description thereof. Such detailed description makes reference to the following drawings, wherein:

FIG. 1A show tables listing a set of 28 radiation modulated (RM) genes and their expression pattern at various time points following absorption of ionizing radiation.

FIG. 1B show tables listing a set of 28 radiation modulated (RM) genes and their expression pattern at various time points following absorption of ionizing radiation.

FIG. 2 shows a time series (days 1-7) of plots of actual delivered ionizing radiation dosage values (0 Gy to 10 Gy) versus estimated absorbed dose of radiation based on changes in RM gene expression in peripheral blood

FIG. 3 shows a table providing the percentage accuracy (within 1 Gy) of the biodosimetry algorithm's absorbed radiation dose estimate based on expression of 29 RM genes in peripheral blood collected from rhesus macaque non-human primate (NHPs) at various time points (1-7 days) following exposure to irradiation doses ranging from 0 Gy to 10 Gy.

FIG. 4 shows a table providing the percentage accuracy (within 0.5 Gy) of the biodosimetry algorithm's absorbed radiation dose estimate based on expression of 29 RM genes in peripheral blood from NHPs at various time points (1-7 days) following exposure to irradiation doses ranging from 0 Gy to 10 Gy.

FIG. 5 shows scatter plots of changes in RM gene expression in male vs. female NHPs following radiation exposure of various doses and at different time points following radiation exposure. As shown, male and female RM gene expression responses were very closely correlated for the 29 RM genes.

FIG. 6 shows a table describing the sensitivity and specificity of the biodosimetry algorithm in various NHP and human irradiation models.

FIG. 7 shows an overview of an exemplary, non-limiting, embodiment of biodosimetry workflow illustrating the steps of: blood sample collection, RNA isolation, reverse transcription to obtain cDNA, pre-amplification of the cDNA, and qPCR assay of a RM biomarker and reference gene panel.

FIG. 8 shows a single regression tree in a random forest example. This tree generates an estimated absorbed dose using the relative expression levels of gene biomarkers, HBA2 and IL27RA, and the absolute expression level of gene biomarker, COCH.

FIG. 9 shows a schematic overview on human and NHP data sets, cross-species conversion approaches to utilize the NHP single-dose (SD) biodosimetry algorithm to predict absorbed dose in human in case of acute radiation exposure. Cross-species conversion algorithms were developed with human and NHP fractionated-dose (FD) models that showed a good cross-model compatibility with NHP SD models.

FIG. 10A shows a schematic overview on the approach to convert NHP fractionated dose (FD) data to the corresponding values in NHP single-dose (SD) data by 3-dimensional linear scaling of day, dose, and expression values.

FIG. 10B shows the optimal range (in blue) of dose/day scaling factors for 12 Gy/day-6 data points of individual biomarkers (top panels) and a unified scaling factor (bottom panel) for 29 tested biomarkers.

FIG. 11A shows dose prediction performances of a random forests model based on 7 correlated biomarker genes on NHP SD data (for day 3, as an example).

FIG. 11B shows dose prediction performances of a random forests model based on 7 correlated biomarker genes on converted NHP FD values across all days by matching day/cumulative dose, 3D scaling, and 3D scaling followed by multi-gene regression. Prediction accuracies within 1.0 Gy are shown.

FIG. 12A shows correlation of individual biomarker expression values between NHP fractionated dose (FD) and human TBI, magnitude of expressional changes across dose, and mean absolute difference (MAD) between NHP FD and human TBI data points.

FIG. 12B shows dose response curves of the top 4 inter-species correlated genes in NHP FD and human TBI data.

FIG. 13A shows dose prediction performances of a random forests model based on 10 inter-species biomarker genes on NHP FD data.

FIG. 13B shows dose prediction performances of a random forests model based on 10 inter-species biomarker genes on unconverted and converted human TBI values by value shift, and value shift followed by multi-gene regression. Prediction accuracies within 1.0 Gy are shown.

DETAILED DESCRIPTION

In General. Before the present materials and methods are described, it is understood that this invention is not limited to the particular methodology, protocols, materials, and reagents described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise. As well, the terms “a” (or “an”), “one or more” and “at least one” can be used interchangeably herein. It is also to be noted that the terms “comprising”, “including”, and “having” can be used interchangeably.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications and patents specifically mentioned herein are incorporated by reference for all purposes including describing and disclosing the chemicals, cell lines, vectors, animals, instruments, statistical analysis and methodologies which are reported in the publications which might be used in connection with the invention. All references cited in this specification are to be taken as indicative of the level of skill in the art. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

The Invention. The present invention provides methods for estimating absorbed dose of ionizing radiation by a subject, which includes the steps of: (i) determining the mRNA expression levels of mRNAs comprising the nucleotide sequences referred to in SEQ ID NOs: 1-39 in a biological sample comprising peripheral blood mRNA collected from the subject to obtain an expression profile; and (ii) transforming the gene expression profile and when available, the duration of time from exposure to sample collection into an estimated absorbed dose of ionizing radiation and confidence limits for a subject based on a mathematical algorithm. For each of several durations for which training data were available, one primary random forest was developed to estimate absorbed dose of radiation. Additional secondary random forests were developed to provide more accurate dosimetry in narrow dosage intervals. The top-level logic layer uses the primary random forest to generate an initial estimate of absorbed dose of radiation, and based on that value, may select additional random forests to construct more refined estimates of absorbed dose, with confidence limits.

In some embodiments the method also includes treating the subject based on the absorbed dose of ionizing radiation determined in step (ii) above. In some embodiments the absorbed dose of ionizing radiation is determined within about seven days of exposure to the ionizing radiation, e.g., within about 30 minutes, 1 hour, 3 hours, 6 hours, 8 hours, 24 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or another time period within seven days following ionizing irradiation. In some embodiments, the absorbed dose of ionizing radiation is within the range of about 0.5 Grays (Gy) to about 10 Gy, e.g., about 1 Gy, 2 Gy, 3 Gy, 4 Gy, 6 Gy, 7 Gy, 8 Gy, 9 Gy, or another absorbed dose of ionizing radiation from about 0.5 Gy to about 10 Gy.

In some embodiments, the method also includes obtaining the biological sample from the irradiated subject prior to step (i) above.

In one embodiment, a whole blood sample, or other blood fraction containing lymphocytes, (including a finger stick or POC device) is collected from a subject known to be or suspected of being irradiated into a PAXGENE™ Blood RNA tube. The PAXGENE™ Blood RNA contains an additive that stabilizes in vitro gene expression and RNA degradation. Subsequently, RNA is extracted from the stabilized blood sample by using a Stabilized BLOOD-TO-CT™ Nucleic Acid Preparation Kit for qPCR (Life Technologies, Inc.). The RNA sample is then subjected to reverse transcription, e.g., using the INVITROGEN™ SUPERSCRIPT© VILO™ (Variable Input, Linear Output) cDNA synthesis kit (Life Technologies, Inc.) or equivalent kit. Afterwards, the resulting cDNA is pre-amplified using a TAQMAN® probe PreAmp Master Mix Kit (Life Technologies, Inc.) and the pre-amplified cDNA is then assayed by TAQMAN© probe-based qPCR in a 96-well or 384-well format using QUANTSTUDIO™ Dx or ABI7500 Fast Dx quantitative Real-Time PCR Instruments (Life Technologies, Inc.). Typically, expression levels of RM mRNAs will be expressed as a difference in C_(T) between a test gene and a reference (“housekeeping”) gene C_(T).

In some embodiments the panel of RM mRNAs to be assayed include at least some combination of mRNAs for one or all of the following (human) genes: CR2 (SEQ ID NO: 1), DHRS4L1 (SEQ ID NO: 2), HCK (SEQ ID NO: 3), IL1RAP (SEQ ID NO: 4), LYRM4 (SEQ ID NO: 5), MYC (SEQ ID NO: 6), TMEM63B (SEQ ID NO: 7), ALOX5 (SEQ ID NO: 8), CAMK4 (SEQ ID NO: 9), CDKN1A (SEQ ID NO: 10), COCH (SEQ ID NO: 11), DHRS4 (SEQ ID NO: 12), MICAL1 (SEQ ID NO: 13), MOB3B (SEQ ID NO: 14), NUSAP1 (SEQ ID NO: 15), IL27RA (SEQ ID NO: 16), HBA2 (SEQ ID NO: 17), PPM1F (SEQ ID NO: 18), PPP2RA (SEQ ID NO: 19), CLAR (SEQ ID NO: 20), DHRS13 (SEQ ID NO: 21), ACAA1 (SEQ ID NO: 22), INPP5J (SEQ ID NO: 23), OAZ1 (SEQ ID NO: 24), PNOC (SEQ ID NO: 25), PDE4B (SEQ ID NO: 26), SCARB1 (SEQ ID NO: 27), TMEM9B (SEQ ID NO: 28), CXXC5 (SEQ ID NO: 29), CD97 (SEQ ID NO: 30), TEX10 (SEQ ID NO: 31), SPECC1 (SEQ ID NO: 32), ALAS2 (SEQ ID NO: 33), ALPK1 (SEQ ID NO: 34), ESD (SEQ ID NO: 35), GPR183 (SEQ ID NO: 36), ESD (SEQ ID NO: 37), PPMK (SEQ ID NO: 38), and SLC6A6 (SEQ ID NO: 39) (collectively, SEQ ID NOs: 1-39).

In other embodiments RM mRNAs to be assayed can include at least some combination of one or all of the following genes: ADAM17, AKT1, ANK, ANXA3, ARHGAP26, ARID4A, ATG2A, ATIC, BCL11A, BCL6, BID, CFLAR, CIT, CPVL, CYTH4, DDB2, DDX58, DTL, EHBPL1, FCGR2A, FGR, HPRT1, HSP90AB1, HTRA2, IDOL, IRF1, JMJD1C, KIAA0101, LARP4B, LRRC6, LYN, MAP3K1, MAPK3, MDM1, MKNK1, MXD1, NAIP, NFE2L2, NRG1, NUSAP, PCNA, PGK1, PMP22, RARA, RNASE6, RPL13A, RPL6, RPS14, SP10, SPOCK2, TAPBP, TBP, TCF3, TNFRSF1A, TNFRSF1B, TNFSF14, USP38, WDR48, XAF1, ZAK, NPM, CPSF1, COASY, DNAJC10, DYNLRB1, ELK4, GPRIN, NDE1, PGS1, PPM1K, and PTAFR. In some embodiments, the reference gene to be assayed is PPP6R3. In other embodiments the reference gene to be assayed may be USP38, WDR48 or LARP4B or some combination thereof.

In some embodiments, qPCR reactions are multiplexed such that multiple mRNAs (including a reference mRNA) are assayed in a single qPCR reaction.

Also disclosed herein is a method for radiation treatment triage of a subject in need thereof, which includes the steps of: (i) determining the mRNA expression levels of mRNAs comprising the nucleotide sequences referred to in any of SEQ ID NOS: 1-39 (or any combination of any other SEQ ID NO provided herein) in a biological sample comprising mRNA from the subject to obtain an expression profile; and (ii) providing a suitable treatment for radiation exposure to the subject based on the expression levels of the genes. Exemplary treatments for radiation exposure based on radiation dosage are shown in Table 1 below:

TABLE 1 Exemplary treatments for radiation exposure based on radiation dosage. Very Symptoms and Mild Moderate Severe severe Lethal (a) treatment strategy (1-2 Gy) (2-4 Gy) (4-6 Gy) (6-8 Gy) (>8 Gy) Vomiting Onset After 2 hr. After 1-2 Within Within 30 Within 10 min. Incidence 10-50% hrs. 1 hr. min. 100% 70-90% 100% 100% Diarrhea Onset None None Mild Heavy Heavy Incidence 3-8 hrs. 1-3 hrs. Within min. −1 hr. <10% >10% almost 100% Headache Onset Slight Mild Moderate Severe Severe Incidence 4-24 hrs. 3-4 hrs. 1-2 hrs. 50% 80% 80-90% Conscious- Onset Alert Alert Alert Possibility Unconsciousness ness Incidence of by order of seconds impairment or minutes Seconds-minutes 100% (>50 Gy) Body Onset Normal Increased Fever High fever High fever Temperature Incidence 1-3 hrs. 1-2 hrs. <1 hrs. <1 hrs. 10-80% 80-100% 100% 100% Treatment Outpatient Observation Treatment Treatment Palliative treatment Strategy observation at general at at (a) (advanced hospital, specialized specialized medical care treatment at Hospital hospital including stem cell specialized transplantation) hospital if required

Also described herein is a radiation biodosimetry assay system that includes multiple nucleic acid amplification reactions containing the following: (i) mRNA or cDNA from a human subject suspected of suffering from radiation exposure; (ii) primer pairs capable of hybridizing under stringent conditions to mRNAs or cDNAs comprising the nucleotide sequences referred to in SEQ ID NOS: 1-39 (or any other SEQ ID NO provided herein), or the complementary sequences thereof, wherein each primer pair hybridizes to a different one of the mRNAs or cDNAs; and (iii) A mathematical algorithm the converts gene expression results to estimated absorbed dose of radiation.

In one embodiment, the mathematical algorithm of the present invention The Radiation Biodosimetry Absorbed Dose Estimation algorithm described herein takes as input sample qPCR data, sample barcode, and available information about the date and time of the exposure event and sample collection. The primary output of the algorithm is an absorbed dose report that contains an estimated absorbed dose and a dose interval that provides a range of dose values for the patient based on prediction intervals. The algorithm contains 6 basic steps, which are summarized in Table 2.

In Step 1, patient qPCR data are combined with the available information about the date and time of the event and sample collection using the patient barcode.

In Step 2, several quality control metrics are calculated for the qPCR data. Depending on the values of these metrics, the algorithm may determine that a sample requires re-testing. If the sample does not require re-testing, the quality control metrics will be utilized in the estimation of absorbed radiation dose, and in particular may affect the estimation interval.

In step 3, the qPCR data are checked against expected ranges for each biomarker.

In step 4, quality control metrics and the results of the biomarker range checks are used to determine whether specific biomarker values are invalid and whether sufficient biomarker values are valid for dose estimation.

In step 5, the qPCR data and the available temporal information for the event and sample collection are processed through a random forest-based mathematical algorithm that yields an estimated dose and a dose interval. The mathematical algorithm in Step 5 utilizes Random Forests™ method, introduced by Breiman (2001). Random forests is a popular machine-learning tool for prediction that combines large numbers of classification or regression trees to yield accurate and robust predictions. A random forest is a collection of classification or regression trees that we denote by R={T₁, . . . , T_(n)}. The input to the forest is a vector X of relative and/or absolute expression levels of a set of genes. In a regression random forest, each tree T_(i) takes X as input and outputs an estimate of absorbed dose, T_(i)(X). For example, FIG. 8 depicts a single tree in a random forest that utilizes the relative expression levels for two gene biomarkers (HBA2 and IL27RA) and the absolute expression level for one gene biomarker (COCH). The estimate of absorbed dose from a regression random forest R is then the average of estimated absorbed doses from the trees within the forest. We write this estimate as:

${AD} = {{R(X)} = {\frac{1}{n} \times {\sum\limits_{i = 1}^{n}{T_{i}(X)}}}}$

In a classification random forest, samples are partitioned into several non-intersecting groups. For example, samples may be partitioned based upon dose and each group then represents an interval for the absorbed dose. Each tree T_(i) takes as input X and outputs the identity of a single group, T_(i)(X). The output from the classification random forest is a probability distribution on the set of groups, where the probability assigned to each group is the proportion of trees that yield the group.

The inputs to the mathematical algorithm in Step 5 are a set of absolute and relative expression levels, X for a set of genes, and a probability distribution w that reflects the uncertainty in D, the duration of time from irradiation to sample collection. If the duration of time is known precisely, w will be a point mass distribution on that known duration of time. If the duration is only known to fall within an interval, then may be any probability distribution on that interval such as a uniform distribution or a symmetric triangular distribution. If the duration is entirely unknown or not provided, then w may be calculated using a classification random forest that takes as input X and yields as output a probability distribution over a fixed set of duration values.

The outputs are an estimated absorbed dose, AD and a 95% prediction interval for the absorbed dose, (AD_(low), AD_(high)). For NHP samples that were irradiated with a single acute dose (NHP SD), these outputs are computed in two steps. First, we compute an initial estimate of absorbed dose, AD. Secondly, we correct for bias in the estimate to yield the final estimate of absorbed dose, AD and generate the 95% prediction interval.

A novel aspect of our algorithm is the use of multiple random forests for each of several fixed durations, D₁, . . . , D_(k). For duration D_(i), we use n_(i) random forests, denoted by RF_(i,1), . . . , RF_(i,n) _(i) , to construct initial estimates of absorbed dose. A decision tree T_(i) combines the outputs from RF_(i,1), . . . , RF_(i,n) _(i) into a single initial estimate of absorbed dose. One additional random forest, denoted by RF_(i) ^(E), is a quantile regression random forest for error that uses the expression values X′ and the output from T_(i) for bias correction and construction of prediction intervals. These n_(i)+1 random forests utilize different, but possibly overlapping sets of genes, may be trained on different sets of samples and may include both regression forests and classification forests. Hence, if the duration is known to equal D_(i), the initial estimate of absorbed dose, denoted by AD^(I) (D_(i)), is computed as:

AD^(I)(D _(i))=T _(i)(RF_(i,1)(X′), . . . ,RF_(i,n) _(i) (X′))

This estimate and the transformed expression levels X′ are then passed to the random forest RF_(i) ^(E). The output from RF_(i) ^(E) is the conditional probability distribution for the error in the estimate AD^(I)(D_(i)). We denote the cumulative distribution function for this conditional distribution by F(⋅|D=D_(i)). The bias corrected estimate of absorbed dose is then AD(D_(i))=AD^(I)(D_(i))−F⁻¹(0.5). If the duration is known to equal D* where D_(i)<D*<D_(i+1), the estimated absorbed dose is computed as:

${A{D\left( D^{*} \right)}} = {{\frac{D_{i + 1} - D^{*}}{D_{i + 1} - D_{i}} \times A{D\left( D_{i} \right)}} + {\frac{D^{*} - D_{i}}{D_{i + 1} - D_{i}} \times A{D\left( D_{i + 1} \right)}}}$

The final estimate of absorbed dose is computed by averaging over the probability distribution π, that is, AD=∫AD(D)×π(D)dD.

Similarly, we define F(⋅|D=D*) by:

${F\left( {{\cdot \left| D \right.} = D^{*}} \right)} = {{\frac{D_{i + 1} - D^{*}}{D_{i + 1} - D_{i}} \times {F\left( {{\cdot \left| D \right.} = D_{i}} \right)}} + {\frac{D^{*} - D_{i}}{D_{i + 1} - D_{i}} \times {F\left( {{\cdot \left| D \right.} = D_{i + 1}} \right)}}}$

The 95% prediction interval for the absorbed dose is then found by solving the equations:

∫F(e ₁ |D)×π(D)dD=0.025, and

∫F(e ₂ |D)×n(D)dD=0.975

for e₁ and e₂, respectively, and setting AD_(low)=AD−e₂ and AD_(high)=AD−e₁.

In step 6, an absorbed dose estimation report is constructed utilizing the estimated dose and dose interval.

In actual events of acute radiation exposure, to predict absorbed dose of human samples with the NHP-based biodosimetry algorithm, conceptually, gene expression measurements of each biomarker in a human sample need to be transformed by cross-species (i.e. human to NHP) algorithms. Ideal cross-conversion models could be built on two directly comparable single-dose (SD) data sets in human and NHP. However, due to practical difficulties in obtaining human blood samples with single acute irradiation, as an alternative, we obtain samples from human subjects who undergo total body irradiation (TBI). Unlike the acute single-dose (SD) irradiation that we used for development of a biodosimetry algorithm, these subjects under a fractionated dose (FD) schedule were irradiated three times (1.2 Gy each) a day for 6 days. Therefore, we obtained gene expression data from NHP-equivalents of human TBI subjects that underwent the identical fractionated irradiation, and developed novel gene-specific cross-species conversion algorithms. These algorithms will be used to transform human values prior to dose prediction (FIG. 9).

Unlike SD models that measure gene expression levels over the time after a single acute irradiation, data from a FD model has a linear relationship between cumulative dose and day. Therefore, prior to development of cross-species conversion algorithms based on human and NHP FD data sets, we first examined whether expression profiles of biomarker genes in NHP FD model were comparable to those in NHP SD model and thus could predict absorbed dose via the NHP SD model-based biodosimetry algorithm. For meta analyses of FD and SD data sets, we developed a three-dimensional (3D) curve fitting strategy to match the FD data to the SD data. Specifically, for each biomarker b we generate an FD curve of the mean expression level of NHP FD samples (2 Gy per day for 6 days) as a function of cumulative dose and day, FD_(b) (dose, clay), and a SD response surface of the mean expression level of NHP SD samples (0 to 6 days, 0 to 7 Gy) as a function of dose and day, SD_(b)(dose, clay) (FIG. 10A). First, the entire FD curve for each biomarker is shifted to match the mean basal level (i.e. 0 Gy/Day 0) of SD values, which produces a scaling factor α_(b) for expression values for each biomarker. The shifted FD curve is denoted FD_(b)′(close, clay)=FD_(b)(dose, clay)+α_(b), where α_(b)=SD_(b)(0, 0)−FD_(b)(0, 0). Second, for each biomarker, optimal biomarker-specific dose and day scaling factors β_(b,dose) and β_(b,day), are found that minimize the sum of absolute differences between the SD and scaled FD data.

Specifically, β_(b,dose) and β_(b,day) minimize the following expression,

$\sum\limits_{{d1},{d\; 2}}{{{\frac{{FD}_{b}^{\prime}\left( {{d\; 1},{d\; 2}} \right)}{{FD}_{b}^{\prime}\left( {12,6} \right)} \times S{D_{b}\left( {{\beta_{b,{dose}} \times d1},{\beta_{b,{day}} \times d2}} \right)}} - {{SD}_{b}\left( {{\beta_{b,{dose}} \times d1},{\beta_{b,{day}} \times d\; 2}} \right)}}}$

By repeating this for all biomarkers and searching for common dose and day scaling factors that minimize the sum of absolute differences across biomarkers, doses and days, unified FD to SD scaling factors of β_(dose)=0.517 for dose (i.e. 12 Gy to 6.2 Gy) and β_(day)=0.933 for day (i.e. day 6 to day 5.6) (FIG. 10B) are obtained.

Mathematically, β_(dose) and β_(day) are defined to minimize

$\Sigma_{b}\Sigma_{{d\; 1},{d\; 2}}{{{{\frac{F{D_{b}^{\prime}\left( {{d\; 1},{d\; 2}} \right)}}{F{D_{b}^{\prime}\left( {12,6} \right)}} \times S{D_{b}\left( {{\beta_{dose} \times d\; 1},{\beta_{day} \times d2}} \right)}} - {S{D_{b}\left( {{\beta_{dose} \times d1},{\beta_{day} \times d\; 2}} \right)}}}}.}$

Third, linear transformation of FD curves by the scaling factors yields the converted expression values,

$\begin{matrix} {{{FD}_{b}^{''}\left( {{d\; 1},{d\; 2}} \right)} = {\frac{F{D_{b}^{\prime}\left( {{d1},{d2}} \right)}}{F{D_{b}^{\prime}\left( {{12},6} \right)}} \times S{{D_{b}\left( {{\beta_{dose} \times d1},\ {\beta_{day} \times {d2}}} \right)}.}}} & \left( {{{FIG}.\mspace{11mu} 10}A} \right) \end{matrix}$

To test the conversion strategy from NHP FD to NHP SD data, based on seven biomarkers (COCH, DHRS4L1, IL27RA, INPP5J, PNOC, SCARB1, and TEX10 in this example) with correlated dose responses between the data sets, random forests dose prediction models were generated on NHP SD data, which showed 84% to 98% dose prediction accuracy across days for the model fitting on NHP SD data (FIG. 11A). When expression values of NHP FD data were converted by matching days or doses and then applied to the NHP SD random forests model, dose prediction accuracies within 1.0 Gy were only 21% and 31%, respectively. After the FD values were transformed by the 3D scaling factors (i.e. for expression value, dose, and day), the accuracy was increased to 60% (FIG. 11B).

To increase performance of conversion algorithm, we explored a multi-gene regression approach that utilizes linear combinations of gene expression values rather than the expression values of individual biomarkers. This concept has been applied to predict missing values in large gene expression data sets. Since the biomarkers are functionally related within the key biological pathways related to radiation response, we hypothesized that expression profiles of other biomarkers could be informative in predicting expression values of a given gene. We employed Ridge regressions that provide robustness by constraining the size of coefficients by minimizing the summed squares of residuals and coefficients. By using converted NHP FD values by 3D scaling, a multi-gene regression model for each biomarker was generated with all seven genes that were used to build NHP SD biodosimetry algorithm. When the predicted values by the multi-gene regression models were applied to NHP SD algorithm, dose prediction accuracy was increased substantially to 86% (FIG. 11B).

Absolute gene expression values of biomarker genes are highly variable between NHP and human, and, thus, using an NHP biodosimetry algorithm to predict absorbed dose in human requires another step of cross-species expression value transformation from human to NHP. To explore the conversion strategies, we compared two data sets, for human and NHP, that were obtained from subjects treated with an identical irradiation schedule (3 times of irradiation at 1.2 Gy per day for 4 days), which is being used for total body irradiation (TBI) in clinical therapeutic setting. Among 29 biomarkers tested, although 17 genes had inter-species correlation coefficient above 0.6 between these two data sets (FIG. 12A), many genes showed substantial differences in absolute expression levels across doses (FIG. 12B). Therefore, we calculated the mean difference of expression for each biomarker and then applied the value to shift the entire expression values the gene across doses. This process decreased the mean absolute differences to less than 1.0 ΔCt for the majority of 29 biomarkers (FIG. 12A, last two columns).

To test the conversion strategy from human TBI to NHP FD data, based on 10 biomarkers (DHRS4L1, MYC, SPECC1, CXXC5, ALAS2, HBA2, CDKN1A, GPR183, MOB3B, and PNOC in this example) with inter-species correlation above 0.75 (FIG. 12A), random forests dose prediction models were generated on NHP FD data, which showed a 98% dose prediction accuracy during the model fitting on NHP FD data (FIG. 13A). Appling the converted human TBI values to NHP FD random forests model, prediction accuracy within 1.0 Gy was 13%. When expression values of human TBI data were vertically shifted by the predetermined shift factors and then applied to the NHP FD random forests model, dose prediction accuracies within 1.0 Gy was increase marginally to 19%.

We then tested whether the multi-gene regression approaches could improve the cross-species conversion process. As previously done for NHP FD to NHP SD conversion, we also employed Ridge regressions. By using converted human TBI values by vertical shifting factors, a multi-gene regression model for each biomarker was generated with all 10 genes that were used to build the NHP FD biodosimetry algorithm in this example. When the predicted values by the multi-gene regression models were applied to NHP FD algorithm, dose prediction accuracy was increased substantially to 89%.

TABLE 2 Algorithm Function. Step 1 Combine Traceability Barcode Unique barcode Adds all needed Flags data for operator Patient information to intervention Barcode with qPCR data Date/Time Event Step 2 Quality Control Negative 96-Well Prep Plate No Ct (Ref)(2) > 37 Cross- Retest Samples Check Control Template Control Contamination in (NTC) or Reagent Sample Prep Blank Positive qPCR Standard 1. Ct (Ref) ± 1 1. LLOD Verified Flags data - may affect Controls Curve: 10, 0.1, 0.01, each conc. 2. Reproducibility Dose Estimate and 0.001 ng/μL 2. Amplification Verified Dose interval (Based on standard Efficiency 3. Amplification Or pooled RNA). verifies Require sample retest expected qPCR and function across Alerts Operator (No linear range. operator override) Evogenous Control: Ct (Xeno ™) ± 1 Inhibitors Sample RNA Spike-in Sample Integrity Endogenous Control Ct (Ref) ± 1 1. Adequate Reference Gene(1) Sample RNA Input. 2. Control for variable RNA Input. Step 3 Biomarker Process QC Biomarker integrity QC flag Usability of each Range Check Biomarker Value Step 4 Apply QC and Process QC Analytical integrity QC flag Usability of each Biomarker Biomarker Value Range Flags Step 5 Calculate Quantitative Endogenous Control Absorbed dose Estimated Checks for intended Estimated (Gy) absorbed Dose use dose range Dose Calculate Dose Measurement Confidence Interval Dose Range Dose Interval Checks for acceptable Interval Confidence confidence interval Step 5 Combine Report Report Gy Dose Estimation Clinic Estimated Report Review/Approval Dose and Dose Interval

In one embodiment, the target mRNAs or cDNAs to which the primers hybridize are those from the following (human) RM genes: CR2, DHRS4L1, HCK, IL1RAP, LYRM4, MYC, TMEM63B, ALOX5, CAMK4, CDKN1A, COCH, DHRS4, MICAL1, MOB3B, NUSAP1, IL27RA, HBA2, PPM1F, PPP2R1A, CFLAR, DHRS13, ACAA1, INPP5J, OAZ1, PNOC, PDE4B, SCARB1, and TMEM9B.

In other embodiments, mRNAs or cDNAs to which primers hybridize may include the following genes: ADAM17, AKT1, ANK1, ANXA3, ARHGAP26, ARID4A, ATG2A, ATIC, BCL11A, BCL6, BID, CFLAR, CIT, CPVL, CYTH4, DDB2, DDX58, DTL, EHBPL1, FCGR2A, FGR, HPRT1, HSP90AB1, HTRA2, IDOL, IL27RA, IRF1, JMJD1C, KIAA0101, LARP4B, LRRC6, LYN, MAP3K11, MAPK3, MDM1, MKNK1, MXD1, NAIP, NFE2L2, NRG1, NUSAP, PCNA, PGK1, PMP22, PPP2RA1, RARA, RNASE6, RPL13A, RPL6, RPS14, SCARB1, SP110, SPOCK2, TAPBP, TBP, TCF3, TNFRSF1A, TNFRSF1B, TNFSF14, USP38, WDR48, XAF1, ZAK, NPM1, ALAS2, ALPK1, CD97, CPSF1, COASY, CXXC5, DNAJC10, DYNLRB1, ELK4, ESD, GPR183, GPRIN, NDE1, PGS1, PPM1K, PTAFR, SLC6A6, SPECC1, and TEX10.

In some embodiments, primers are also included that hybridize to PPP6R3 mRNA or cDNA, where PPP6R3 and its mRNA levels serve as a reference gene for relative quantification of RM gene expression levels in an amplification reaction. In other embodiments primers may be included that hybridize to USP38, WDR48 or LARP4B mRNA or cDNA to serve as the reference gene or some combination thereof.

In some embodiments, the nucleic acid amplification reactions are qPCR reactions. In some embodiments the qPCR reactions are TAQMAN® probe qPCR reactions that include, in addition to the target primer pairs, TAQMAN® probes that hybridize under stringent conditions to the RM gene or reference gene mRNAs or cDNAs. TAQMAN® probe-based qPCR assays are well known in the art as described in, e.g., U.S. Pat. Nos. 5,677,152, 5,773,258 and 5,804,375.

Exemplary RM and reference gene primer and TAQMAN® probe sequences are listed below in Table 3.

TABLE 3 RM and reference gene primer and TAQMAN ® probe sequences. Amplicon Length Gene Assay ID Sequence (bp) Tm PPP6R3 Hs00217759_ml TGAGGGAGGAAG 75 55-65° C. ACGGCATGGTTA CATGGGACACCT AACGAGGATAGC TAACTGTATCGT GCACAGCACTGA CAAG CDKN1A Hs00217759_ml GACAGATTTCTA 63 55-65° C. CCACTCCAAACG CCGGCTGATCTT CTCCAAGAGGAA GCCCTAATCCGC CCACAG

Typically, stringent hybridization reaction conditions are defined by use of TAQPATH™ qPCR Mastermix chemistry and cycling conditions listed below in Table 4.

TABLE 4 Thermal Cycling Conditions for Target/ Primer/Probe Hybridization. PCR Cycle (40 cycles) Incubation Activation Anneal/ Step Hold Hold Denature Extend Temperature 50° C. 95° C. 95° C. 60° C. Time 2 min. 20 sec. 1 sec. 20 sec. Volume 10 μL

In some embodiments the plurality of nucleic acid amplification reactions are multiplexed such that multiple mRNAs (including a reference mRNA) are assayed in a single qPCR reaction, i.e., nine qPCR reactions would be needed to assay the entire panel of RM gene mRNAs from one sample, where each of the reactions are “tetraplexed,” 14 reactions would be needed per sample where each reaction is “triplexed”, and 28 reactions would be needed per sample when each qPCR reactions includes primers to a single RM gene mRNA and a reference gene mRNA. In some embodiments, the plurality of qPCR reactions can include different multiplexing, i.e., some reactions may contain primer pairs directed to three RM gene mRNAs and others a primer pair to only two or a single RM gene mRNA. The plurality of reactions can be provided in a number of formats, e.g., 96-, 384-, or even 1536-well formats.

In various embodiments, the mRNA or cDNA in the biodosimetry assay system is from a biological sample from a subject subjected to radiation exposure from about 30 minutes to about seven days prior to the time point at which the biological sample was obtained from the subject, e.g., one hour, three hours, 4 hours, six hours, twelve hours, 1 day, 2 days, 3 days, 4 days, 5 days, 7 days or another time period before biological sample collection from the subject ranging from about 30 minutes to about seven days.

Also contemplated herein is a radiation biomarker assay kit that includes a nucleic acid probe set consisting essentially of nucleic acid probes that hybridize specifically with nucleic acid targets comprising at least one of SEQ ID NOS: 1-39 or the complementary sequences thereof.

In some embodiments the probe set includes no more than about 200 probes, e.g., PCR primers. In other embodiments the probe set includes no more than about 100 probes.

In some embodiments the nucleic acid probe set includes primer pairs and TAQMAN® probes suitable for qPCR analysis of mRNAs or cDNAs comprising at least one of SEQ ID NOS: 1-39.

In some embodiments the kit also includes a thermostable polymerase suitable for qPCR, e.g., Taq polymerase and variants thereof known in the art.

In some embodiments a qPCR probe set in the kit is provided in a multi-well plate format. In some a multi-well plate is provided in which at least two nucleic acid probes that hybridize to at least two different nucleic acid targets are in the same wells, i.e., the probes can be multiplexed, as described above such that up to four different targets can be assayed by qPCR in the same reaction.

In some embodiments the kit also includes radiation exposure positive and negative control mRNA samples, which ensure that a qPCR biodosimetry assay is working properly, i.e., modulation of RM gene expression is detected in the positive control sample and no modulation of RM gene expression is detected in the negative control sample.

EXAMPLES

The invention will be more fully understood upon consideration of the following non-limiting Examples. The invention has been described in connection with what are presently considered to be the most practical and preferred embodiments. However, the present invention has been presented by way of illustration and is not intended to be limited to the disclosed embodiments. Accordingly, those skilled in the art will realize that the invention is intended to encompass all modifications and alternative arrangements within the spirit and scope of the invention as set forth in the appended claims.

Example 1: Description of Test Experiments Used to Develop Biomarkers

Rhesus macaque non-human primate (NHP) in vivo testing was conducted to produce single-dose biodosimetry samples and age/gender confounded samples to calibrate the biodosimeter.

NHP in vivo dose response to radiation: The animal test laboratory completed NHP Cobalt-60 irradiations at 0, 2, 4, and 6 (LD30/60), 7 Gy (LD70/60), and 10 Gy with cohorts of 16 (8 male and 8 female), at dose rate of approximately 0.6 Gy/min. Samples of 2.5 ml peripheral blood (PAXGENE™ blood RNA tube) were obtained from each rhesus macaque −2 week and −24 hr. prior to irradiation and 4 hr., 24 hr., 36 hr. post radiation, and on days 2, 3, 5, and 7 for a total of 9 blood draws per animal. Samples (0.5 ml) were also obtained in EDTA tubes to determine WBC differentials. Tests were staged to provide 4 NHP at each condition to determine target genes using discovery techniques (Phase 1), 10 NHP at each condition to determine biomarkers and 2 NHP at each condition to test the biodosimeter (algorithm) accuracy (Phase 2).

NHP confounder analysis; old age and juvenile. The animal test laboratory completed testing of 4 rhesus macaques (2 male and 2 female) exposed to 6 Gy (LD30/60) at a dose rate of approximately 0.6 Gy/min for both geriatric (>15 years) and juvenile (10-14 months) cohorts. Samples of 2.5 ml peripheral blood (PAXGENE™ blood RNA tube) were collected from each NHP −2 week and −24 hr. prior to irradiation and 4 hr., 24 hr., 36 hr. post radiation, and on days 2, 3, 5, and 7 for a total of 9 blood draws per animal. Samples (0.5 ml) were also obtained in EDTA tubes to determine WBC differentials.

NHP Fractionated Dose Testing: Two NHP models were developed to compare NHP gene response to human gene response for fractionated dose radiotherapy models.

NHP Fractionated Dose Models: Blood (2.5 ml) was collected from 6 female and 6 male rhesus NHP into PAXGENE™ blood RNA tubes. The NHP were irradiated in vivo to parallel the 4 human in vivo test protocols as described below. For Study 1: Twelve (12) NHPs were exposed to 1.5 Gy twice per day (dose rate 0.6-0.8 Gy/min.) for 4 days at the same time each day. The blood samples were collected within 24 hr. prior to irradiation and 24 hrs. after each daily exposure (6 draws). For Study 2: Twelve (12) NHPs were exposed to 1.2 Gy (dose rate 0.6-0.8 Gy/min.) 3 times per day at the same time each day for 4-days. Blood samples were collected prior to irradiation and 24 hr. following each exposure (prior to the next exposure) for a total of 6 draws. The NHPs were irradiated by LINAC. At the time of sample collection, a complete differential white cell count was conducted.

Human Fractionated Dose Models: Four human in vivo models were co-developed with Mayo Clinic, City of Hope and Stanford to provide blood samples from humans undergoing whole body and fractional radiation.

Model 1—Bone Marrow Transplant Patients (BMT): Radiation dose is 1.65 to 2 Gy twice daily for 3 to 4 days. Samples are taken prior to and 24 hr. after daily irradiations. The last draw is on Day-7; 7 days after the first dose. (4-6 samples/Series).

Model 2—Bone Marrow Transplant Patients (BMT): Radiation dose is 1.2 Gy three times daily for 4 days. Samples are taken prior to and 24 hr. after irradiation daily irradiations. The last draw is on Day-3 or 4; 3 or 4 days after the first dose. (5-7 samples/Series).

Model 3—Bone Marrow Transplant Patients (BMT): Radiation dose is a single fraction related to models 1 and 2. Samples are taken prior to and every 24 hr. after irradiation. The last draw is on Day-6; 6 days after the first dose. (6-7 samples/Series).

Model 4—X-Ray Therapy (XRT) Patients (>7% bone marrow exposure): Radiation dose is 2-8 Gy each day for multiple days. Samples are taken prior to and 24 hr. after irradiation. The last draw is taken 7 days after the last exposure.

TABLE 5 Nucleotide Sequences of Biodosimetry Biomarker Genes CR2 (SEQ ID NO: 1; GenBank NM_001006658.2). ATTTAAGGGCCCGCCTCTCCTGGCTCACAGCTGCTTGCTGCTCCAGCCTTGCCCTCCC AGAGCTGCCGGACGCTCGCGGGTCTCGGAACGCATCCCGCCGCGGGGGCTTCGGCC GTGGCATGGGCGCCGCGGGCCTGCTCGGGGTTTTCTTGGCTCTCGTCGCACCGGGGG TCCTCGGGATTTCTTGTGGCTCTCCTCCGCCTATCCTAAATGGCCGGATTAGTTATTA TTCTACCCCCATTGCTGTTGGTACCGTGATAAGGTACAGTTGTTCAGGTACCTTCCGC CTCATTGGAGAAAAAAGTCTATTATGCATAACTAAAGACAAAGTGGATGGAACCTG GGATAAACCTGCTCCTAAATGTGAATATTTCAATAAATATTCTTCTTGCCCTGAGCCC ATAGTACCAGGAGGATACAAAATTAGAGGCTCTACACCCTACAGACATGGTGATTC TGTGACATTTGCCTGTAAAACCAACTTCTCCATGAACGGAAACAAGTCTGTTTGGTG TCAAGCAAATAATATGTGGGGGCCGACACGACTACCAACCTGTGTAAGTGTTTTCCC TCTCGAGTGTCCAGCACTTCCTATGATCCACAATGGACATCACACAAGTGAGAATGT TGGCTCCATTGCTCCAGGATTGTCTGTGACTTACAGCTGTGAATCTGGTTACTTGCTT GTTGGAGAAAAGATCATTAACTGTTTGTCTTCGGGAAAATGGAGTGCTGTCCCCCCC ACATGTGAAGAGGCACGCTGTAAATCTCTAGGACGATTTCCCAATGGGAAGGTAAA GGAGCCTCCAATTCTCCGGGTTGGTGTAACTGCAAACTTTTTCTGTGATGAAGGGTA TCGACTGCAAGGCCCACCTTCTAGTCGGTGTGTAATTGCTGGACAGGGAGTTGCTTG GACCAAAATGCCAGTATGTGAAGAAATTTTTTGCCCATCACCTCCCCCTATTCTCAA TGGAAGACATATAGGCAACTCACTAGCAAATGTCTCATATGGAAGCATAGTCACTTA CACTTGTGACCCGGACCCAGAGGAAGGAGTGAACTTCATCCTTATTGGAGAGAGCA CTCTCCGTTGTACAGTTGATAGTCAGAAGACTGGGACCTGGAGTGGCCCTGCCCCAC GCTGTGAACTTTCTACTTCTGCGGTTCAGTGTCCACATCCCCAGATCCTAAGAGGCC GAATGGTATCTGGGCAGAAAGATCGATATACCTATAACGACACTGTGATATTTGCTT GCATGTTTGGCTTCACCTTGAAGGGCAGCAAGCAAATCCGATGCAATGCCCAAGGC ACATGGGAGCCATCTGCACCAGTCTGTGAAAAGGAATGCCAGGCCCCTCCTAACAT CCTCAATGGGCAAAAGGAAGATAGACACATGGTCCGCTTTGACCCTGGAACATCTA TAAAATATAGCTGTAACCCTGGCTATGTGCTGGTGGGAGAAGAATCCATACAGTGTA CCTCTGAGGGGGTGTGGACACCCCCTGTACCCCAATGCAAAGTGGCAGCGTGTGAA GCTACAGGAAGGCAACTCTTGACAAAACCCCAGCACCAATTTGTTAGACCAGATGT CAACTCTTCTTGTGGTGAAGGGTACAAGTTAAGTGGGAGTGTTTATCAGGAGTGTCA AGGCACAATTCCTTGGTTTATGGAGATTCGTCTTTGTAAAGAAATCACCTGCCCACC ACCCCCTGTTATCTACAATGGGGCACACACCGGGAGTTCCTTAGAAGATTTTCCATA TGGAACCACGGTCACTTACACATGTAACCCTGGGCCAGAAAGAGGAGTGGAATTCA GCCTCATTGGAGAGAGCACCATCCGTTGTACAAGCAATGATCAAGAAAGAGGCACC TGGAGTGGCCCTGCTCCCCTGTGTAAACTTTCCCTCCTTGCTGTCCAGTGCTCACATG TCCATATTGCAAATGGATACAAGATATCTGGCAAGGAAGCCCCATATTTCTACAATG ACACTGTGACATTCAAGTGTTATAGTGGATTTACTTTGAAGGGCAGTAGTCAGATTC GTTGCAAAGCTGATAACACCTGGGATCCTGAAATACCAGTTTGTGAAAAAGGCTGC CAGTCACCTCCTGGGCTCCACCATGGTCGTCATACAGGTGGAAATACGGTCTTCTTT GTCTCTGGGATGACTGTAGACTACACTTGTGACCCTGGCTATTTGCTTGTGGGAAAC AAATCCATTCACTGTATGCCTTCAGGAAATTGGAGTCCTTCTGCCCCACGGTGTGAA GAAACATGCCAGCATGTGAGACAGAGTCTTCAAGAACTTCCAGCTGGTTCACGTGTG GAGCTAGTTAATACGTCCTGCCAAGATGGGTACCAGTTGACTGGACATGCTTATCAG ATGTGTCAAGATGCTGAAAATGGAATTTGGTTCAAAAAGATTCCACTTTGTAAAGTT ATTCACTGTCACCCTCCACCAGTGATTGTCAATGGGAAGCACACAGGCATGATGGCA GAAAACTTTCTATATGGAAATGAAGTCTCTTATGAATGTGACCAAGGATTCTATCTC CTGGGAGAGAAAAAATTGCAGTGCAGAAGTGATTCTAAAGGACATGGATCTTGGAG CGGGCCTTCCCCACAGTGCTTACGATCTCCTCCTGTGACTCGCTGCCCTAATCCAGA AGTCAAACATGGGTACAAGCTCAATAAAACACATTCTGCATATTCCCACAATGACAT AGTGTATGTTGACTGCAATCCTGGCTTCATCATGAATGGTAGTCGCGTGATTAGGTG TCATACTGATAACACATGGGTGCCAGGTGTGCCAACTTGTATCAAAAAAGCCTTCAT AGGGTGTCCACCTCCGCCTAAGACCCCTAACGGGAACCATACTGGTGGAAACATAG CTCGATTTTCTCCTGGAATGTCAATCCTGTACAGCTGTGACCAAGGCTACCTGCTGGT GGGAGAGGCACTCCTTCTTTGCACACATGAGGGAACCTGGAGCCAACCTGCCCCTC ATTGTAAAGAGGTAAACTGTAGCTCACCAGCAGATATGGATGGAATCCAGAAAGGG CTGGAACCAAGGAAAATGTATCAGTATGGAGCTGTTGTAACTCTGGAGTGTGAAGA TGGGTATATGCTGGAAGGCAGTCCCCAGAGCCAGTGCCAATCGGATCACCAATGGA ACCCTCCCCTGGCGGTTTGCAGATCCCGTTCACTTGCTCCTGTCCTTTGTGGTATTGC TGCAGGTTTGATACTTCTTACCTTCTTGATTGTCATTACCTTATACGTGATATCAAAA CACAGAGCACGCAATTATTATACAGATACAAGCCAGAAAGAAGCTTTTCATTTAGA AGCACGAGAAGTATATTCTGTTGATCCATACAACCCAGCCAGCTGATCAGAAGACA AACTGGTGTGTGCCTCATTGCTTGGAATTCAGCGGAATATTGATTAGAAAGAAACTG CTCTAATATCAGCAAGTCTCTTTATATGGCCTCAAGATCAATGAAATGATGTCATAA GCGATCACTTCCTATATGCACTTATTCTCAAGAAGAACATCTTTATGGTAAAGATGG GAGCCCAGTTTCACTGCCATATACTCTTCAAGGACTTTCTGAAGCCTCACTTATGAG ATGCCTGAAGCCAGGCCATGGCTATAAACAATTACATGGCTCTAAAAAGTTTTGCCC TTTTTAAGGAAGGCACTAAAAAGAGCTGTCCTGGTATCTAGACCCATCTTCTTTTTG AAATCAGCATACTCAATGTTACTATCTGCTTTTGGTTATAATGTGTTTTTAATTATCT AAAGTATGAAGCATTTTCTGGGGTTATGATGGCTTTACCTTTATTAGGAAGTATGGT TTTATTTTGATAGTAGCTTCCTCCTCTGGTGGTGTTAATCATTTCATTTTTACCCTTAC TTGGTTTGAGTTTCTCTCACATTACTGTATATACTTTGCCTTTCCATAATCACTCAGTG ATTGCAATTTGCACAAGTTTTTTTAAATTATGGGAATCAAGATTTAATCCTAGAGATT TGGTGTACAATTCAGGCTTTGGATGTTTCTTTAGCAGTTTTGTGATAAGTTCTAGTTG CTTGTAAAATTTCACTTAATAATGTGTACATTAGTCATTCAATAAATTGTAATTGTAA AGAAAACATACAAAAAAAAAAAAAAAA DHRS4L1 (SEQ ID NO: 2; GenBank NM_001277864.1). AGTCGGGCAGCTCTCCGGGCCGGCGTGGGAGCCCGCGCTCCAAAGCCCGGTGGGGG GAGGGGCGCTCACGCAACCGCCACTGTCTGGAGCGGGCTCGCCTCTGCGGCGGCAC TCACCGCCCGGGCTTTACTGAAGCGGAGTCTAGCATGTGCGGCTGCTCCACAGCGGT GTGGGTGGCGGCGGCTCCTCTGCAGCAGCCTCGGCAGTAGGGGTCACGGTGGCCAA GCCCACCGTGGAGCTCATCTGAGAGTTGTAAGGTACGGGACTGCCTCGGTCTTTGGG ACGCCCCGTCTGGTAGCATCCCAGATCCAGCACGTTCCTTCCGGCCCTGCACCCCGG CCCGGTGCCTCACACCCCGCTACCCCATGCATCCAGACTCTAAGGCAGCCCCTGCAT CTCAGTCCTGACATCGCTGTCCCTGGAGCATCCTCCGCTGGAGCTGGAGCTTGACAG GATCGGCTTCGCCGTCGCCCAGCGTCTGGCCCAAGACGGGGCCCACGTGGTAGTCA GCCGCCGGAAGCAGCAGAATGTGGACCAGGCAGTGGCCACGCTGCAGGGGGAGGG GCTGAGCATGACGGGCACTGTGTGCCATGTGGGGAAGATGAAGGACTGGGAGCGGC TGGTGGCCACAGTGAGCTGCAGGGAAATGGGCACAGAGCCAGGAGGTGGAAAAGG GAGCCAGCCTGAGCCTCCTTCCCTGCTTTCCTGGACAGCATTGGGCTTCAGTCCTTAC AATGTCAGTAAAACAGCCTTGCTGGGCCTCAACAAGACCTTGGCCATAGAGCTGGC CCCAAGGAACATTAGGGTGAACTGCCTAGCACCTGGACTTATCAAGACTAGCTTCAG CAGGATGCTCTGGATGGACAAGGAAAAAGAGGAAAGCATGAAAGAAACCCTGCGG ATAAGAAGGTTAGGCGAGCCAGAGGATTCTCTTGGCATCGTGTCTTTCCTGTGCTCT GAAGATGCCAGCTACCTCACTGGGGAAACAGTGATGGTGGGTGGAGGAACCCCGTC CCGCCTCTGAGGACCCGGAGACAGCCCACAGGCCAGAGTTGGGCTCTAGCTCCTGG TGCTGTTCCTGCATTCACCCACTGGCCTTTCCCACCTCTGCTCACCTTACTGTTCACC TCATCAAATCAGTTCTGCCCTGTGAAAAGATCCAGCCTTCCCTGCCGTCAAGGTGGT GTCTTACTCGGGATTCCTGCTGTTGTTGTGGCCTTGGGTAAAGGCCTCCCCTGAGAA CACAGGACAGGCCTGCTGACAAGGCTGAGTCTACCTTGGCAAAGACCAAGATATTT TTTGCCCAGGCCACTGGGGAATTTGAGGGGAGATGAGAGAGAAGGAAGCTGGAGTG GAAGGAGCAGAGTTGCAAATTAACAACTTGCAAATGAGGTGCAAATAAAATGCAGA TGATTGCGCGGCTTTGAATCGAAAAAAAAAAA HCK (SEQ ID NO: 3; GenBank NM_001172129.1). GGAGTTAGCCTCGCTCAGGGCGCGGCTAAGGCGCCCAGATGGCCTGCGGGCGCCAC CACGTCCCTGGTCCCAGCTCGGGAGCACATCAGAGGCTTAGAGGCGAGTGGGAAGG GACTCAGACAGTGCAGGACGAGAAACGCCCGCGGCACCAAAGCCCCTCAGAGCGTC GCCCCCGCCTCTAGTTCTAGAAAGTCAGTTTCCCGGCACTGGCACCCCGGAACCTCA GGGGCTGCCGAGCTGGGGGGGCGCTCAAGCTGCGAGGATCCGGGCTGCCCGCGAGA CGAGGAGCGGGCGCCCAGGATGGGGTGCATGAAGTCCAAGTTCCTCCAGGTCGGAG GCAATACATTCTCAAAAACTGAAACCAGCGCCAGCCCACACTGTCCTGTGTACGTGC CGGATCCCACATCCACCATCAAGCCGGGGCCTAATAGCCACAACAGCAACACACCA GGAATCAGGGAGGCAGGCTCTGAGGACATCATCGTGGTTGCCCTGTATGATTACGA GGCCATTCACCACGAAGACCTCAGCTTCCAGAAGGGGGACCAGATGGTGGTCCTAG AGGAATCCGGGGAGTGGTGGAAGGCTCGATCCCTGGCCACCCGGAAGGAGGGCTAC ATCCCAAGCAACTATGTCGCCCGCGTTGACTCTCTGGAGACAGAGGAGTGGTTTTTC AAGGGCATCAGCCGGAAGGACGCAGAGCGCCAACTGCTGGCTCCCGGCAACATGCT GGGCTCCTTCATGATCCGGGATAGCGAGACCACTAAAGGAAGCTACTCTTTGTCCGT GCGAGACTACGACCCTCGGCAGGGAGATACCGTGAAACATTACAAGATCCGGACCC TGGACAACGGGGGCTTCTACATATCCCCCCGAAGCACCTTCAGCACTCTGCAGGAGC TGGTGGACCACTACAAGAAGGGGAACGACGGGCTCTGCCAGAAACTGTCGGTGCCC TGCATGTCTTCCAAGCCCCAGAAGCCTTGGGAGAAAGATGCCTGGGAGATCCCTCG GGAATCCCTCAAGCTGGAGAAGAAACTTGGAGCTGGGCAGTTTGGGGAAGTCTGGA TGGCCACCTACAACAAGCACACCAAGGTGGCAGTGAAGACGATGAAGCCAGGGAG CATGTCGGTGGAGGCCTTCCTGGCAGAGGCCAACGTGATGAAAACTCTGCAGCATG ACAAGCTGGTCAAACTTCATGCGGTGGTCACCAAGGAGCCCATCTACATCATCACG GAGTTCATGGCCAAAGGAAGCTTGCTGGACTTTCTGAAAAGTGATGAGGGCAGCAA GCAGCCATTGCCAAAACTCATTGACTTCTCAGCCCAGATTGCAGAAGGCATGGCCTT CATCGAGCAGAGGAACTACATCCACCGAGACCTCCGAGCTGCCAACATCTTGGTCTC TGCATCCCTGGTGTGTAAGATTGCTGACTTTGGCCTGGCCCGGGTCATTGAGGACAA CGAGTACACGGCTCGGGAAGGGGCCAAGTTCCCCATCAAGTGGACAGCTCCTGAAG CCATCAACTTTGGCTCCTTCACCATCAAGTCAGACGTCTGGTCCTTTGGTATCCTGCT GATGGAGATCGTCACCTACGGCCGGATCCCTTACCCAGGGATGTCAAACCCTGAAG TGATCCGAGCTCTGGAGCGTGGATACCGGATGCCTCGCCCAGAGAACTGCCCAGAG GAGCTCTACAACATCATGATGCGCTGCTGGAAAAACCGTCCGGAGGAGCGGCCGAC CTTCGAATACATCCAGAGTGTGCTGGATGACTTCTACACGGCCACAGAGAGCCAGTA CCAACAGCAGCCATGATAGGGAGGACCAGGGCAGGGCCAGGGGGTGCCCAGGTGG TGGCTGCAAGGTGGCTCCAGCACCATCCGCCAGGGCCCACACCCCCTTCCTACTCCC AGACACCCACCCTCGCTTCAGCCACAGTTTCCTCATCTGTCCAGTGGGTAGGTTGGA CTGGAAAATCTCTTTTTGACTCTTGCAATCCACAATCTGACATTCTCAGGAAGCCCCC AAGTTGATATTTCTATTTCCTGGAATGGTTGGATTTTAGTTACAGCTGTGATTTGGAA GGGAAACTTTCAAAATAGTGAAATGAATATTTAAATAAAAGATATAAATGCCAAAG TCTTTACCAAAAAAAAAAAAAAAAA IL1RAP (SEQ ID NO: 4; GenBank NM_002182.3). AAAGGGGGAAAAGAAAGTGCGGCGGAAAGTAAGAGGCTCACTGGGGAAGACTGCC GGGATCCAGGTCTCCGGGGTCCGCTTTGGCCAGAGGCGCGGAAGGAAGCAGTGCCC GGCGACACTGCACCCATCCCGGCTGCTTTTGCTGCGCCCTCTCAGCTTCCCAAGAAA GGCATCGTCATGTGATCATCACCTAAGAACTAGAACATCAGCAGGCCCTAGAAGCC TCACTCTTGCCCCTCCCTTTAATATCTCAAAGGATGACACTTCTGTGGTGTGTAGTGA GTCTCTACTTTTATGGAATCCTGCAAAGTGATGCCTCAGAACGCTGCGATGACTGGG GACTAGACACCATGAGGCAAATCCAAGTGTTTGAAGATGAGCCAGCTCGCATCAAG TGCCCACTCTTTGAACACTTCTTGAAATTCAACTACAGCACAGCCCATTCAGCTGGC CTTACTCTGATCTGGTATTGGACTAGGCAGGACCGGGACCTTGAGGAGCCAATTAAC TTCCGCCTCCCCGAGAACCGCATTAGTAAGGAGAAAGATGTGCTGTGGTTCCGGCCC ACTCTCCTCAATGACACTGGCAACTATACCTGCATGTTAAGGAACACTACATATTGC AGCAAAGTTGCATTTCCCTTGGAAGTTGTTCAAAAAGACAGCTGTTTCAATTCCCCC ATGAAACTCCCAGTGCATAAACTGTATATAGAATATGGCATTCAGAGGATCACTTGT CCAAATGTAGATGGATATTTTCCTTCCAGTGTCAAACCGACTATCACTTGGTATATG GGCTGTTATAAAATACAGAATTTTAATAATGTAATACCCGAAGGTATGAACTTGAGT TTCCTCATTGCCTTAATTTCAAATAATGGAAATTACACATGTGTTGTTACATATCCAG AAAATGGACGTACGTTTCATCTCACCAGGACTCTGACTGTAAAGGTAGTAGGCTCTC CAAAAAATGCAGTGCCCCCTGTGATCCATTCACCTAATGATCATGTGGTCTATGAGA AAGAACCAGGAGAGGAGCTACTCATTCCCTGTACGGTCTATTTTAGTTTTCTGATGG ATTCTCGCAATGAGGTTTGGTGGACCATTGATGGAAAAAAACCTGATGACATCACTA TTGATGTCACCATTAACGAAAGTATAAGTCATAGTAGAACAGAAGATGAAACAAGA ACTCAGATTTTGAGCATCAAGAAAGTTACCTCTGAGGATCTCAAGCGCAGCTATGTC TGTCATGCTAGAAGTGCCAAAGGCGAAGTTGCCAAAGCAGCCAAGGTGAAGCAGAA AGTGCCAGCTCCAAGATACACAGTGGAACTGGCTTGTGGTTTTGGAGCCACAGTCCT GCTAGTGGTGATTCTCATTGTTGTTTACCATGTTTACTGGCTAGAGATGGTCCTATTT TACCGGGCTCATTTTGGAACAGATGAAACCATTTTAGATGGAAAAGAGTATGATATT TATGTATCCTATGCAAGGAATGCGGAAGAAGAAGAATTTGTATTACTGACCCTCCGT GGAGTTTTGGAGAATGAATTTGGATACAAGCTGTGCATCTTTGACCGAGACAGTCTG CCTGGGGGAATTGTCACAGATGAGACTTTGAGCTTCATTCAGAAAAGCAGACGCCTC CTGGTTGTTCTAAGCCCCAACTACGTGCTCCAGGGAACCCAAGCCCTCCTGGAGCTC AAGGCTGGCCTAGAAAATATGGCCTCTCGGGGCAACATCAACGTCATTTTAGTACAG TACAAAGCTGTGAAGGAAACGAAGGTGAAAGAGCTGAAGAGGGCTAAGACGGTGC TCACGGTCATTAAATGGAAAGGGGAAAAATCCAAGTATCCACAGGGCAGGTTCTGG AAGCAGCTGCAGGTGGCCATGCCAGTGAAGAAAAGTCCCAGGCGGTCTAGCAGTGA TGAGCAGGGCCTCTCGTATTCATCTTTGAAAAATGTATGAAAGGAATAATGAAAAG GGTAAAAAGAACAAGGGGTGCTCCAGGAAGAAAGAGTCCCCCCAGTCTTCATTCGC AGTTTATGGTTTCATAGGCAAAAATAATGGTCTAAGCCTCCCAATAGGGATAAATTT AGGGTGACTGTGTGGCTGACTATTCTGCTTCCTCAGGCAACACTAAAGTTTAGAAAG ATATCATCAACGTTCTGTCACCAGTCTCTGATGCCACTATGTTCTTTGCAGGCAAAG ACTTGTTCAATGCGAATTTCCCCTTCTACATTGTCTATCCCTGTTTTTATATGTCTCCA TTCTTTTTAAAATCTTAACATATGGAGCAGCCTTTCCTATGAATTTAAATATGCCTTT AAAATAAGTCACTGTTGACAGGGTCATGAGTTTCCGAGTATAGTTTTCTTTTTATCTT ATTTTTACTCGTCCGTTGAAAAGATAATCAAGGCCTACATTTTAGCTGAGGATAATG AACTTTTTTCCTCATTCGGCTGTATAATACATAACCACAGCAAGACTGACATCCACTT AGGATGATACAAAGCAGTGTAACTGAAAATGTTTCTTTTAATTGATTTAAAGGACTT GTCTTCTATACCACCCTTGTCCTCATCTCAGGTAATTTATGAAATCTATGTAAACTTG AAAAATATTTCTTAATTTTTGTTTTTGCTCCAGTCAATTCCTGATTATCCACAGGTCA ACCCACATTTTTTCATTCCTTCTCCCTATCTGCTTATATCGCATTGCTCATTTAGAGTT TGCAGGAGGCTCCATACTAGGTTCAGTCTGAAAGAAATCTCCTAATGGTGCTATAGA GAGGGAGGTAACAGAAAGACTCTTTTAGGGCATTTTTCTGACTCATGAAAAGAGCA CAGAAAAGGATGTTTGGCAATTTGTCTTTTAAGTCTTAACCTTGCTAATGTGAATACT GGGAAAGTGATTTTTTCTCACTCGTTTTTGTTGCTCCATTGTAAAGGGCGGAGGTCA GTCTTAGTGGCCTTGAGAGTTGCTTTTGGCATTAATATTCTAAGAGAATTAACTGTAT TTCCTGTCACCTATTCACTAGTGCAGGAAATATACTTGCTCCAAATAAGTCAGTATG AGAAGTCACTGTCAATGAAAGTTGTTTTGTTTGTTTTCAGTAATATTTTGCTGTTTTT AAGACTTGGAAAACTAAGTGCAGAGTTTACAGAGTGGTAAATATCTATGTTACATGT AGATTATACATATATATACACACGTGTATATGAGATATATATCTTATATCTCCACAA ACACAAATTATATATATACATATCCACACACATACATTACATATATCTGTGTATATA AATCCACATGCACATGAAATATATATATATATATAATTTGTGTGTGTGTATGTGTAT GTATATGACTTTAAATAGCTATGGGTACAATATTAAAAACCACTGGAACTCTTGTCC AGTTTTTAAATTATGTTTTTACTGGAATGTTTTTGTGTCAGTGTTTTCTGTACATATTA TTTGTTAATTCACAGCTCACAGAGTGATAGTTGTCATAGTTCTTGCCTTCCCTAAGTT TATATAAATAACTTAAGTATTGCTACAGTTTATCTAGGTTGCAGTGGCATCTGCTGTG CACAGAGCTTCCATGGTCACTGCTAAGCAGTAGCCAGCCATCGGGCATTAATTGATT TCCTACTATATTCCCAGCAGACACATTTAGAAACTAAGCTATGTTAACCTCAGTGCT CAACTATTTGAACTGTTGAGTGATAAAGGAAACAAATATAACTGTAAATGAATCTTG GTATCCTGTGAAACAGAATAATTCGTAATTTAAGAAAGCCCTTATCCCGGTAACATG AATGTTGATGAACAAATGTAAAATTATATCCTATATTTAAGTACCCATAATAAATCA TTTCCCTCTATAAGTGTTATTGATTATTTTAAATTGAAAAAAGTTTCACTTGGATGAA AAAAGTAGAAAAGTAGGTCATTCTTGGATCTACTTTTTTTTAGCCTTATTAATATTTT TCCCTATTAGAAACCACAATTACTCCCTCTATTAACCCTTCACTTACTAGACCAGAA AAGAACTTATTCCAGATAAGCTTTGAATATCAATTCTTACATAAACTTTAGGCAAAC AGGGAATAGTCTAGTCACCAAAGGACCATTCTCTTGCCAATGCTGCATTCCTTTTGC ACTTTTGGATTCCATATTTATCCCAAATGCTGTTGGGCACCCCTAGAAATACCTTGAT GTTTTTTCTATTTATATGCCTGCCTTTGGTACTTAATTTTACAAATGCTGTAATATAA AGCATATCAAGTTTATGTGATACGTATCATTGCAAGAGAATTTGTTTCAAGATTTTTT TTTAATGTTCCAGAAGATGGCCAATAGAGAACATTCAAGGGAAATGGGGAAACATA ATTTAGAGAACAAGAACAAACCATGTCTCAAATTTTTTTAAAAAAAATTAATGGTTT TAAATATATGCTATAGGGACGTTCCATGCCCAGGTTAACAAAGAACTGTGATATATA GAGTGTCTAATTACAAAATCATATACGATTTATTTAATTCTCTTCTGTATTGTAACTT AGATGATTCCCAAGGACTCTAATAAAAAATCACTTCATTGTATTTGGAAACAAAAAC ATCATTCATTAATTACTTATTTTCTTTCCATAGGTTTTAATATTTTGAGAGTGTCTTTT TTATTTCATTCATGAACTTTTGTATTTTTCATTTTTCATTTGATTTGTAAATTTACTTAT GTTAAAAATAAACCATTTATTTTCAGCTTTGAATTTTAAAAAAAAAAAAAAAAAA LYRM4 (SEQ ID NO: 5; GenBank NM_020408.5). GAGCCCTGCCTGCGCCCGCCCCCGAAGCGGCGCGGGACGCCTGGCGCCGTCCGCGA TCCGCAGGGCTGCCCGCTTAGGCTTAGGCCCGGCCCGCTGGCAAAGCCGAGCCGCA GCATTTTATTTCGTTCGTGGTTTCCGCACAGGCTGGAGTTTCGTGGGTTGGGTCGTAC TTGGGACCTCGGCGAAGAGGACCCGTTTATTTTTTTTTCTTTCCAAAATGGCAGCCTC CAGTCGCGCACAAGTGTTATCTCTGTACCGGGCGATGCTGAGAGAGAGCAAGCGTTT CAGCGCCTACAATTACAGAACATATGCTGTCAGGAGGATAAGAGATGCCTTCAGAG AAAATAAAAATGTAAAGGATCCTGTAGAAATTCAAACCCTAGTGAATAAAGCCAAG AGAGACCTTGGAGTAATTCGTCGACAGGTCCACATTGGCCAACTGTATTCAACTGAC AAGCTGATCATTGAGAATCGAGACATGCCCAGGACCTAGCAAGCCGGGGACCAGCC ACCAGTGGCGGCCAGGGACCACCTTCAGCATCCACTCTCTGTTTGAGATGGGGGCTC CCAAAACCAGCTTACAATAGCCTTTTGCGCTGCCTGTCCTGTGGGAGCTGATAAACC AAGTCACATTTGCATTCTGTTGCAGGCTTAGTGAAAAAGGACTGCTGTCTTTCCTTG GTTCAAGTGTTAGAATGGAGAGCTGGAGTTCGTTCAGAATAGTGCTGTGTGTTACCA CGTCTCCCCTGCACCCCATTCCTACCTTGTAGCTCATGACCATTGTGTATAGCATTTC TACACTTTGTTTCTTGGTCCTTGGCAATAAAAAGAATGATCTCCCTGAGCCTTTGACC CCAGATAAACCCCTCCCAATTAATGCATTTTCATTTCCTACTGATACAAGGCCTGGA GAGGGCTGTTGGGGGCCCTCAGGGAGGGTTCAACTCTGAGACGAGAACTGCCTTGG TGAAGGCAAGTTCAAGCACCACTTGAGACTGGGGGCAGCATGGAGTAGGGCAGGGC TACGGGGATACACGGTGCACCCTGCAACTTATACCTGAGCCCAGTACAACAAAGGT GACGGGTGTGTAGGTACACACCCAGAGATGGAGCACTGCAGATCAGCAACCTCAGC CCCACCTGGGAATTTGCTGGAAATGCAGGCTCAAGCCCCTCCCCACACCTGGTGAAT GAGAGAGCCCCAGCCTGACCCAAGCCCAGGGCGACTCCCATACCCTGAAGCCTGGG GCATGCTGGGCAGCACCGGTGCCCAAATCTGGCTGGTGGACAGAAGCACCTGGAGA GTTGGAGAGCTTTTTAAAAAGACATCTCTCAGCACTTCCCTCTCTGCAGATTCTGACT CAGTAAGTGAGGGGTGAGGCACAGTCATTTTTCTCTATTCTGAAGCTCTCCCACTGT TTTCAATGTTTAACCAACTGGGGACCCCTGCTCTTTAAGTATATTACAGGTAATAAA GATATTGTTTGTATGCTTTTAAAAAAAAAAAAAAAAAA. MYC (SEQ ID NO: 6; GenBank NM_002467). GACCCCCGAGCTGTGCTGCTCGCGGCCGCCACCGCCGGGCCCCGGCCGTCCCTGGCT CCCCTCCTGCCTCGAGAAGGGCAGGGCTTCTCAGAGGCTTGGCGGGAAAAAGAACG GAGGGAGGGATCGCGCTGAGTATAAAAGCCGGTTTTCGGGGCTTTATCTAACTCGCT GTAGTAATTCCAGCGAGAGGCAGAGGGAGCGAGCGGGCGGCCGGCTAGGGTGGAA GAGCCGGGCGAGCAGAGCTGCGCTGCGGGCGTCCTGGGAAGGGAGATCCGGAGCG AATAGGGGGCTTCGCCTCTGGCCCAGCCCTCCCGCTGATCCCCCAGCCAGCGGTCCG CAACCCTTGCCGCATCCACGAAACTTTGCCCATAGCAGCGGGCGGGCACTTTGCACT GGAACTTACAACACCCGAGCAAGGACGCGACTCTCCCGACGCGGGGAGGCTATTCT GCCCATTTGGGGACACTTCCCCGCCGCTGCCAGGACCCGCTTCTCTGAAAGGCTCTC CTTGCAGCTGCTTAGACGCTGGATTTTTTTCGGGTAGTGGAAAACCAGCAGCCTCCC GCGACGATGCCCCTCAACGTTAGCTTCACCAACAGGAACTATGACCTCGACTACGAC TCGGTGCAGCCGTATTTCTACTGCGACGAGGAGGAGAACTTCTACCAGCAGCAGCA GCAGAGCGAGCTGCAGCCCCCGGCGCCCAGCGAGGATATCTGGAAGAAATTCGAGC TGCTGCCCACCCCGCCCCTGTCCCCTAGCCGCCGCTCCGGGCTCTGCTCGCCCTCCTA CGTTGCGGTCACACCCTTCTCCCTTCGGGGAGACAACGACGGCGGTGGCGGGAGCTT CTCCACGGCCGACCAGCTGGAGATGGTGACCGAGCTGCTGGGAGGAGACATGGTGA ACCAGAGTTTCATCTGCGACCCGGACGACGAGACCTTCATCAAAAACATCATCATCC AGGACTGTATGTGGAGCGGCTTCTCGGCCGCCGCCAAGCTCGTCTCAGAGAAGCTG GCCTCCTACCAGGCTGCGCGCAAAGACAGCGGCAGCCCGAACCCCGCCCGCGGCCA CAGCGTCTGCTCCACCTCCAGCTTGTACCTGCAGGATCTGAGCGCCGCCGCCTCAGA GTGCATCGACCCCTCGGTGGTCTTCCCCTACCCTCTCAACGACAGCAGCTCGCCCAA GTCCTGCGCCTCGCAAGACTCCAGCGCCTTCTCTCCGTCCTCGGATTCTCTGCTCTCC TCGACGGAGTCCTCCCCGCAGGGCAGCCCCGAGCCCCTGGTGCTCCATGAGGAGAC ACCGCCCACCACCAGCAGCGACTCTGAGGAGGAACAAGAAGATGAGGAAGAAATC GATGTTGTTTCTGTGGAAAAGAGGCAGGCTCCTGGCAAAAGGTCAGAGTCTGGATC ACCTTCTGCTGGAGGCCACAGCAAACCTCCTCACAGCCCACTGGTCCTCAAGAGGTG CCACGTCTCCACACATCAGCACAACTACGCAGCGCCTCCCTCCACTCGGAAGGACTA TCCTGCTGCCAAGAGGGTCAAGTTGGACAGTGTCAGAGTCCTGAGACAGATCAGCA ACAACCGAAAATGCACCAGCCCCAGGTCCTCGGACACCGAGGAGAATGTCAAGAGG CGAACACACAACGTCTTGGAGCGCCAGAGGAGGAACGAGCTAAAACGGAGCTTTTT TGCCCTGCGTGACCAGATCCCGGAGTTGGAAAACAATGAAAAGGCCCCCAAGGTAG TTATCCTTAAAAAAGCCACAGCATACATCCTGTCCGTCCAAGCAGAGGAGCAAAAG CTCATTTCTGAAGAGGACTTGTTGCGGAAACGACGAGAACAGTTGAAACACAAACT TGAACAGCTACGGAACTCTTGTGCGTAAGGAAAAGTAAGGAAAACGATTCCTTCTA ACAGAAATGTCCTGAGCAATCACCTATGAACTTGTTTCAAATGCATGATCAAATGCA ACCTCACAACCTTGGCTGAGTCTTGAGACTGAAAGATTTAGCCATAATGTAAACTGC CTCAAATTGGACTTTGGGCATAAAAGAACTTTTTTATGCTTACCATCTTTTTTTTTTCT TTAACAGATTTGTATTTAAGAATTGTTTTTAAAAAATTTTAAGATTTACACAATGTTT CTCTGTAAATATTGCCATTAAATGTAAATAACTTTAATAAAACGTTTATAGCAGTTA CACAGAATTTCAATCCTAGTATATAGTACCTAGTATTATAGGTACTATAAACCCTAA TTTTTTTTATTTAAGTACATTTTGCTTTTTAAAGTTGATTTTTTTCTATTGTTTTTAGAA AAAATAAAATAACTGGCAAATATATCATTGAGCCAAATCTTAAAAAAAAAAAAAAA TMEM63B (SEQ ID NO: 7; GenBank NM_018426.1). AACCCGGGGCTCCGAGCCGGAGCCGAGTCTGCGCCTGGGGGAGGACCATGCGGCAG TAGCAGCCATGCTGCCCTTTCTGCTGGCCACACTGGGCACCACAGCCCTCAACAACA GCAACCCCAAGGACTACTGCTACAGCGCCCGCATCCGCAGCACTGTCCTGCAGGGC CTGCCCTTTGGGGGCGTCCCCACCGTGCTGGCTCTCGACTTCATGTGCTTCCTTGCAC TGCTGTTCTTATTCTCTATCCTCCGGAAGGTGGCCTGGGACTATGGGCGGCTGGCCTT GGTGACAGATGCAGACAGGCTTCGGCGGCAGGAGAGGGACCGAGTGGAACAGGAA TATGTGGCTTCAGCTATGCACGGGGACAGCCATGACCGGTATGAGCGTCTCACCTCT GTCTCCAGCTCCGTTGACTTTGACCAAAGGGACAATGGTTTCTGTTCCTGGCTGACA GCCATCTTCAGGATAAAGGATGATGAGATCCGGGACAAATGTGGGGGCGATGCCGT GCACTACCTGTCCTTTCAGCGGCACATCATCGGGCTGCTGGTGGTTGTGGGCGTCCT CTCCGTAGGCATCGTGCTGCCTGTCAACTTCTCAGGGGACCTGCTGGAGAACAATGC CTACAGCTTTGGGAGAACCACCATTGCCAACTTGAAATCAGGGAACAACCTGCTATG GCTGCACACCTCCTTCGCCTTCCTGTATCTGCTGCTCACCGTCTACAGCATGCGTAGA CACACCTCCAAGATGCGCTACAAGGAGGATGATCTGGTGAAGCGGACCCTCTTCAT CAATGGAATCTCCAAATATGCAGAGTCAGAAAAGATCAAGAAGCATTTTGAGGAAG CCTACCCCAACTGCACAGTTCTCGAAGCCCGCCCGTGTTACAACGTGGCTCGCCTAA TGTTCCTCGATGCAGAGAGGAAGAAGGCCGAGCGGGGAAAGCTGTACTTCACAAAC CTCCAGAGCAAGGAGAACGTGCCTACCATGATCAACCCCAAGCCCTGTGGCCACCT CTGCTGCTGTGTGGTGCGAGGCTGTGAGCAGGTGGAGGCCATTGAGTACTACACAA AGCTGGAGCAGAAGCTGAAGGAAGACTACAAGCGGGAGAAGGAGAAGGTGAATGA GAAGCCTCTTGGCATGGCCTTTGTCACCTTCCACAATGAGACTATCACCGCCATCAT CCTGAAGGACTTCAACGTGTGTAAATGCCAGGGCTGCACCTGCCGTGGGGAGCCAC GCCCCTCATCCTGCAGCGAGTCCCTGCACATCTCCAACTGGACCGTGTCCTATGCCC CTGACCCTCAGAACATCTACTGGGAGCACCTCTCCATCCGAGGCTTCATCTGGTGGC TGCGCTGCCTGGTCATCAATGTCGTCCTCTTCATCCTCCTCTTCTTCCTCACCACTCC AGCCATCATCATCACCACCATGGACAAGTTCAACGTCACCAAGCCTGTGGAGTACCT CAACAACCCCATCATCACCCAGTTCTTCCCCACCCTGCTGCTGTGGTGCTTCTCGGCC CTCCTTCCCACCATCGTCTACTACTCAGCCTTCTTTGAAGCCCACTGGACACGCTCTG GGGAGAACAGGACAACCATGCACAAGTGCTACACTTTCCTCATCTTCATGGTGCTGC TCCTACCCTCGCTGGGACTGAGCAGCCTGGACCTCTTCTTCCGCTGGCTCTTTGATAA GAAATTCTTGGCTGAGGCAGCTATTCGGTTTGAGTGTGTGTTCCTGCCCGACAACGG CGCCTTCTTCGTGAACTACGTCATTGCCTCAGCCTTTATCGGCAACGCCATGGACCT GCTGCGCATCCCAGGCCTGCTCATGTACATGATCCGGCTCTGCCTGGCGCGCTCGGC CGCCGAGAGGCGCAACGTGAAGCGGCATCAGGCCTACGAGTTCCAGTTTGGCGCAG CCTACGCCTGGATGATGTGCGTCTTCACGGTGGTCATGACCTACAGTATCACCTGCC CCATCATCGTGCCCTTCGGGCTCATGTACATGCTGCTGAAGCACCTGGTAGACAGGT ACAATCTCTACTACGCCTACCTGCCGGCCAAGCTGGACAAGAAGATCCACTCGGGG GCTGTGAACCAGGTGGTGGCCGCGCCCATCCTCTGCCTCTTCTGGCTGCTCTTCTTTT CCACCATGCGCACGGGGTTCCTAGCTCCCACGTCTATGTTCACATTTGTGGTCCTGGT CATCACCATCGTCATCTGTCTCTGCCACGTCTGCTTTGGACACTTCAAATACCTCAGT GCCCACAACTACAAGATTGAGCACACGGAGACAGATACTGTGGACCCCAGAAGCAA TGGACGGCCCCCCACTGCTGCTGCTGTCCCCAAATCTGCGAAATACATCGCTCAGGT GCTGCAGGACTCAGAGGTGGACGGGGATGGGGATGGGGCTCCTGGGAGCTCAGGGG ATGAGCCCCCATCATCCTCATCCCAAGATGAGGAGTTGCTGATGCCACCCGACGCCC TCACGGACACAGACTTCCAGTCTTGCGAGGACAGCCTCATAGAGAATGAGATTCAC CAGTAAGGGGAGGGAGGGGCCCTGGAGGCCACATCCTGCCCCACCCCACCCCCACT CCCACGGACACTAAAACGCTAATAATTTATTAGATCTAAAGCCCCTTCCTCCCCAGC CCCTGCTTTCATTAAGGTATTTAAACTTGGGGGTTTCACTGCTCTCCCCCATGATGGA GGGAGGGAGCCCCCCAACCTCAGTGAGGAGAGCCCCGAGCCGGCCCCGGGGCAAA GAGGGGTGCAGAGGGAGTTCCCCCAGATCAGTACCCCCCACCCCTCCCCAGCTAGT AGCATGACCAGGAGAGGGTTAATGAGAGCCAAGAGGAGTACCTGGTGCACCTGGTG CCGGTGGCTGGAGACCTGGGGGGCAGGTGGATCTGGGGCTGTTCCCCCCCCTCCGTT TTTTCCACCCCACAGTTCCTCCTGGGATCTGGCCCTCCAGGGAAGTGGAGCCTCCAG CCCCTAGGGGATGCATGAGGGGGGAGGGGGTGCTGAGTGGGAGGAAGAGTCAGGC TCACAGCTGGGGTGGCCTGGGGGTGGGGGTGGGCAAGGCTGACACTGGAAAATGGG TTTTTGCACTGTTTTTTTTTTGGTTTTTTTGTTCTTTTTTGTTTTTTTCCTTTAAAATAA AAACAAAGAAAAGCTCTGAAAAAAAAAAAAAAAAA ALOX5 (SEQ ID NO: 8; GenBank NM_000698.3). CCGGGGCCAGGGACCAGTGGTGGGAGGAGGCTGCGGCGCTAGATGCGGACACCTG GACCGCCGCGCCGAGGCTCCCGGCGCTCGCTGCTCCCGCGGCCCGCGCCATGCCCTC CTACACGGTCACCGTGGCCACTGGCAGCCAGTGGTTCGCCGGCACTGACGACTACAT CTACCTCAGCCTCGTGGGCTCGGCGGGCTGCAGCGAGAAGCACCTGCTGGACAAGC CCTTCTACAACGACTTCGAGCGTGGCGCGGTGGATTCATACGACGTGACTGTGGACG AGGAACTGGGCGAGATCCAGCTGGTCAGAATCGAGAAGCGCAAGTACTGGCTGAAT GACGACTGGTACCTGAAGTACATCACGCTGAAGACGCCCCACGGGGACTACATCGA GTTCCCCTGCTACCGCTGGATCACCGGCGATGTCGAGGTTGTCCTGAGGGATGGACG CGCAAAGTTGGCCCGAGATGACCAAATTCACATTCTCAAGCAACACCGACGTAAAG AACTGGAAACACGGCAAAAACAATATCGATGGATGGAGTGGAACCCTGGCTTCCCC TTGAGCATCGATGCCAAATGCCACAAGGATTTACCCCGTGATATCCAGTTTGATAGT GAAAAAGGAGTGGACTTTGTTCTGAATTACTCCAAAGCGATGGAGAACCTGTTCATC AACCGCTTCATGCACATGTTCCAGTCTTCTTGGAATGACTTCGCCGACTTTGAGAAA ATCTTTGTCAAGATCAGCAACACTATTTCTGAGCGGGTCATGAATCACTGGCAGGAA GACCTGATGTTTGGCTACCAGTTCCTGAATGGCTGCAACCCTGTGTTGATCCGGCGC TGCACAGAGCTGCCCGAGAAGCTCCCGGTGACCACGGAGATGGTAGAGTGCAGCCT GGAGCGGCAGCTCAGCTTGGAGCAGGAGGTCCAGCAAGGGAACATTTTCATCGTGG ACTTTGAGCTGCTGGATGGCATCGATGCCAACAAAACAGACCCCTGCACACTCCAGT TCCTGGCCGCTCCCATCTGCTTGCTGTATAAGAACCTGGCCAACAAGATTGTCCCCA TTGCCATCCAGCTCAACCAAATCCCGGGAGATGAGAACCCTATTTTCCTCCCTTCGG ATGCAAAATACGACTGGCTTTTGGCCAAAATCTGGGTGCGTTCCAGTGACTTCCACG TCCACCAGACCATCACCCACCTTCTGCGAACACATCTGGTGTCTGAGGTTTTTGGCA TTGCAATGTACCGCCAGCTGCCTGCTGTGCACCCCATTTTCAAGCTGCTGGTGGCAC ACGTGAGATTCACCATTGCAATCAACACCAAGGCCCGTGAGCAGCTCATCTGCGAG TGTGGCCTCTTTGACAAGGCCAACGCCACAGGGGGCGGTGGGCACGTGCAGATGGT GCAGAGGGCCATGAAGGACCTGACCTATGCCTCCCTGTGCTTTCCCGAGGCCATCAA GGCCCGGGGCATGGAGAGCAAAGAAGACATCCCCTACTACTTCTACCGGGACGACG GGCTCCTGGTGTGGGAAGCCATCAGGACGTTCACGGCCGAGGTGGTAGACATCTAC TACGAGGGCGACCAGGTGGTGGAGGAGGACCCGGAGCTGCAGGACTTCGTGAACGA TGTCTACGTGTACGGCATGCGGGGCCGCAAGTCCTCAGGCTTCCCCAAGTCGGTCAA GAGCCGGGAGCAGCTGTCGGAGTACCTGACCGTGGTGATCTTCACCGCCTCCGCCCA GCACGCCGCGGTCAACTTCGGCCAGTACGACTGGTGCTCCTGGATCCCCAATGCGCC CCCAACCATGCGAGCCCCGCCACCGACTGCCAAGGGCGTGGTGACCATTGAGCAGA TCGTGGACACGCTGCCCGACCGCGGCCGCTCCTGCTGGCATCTGGGTGCAGTGTGGG CGCTGAGCCAGTTCCAGGAAAACGAGCTGTTCCTGGGCATGTACCCAGAAGAGCAT TTTATCGAGAAGCCTGTGAAGGAAGCCATGGCCCGATTCCGCAAGAACCTCGAGGC CATTGTCAGCGTGATTGCTGAGCGCAACAAGAAGAAGCAGCTGCCATATTACTACTT GTCCCCAGACCGGATTCCGAACAGTGTGGCCATCTGAGCACACTGCCAGTCTCACTG TGGGAAGGCCAGCTGCCCCAGCCAGATGGACTCCAGCCTGCCTGGCAGGCTGTCTG GCCAGGCCTCTTGGCAGTCACATCTCTTCCTCCGAGGCCAGTACCTTTCCATTTATTC TTTGATCTTCAGGGAACTGCATAGATTGATCAAAGTGTAAACACCATAGGGACCCAT TCTACACAGAGCAGGACTGCACAGCGTCCTGTCCACACCCAGCTCAGCATTTCCACA CCAAGCAGCAACAGCAAATCACGACCACTGATAGATGTCTATTCTTGTTGGAGACAT GGGATGATTATTTTCTGTTCTATTTGTGCTTAGTCCAATTCCTTGCACATAGTAGGTA CCCAATTCAATTACTATTGAATGAATTAAGAATTGGTTGCCATAAAAATAAATCAGT TCATTTAAAATGAAAAAAAAAAAAAAAAAAAA CAMK4 (SEQ ID NO: 9; GenBank NM_001744.4). AGTCTCCCTCCAGCGGGCGGCGACTCCGGGTTCCCCCTCGCGCCCTCTCGCAGAGGC TCGCCCCCTTCCCCGCCCACCGTCCCTGCGAGCGCGGGCGGCGGCGGTGGGCGTGTG CGCGCGTGAAGGACGCCGCCTCTCTCTCGCTCCTGCGTTCGCAGGCGGCGGCTGGCG GCCGGCTTCTCGCTCGGGCAGCGGCGGCGGCGGCGGCGGCGGCTTCCGGAGTCCCG CTGCGAAGATGCTCAAAGTCACGGTGCCCTCCTGCTCCGCCTCGTCCTGCTCTTCGG TCACCGCCAGTGCGGCCCCGGGGACCGCGAGCCTCGTCCCGGATTACTGGATCGAC GGCTCCAACAGGGATGCGCTGAGCGATTTCTTCGAGGTGGAGTCGGAGCTGGGACG GGGTGCTACATCCATTGTGTACAGATGCAAACAGAAGGGGACCCAGAAGCCTTATG CTCTCAAAGTGTTAAAGAAAACAGTGGACAAAAAAATCGTAAGAACTGAGATAGGA GTTCTTCTTCGCCTCTCACATCCAAACATTATAAAACTTAAAGAGATATTTGAAACC CCTACAGAAATCAGTCTGGTCCTAGAACTCGTCACAGGAGGAGAACTGTTTGATAG GATTGTGGAAAAGGGATATTACAGTGAGCGAGATGCTGCAGATGCCGTTAAACAAA TCCTGGAGGCAGTTGCTTATCTACATGAAAATGGGATTGTCCATCGTGATCTCAAAC CAGAGAATCTTCTTTATGCAACTCCAGCCCCAGATGCACCACTCAAAATCGCTGATT TTGGACTCTCTAAAATTGTGGAACATCAAGTGCTCATGAAGACAGTATGTGGAACCC CAGGGTACTGCGCACCTGAAATTCTTAGAGGTTGTGCCTATGGACCTGAGGTGGACA TGTGGTCTGTAGGAATAATCACCTACATCTTACTTTGTGGATTTGAACCATTCTATGA TGAAAGAGGCGATCAGTTCATGTTCAGGAGAATTCTGAATTGTGAATATTACTTTAT CTCCCCCTGGTGGGATGAAGTATCTCTAAATGCCAAGGACTTGGTCAGAAAATTAAT TGTTTTGGATCCAAAGAAACGGCTGACTACATTTCAAGCTCTCCAGCATCCGTGGGT CACAGGTAAAGCAGCCAATTTTGTACACATGGATACCGCTCAAAAGAAGCTCCAAG AATTCAATGCCCGGCGTAAGCTTAAGGCAGCGGTGAAGGCTGTGGTGGCCTCTTCCC GCCTGGGAAGTGCCAGCAGCAGCCATGGCAGCATCCAGGAGAGCCACAAGGCTAGC CGAGACCCTTCTCCAATCCAAGATGGCAACGAGGACATGAAAGCTATTCCAGAAGG AGAGAAAATTCAAGGCGATGGGGCCCAAGCCGCAGTTAAGGGGGCACAGGCTGAG CTGATGAAGGTGCAAGCCTTAGAGAAAGTTAAAGGTGCAGATATAAATGCTGAAGA GGCCCCCAAAATGGTGCCCAAGGCAGTGGAGGATGGGATAAAGGTGGCTGACCTGG AACTAGAGGAGGGCCTAGCAGAGGAGAAGCTGAAGACTGTGGAGGAGGCAGCAGC TCCCAGAGAAGGGCAAGGAAGCTCTGCTGTGGGTTTTGAAGTTCCACAGCAAGATG TGATCCTGCCAGAGTACTAAACAGCTTCCTTCAGATCTGGAAGCCAAACACCGGCAT TTTATGTACTTTGTCCTTCAGCAAGAAAGGTGTGGAAGCATGATATGTACTATAGTG ATTCTGTTTTTGAGGTGCAAAAAACATACATATATACCAGTTGGTAATTCTAACTTC AATGCATGTGACTGCTTTATGAAAATAATAGTGTCTTCTATGGCATGTAATGGATAC CTAATACCGATGAGTTAAATCTTGCAAGTTAACACAACGTAACACTTAAAAGCATAC ATTTTCAGCAACCAGTGGCACATATTTGAAGTGAATAGTAGCAAATTGTTTTTGCTTT GAAAATCTAGCCATCCTACATCCTTTGGATTTCTTCACAAGGCAGTAATTCCTTTGAA CTACTGCTTAGCTAATACTAGGTAGTGCTAAAAGACATGTTCCCATAACTTTTACAA CATTTTACTTTTTATCATTGATGTGTTCAAACTGTTTACAAGGAGATGCTTATAGATG ATAGTTGTACATATGTGCAAAAAAAAATCCACTTGCAATGGTAAGAAATTGAAGTA TCCTTAAAGGCCATGAAGCCATATGTCCCTAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAA CDKN1A (SEQ ID NO: 10; NM_000389.4). GTTGTATATCAGGGCCGCGCTGAGCTGCGCCAGCTGAGGTGTGAGCAGCTGCCGAA GTCAGTTCCTTGTGGAGCCGGAGCTGGGCGCGGATTCGCCGAGGCACCGAGGCACT CAGAGGAGGCGCCATGTCAGAACCGGCTGGGGATGTCCGTCAGAACCCATGCGGCA GCAAGGCCTGCCGCCGCCTCTTCGGCCCAGTGGACAGCGAGCAGCTGAGCCGCGAC TGTGATGCGCTAATGGCGGGCTGCATCCAGGAGGCCCGTGAGCGATGGAACTTCGA CTTTGTCACCGAGACACCACTGGAGGGTGACTTCGCCTGGGAGCGTGTGCGGGGCCT TGGCCTGCCCAAGCTCTACCTTCCCACGGGGCCCCGGCGAGGCCGGGATGAGTTGG GAGGAGGCAGGCGGCCTGGCACCTCACCTGCTCTGCTGCAGGGGACAGCAGAGGAA GACCATGTGGACCTGTCACTGTCTTGTACCCTTGTGCCTCGCTCAGGGGAGCAGGCT GAAGGGTCCCCAGGTGGACCTGGAGACTCTCAGGGTCGAAAACGGCGGCAGACCAG CATGACAGATTTCTACCACTCCAAACGCCGGCTGATCTTCTCCAAGAGGAAGCCCTA ATCCGCCCACAGGAAGCCTGCAGTCCTGGAAGCGCGAGGGCCTCAAAGGCCCGCTC TACATCTTCTGCCTTAGTCTCAGTTTGTGTGTCTTAATTATTATTTGTGTTTTAATTTA AACACCTCCTCATGTACATACCCTGGCCGCCCCCTGCCCCCCAGCCTCTGGCATTAG AATTATTTAAACAAAAACTAGGCGGTTGAATGAGAGGTTCCTAAGAGTGCTGGGCA TTTTTATTTTATGAAATACTATTTAAAGCCTCCTCATCCCGTGTTCTCCTTTTCCTCTC TCCCGGAGGTTGGGTGGGCCGGCTTCATGCCAGCTACTTCCTCCTCCCCACTTGTCC GCTGGGTGGTACCCTCTGGAGGGGTGTGGCTCCTTCCCATCGCTGTCACAGGCGGTT ATGAAATTCACCCCCTTTCCTGGACACTCAGACCTGAATTCTTTTTCATTTGAGAAGT AAACAGATGGCACTTTGAAGGGGCCTCACCGAGTGGGGGCATCATCAAAAACTTTG GAGTCCCCTCACCTCCTCTAAGGTTGGGCAGGGTGACCCTGAAGTGAGCACAGCCTA GGGCTGAGCTGGGGACCTGGTACCCTCCTGGCTCTTGATACCCCCCTCTGTCTTGTG AAGGCAGGGGGAAGGTGGGGTCCTGGAGCAGACCACCCCGCCTGCCCTCATGGCCC CTCTGACCTGCACTGGGGAGCCCGTCTCAGTGTTGAGCCTTTTCCCTCTTTGGCTCCC CTGTACCTTTTGAGGAGCCCCAGCTACCCTTCTTCTCCAGCTGGGCTCTGCAATTCCC CTCTGCTGCTGTCCCTCCCCCTTGTCCTTTCCCTTCAGTACCCTCTCAGCTCCAGGTG GCTCTGAGGTGCCTGTCCCACCCCCACCCCCAGCTCAATGGACTGGAAGGGGAAGG GACACACAAGAAGAAGGGCACCCTAGTTCTACCTCAGGCAGCTCAAGCAGCGACCG CCCCCTCCTCTAGCTGTGGGGGTGAGGGTCCCATGTGGTGGCACAGGCCCCCTTGAG TGGGGTTATCTCTGTGTTAGGGGTATATGATGGGGGAGTAGATCTTTCTAGGAGGGA GACACTGGCCCCTCAAATCGTCCAGCGACCTTCCTCATCCACCCCATCCCTCCCCAG TTCATTGCACTTTGATTAGCAGCGGAACAAGGAGTCAGACATTTTAAGATGGTGGCA GTAGAGGCTATGGACAGGGCATGCCACGTGGGCTCATATGGGGCTGGGAGTAGTTG TCTTTCCTGGCACTAACGTTGAGCCCCTGGAGGCACTGAAGTGCTTAGTGTACTTGG AGTATTGGGGTCTGACCCCAAACACCTTCCAGCTCCTGTAACATACTGGCCTGGACT GTTTTCTCTCGGCTCCCCATGTGTCCTGGTTCCCGTTTCTCCACCTAGACTGTAAACC TCTCGAGGGCAGGGACCACACCCTGTACTGTTCTGTGTCTTTCACAGCTCCTCCCAC AATGCTGAATATACAGCAGGTGCTCAATAAATGATTCTTAGTGACTTTACTTGTAAA AAAAAAAAAAAAAAA COCH (SEQ ID NO: 11; AY358900.1). GGGGCCTTGCCTTCCGCACTCGGGCGCAGCCGGGTGGATCTCGAGCAGGTGCGGAG CCCCGGGCGGCGGGCGCGGGTGCGAGGGATCCCTGACGCCTCTGTCCCTGTTTCTTT GTCGCTCCCAGCCTGTCTGTCGTCGTTTTGGCGCCCCCGCCTCCCCGCGGTGCGGGG TTGCACACCGATCCTGGGCTTCGCTCGATTTGCCGCCGAGGCGCCTCCCAGACCTAG AGGGGCGCTGGCCTGGAGCAGCGGGTCGTCTGTGTCCTCTCTCCTCTGCGCCGCGCC CGGGGATCCGAAGGGTGCGGGGCTCTGAGGAGGTGACGCGCGGGGCCTCCCGCACC CTGGCCTTGCCCGCATTCTCCCTCTCTCCCAGGTGTGAGCAGCCTATCAGTCACCATG TCCGCAGCCTGGATCCCGGCTCTCGGCCTCGGTGTGTGTCTGCTGCTGCTGCCGGGG CCCGCGGGCAGCGAGGGAGCCGCTCCCATTGCTATCACATGTTTTACCAGAGGCTTG GACATCAGGAAAGAGAAAGCAGATGTCCTCTGCCCAGGGGGCTGCCCTCTTGAGGA ATTCTCTGTGTATGGGAACATAGTATATGCTTCTGTATCGAGCATATGTGGGGCTGC TGTCCACAGGGGAGTAATCAGCAACTCAGGGGGACCTGTACGAGTCTATAGCCTAC CTGGTCGAGAAAACTATTCCTCAGTAGATGCCAATGGCATCCAGTCTCAAATGCTTT CTAGATGGTCTGCTTCTTTCACAGTAACTAAAGGCAAAAGTAGTACACAGGAGGCC ACAGGACAAGCAGTGTCCACAGCACATCCACCAACAGGTAAACGACTAAAGAAAA CACCCGAGAAGAAAACTGGCAATAAAGATTGTAAAGCAGACATTGCATTTCTGATT GATGGAAGCTTTAATATTGGGCAGCGCCGATTTAATTTACAGAAGAATTTTGTTGGA AAAGTGGCTCTAATGTTGGGAATTGGAACAGAAGGACCACATGTGGGCCTTGTTCA AGCCAGTGAACATCCCAAAATAGAATTTTACTTGAAAAACTTTACATCAGCCAAAG ATGTTTTGTTTGCCATAAAGGAAGTAGGTTTCAGAGGGGGTAATTCCAATACAGGAA AAGCCTTGAAGCATACTGCTCAGAAATTCTTCACGGTAGATGCTGGAGTAAGAAAA GGGATCCCCAAAGTGGTGGTGGTATTTATTGATGGTTGGCCTTCTGATGACATCGAG GAAGCAGGCATTGTGGCCAGAGAGTTTGGTGTCAATGTATTTATAGTTTCTGTGGCC AAGCCTATCCCTGAAGAACTGGGGATGGTTCAGGATGTCACATTTGTTGACAAGGCT GTCTGTCGGAATAATGGCTTCTTCTCTTACCACATGCCCAACTGGTTTGGCACCACA AAATACGTAAAGCCTCTGGTACAGAAGCTGTGCACTCATGAACAAATGATGTGCAG CAAGACCTGTTATAACTCAGTGAACATTGCCTTTCTAATTGATGGCTCCAGCAGTGT TGGAGATAGCAATTTCCGCCTCATGCTTGAATTTGTTTCCAACATAGCCAAGACTTTT GAAATCTCGGACATTGGTGCCAAGATAGCTGCTGTACAGTTTACTTATGATCAGCGC ACGGAGTTCAGTTTCACTGACTATAGCACCAAAGAGAATGTCCTAGCTGTCATCAGA AACATCCGCTATATGAGTGGTGGAACAGCTACTGGTGATGCCATTTCCTTCACTGTT AGAAATGTGTTTGGCCCTATAAGGGAGAGCCCCAACAAGAACTTCCTAGTAATTGTC ACAGATGGGCAGTCCTATGATGATGTCCAAGGCCCTGCAGCTGCTGCACATGATGCA GGAATCACTATCTTCTCTGTTGGTGTGGCTTGGGCACCTCTGGATGACCTGAAAGAT ATGGCTTCTAAACCGAAGGAGTCTCACGCTTTCTTCACAAGAGAGTTCACAGGATTA GAACCAATTGTTTCTGATGTCATCAGAGGCATTTGTAGAGATTTCTTAGAATCCCAG CAATAATGGTAACATTTTGACAACTGAAAGAAAAAGTACAAGGGGATCCAGTGTGT AAATTGTATTCTCATAATACTGAAATGCTTTAGCATACTAGAATCAGATACAAAACT ATTAAGTATGTCAACAGCCATTTAGGCAAATAAGCACTCCTTTAAAGCCGCTGCCTT CTGGTTACAATTTACAGTGTACTTTGTTAAAAACACTGCTGAGGCTTCATAATCATG GCTCTTAGAAACTCAGGAAAGAGGAGATAATGTGGATTAAAACCTTAAGAGTTCTA ACCATGCCTACTAAATGTACAGATATGCAAATTCCATAGCTCAATAAAAGAATCTGA TACTTAGACCAAAAAAAAAAA DHRS4 (SEQ ID NO: 12; NM_021004.3). CTACTCTGTCACCGCCCCTGGGAAGAGTGGAACCCATACTTGCTGGTCTGATCCATG CACAAGGCGGGGCTGCTAGGCCTCTGTGCCCGGGCTTGGAATTCGGTGCGGATGGC CAGCTCCGGGATGACCCGCCGGGACCCGCTCGCAAATAAGGTGGCCCTGGTAACGG CCTCCACCGACGGGATCGGCTTCGCCATCGCCCGGCGTTTGGCCCAGGACGGGGCCC ATGTGGTCGTCAGCAGCCGGAAGCAGCAGAATGTGGACCAGGCGGTGGCCACGCTG CAGGGGGAGGGGCTGAGCGTGACGGGCACCGTGTGCCATGTGGGGAAGGCGGAGG ACCGGGAGCGGCTGGTGGCCACGGCTGTGAAGCTTCATGGAGGTATCGATATCCTA GTCTCCAATGCTGCTGTCAACCCTTTCTTTGGAAGCATAATGGATGTCACTGAGGAG GTGTGGGACAAGACTCTGGACATTAATGTGAAGGCCCCAGCCCTGATGACAAAGGC AGTGGTGCCAGAAATGGAGAAACGAGGAGGCGGCTCAGTGGTGATCGTGTCTTCCA TAGCAGCCTTCAGTCCATCTCCTGGCTTCAGTCCTTACAATGTCAGTAAAACAGCCTT GCTGGGCCTGACCAAGACCCTGGCCATAGAGCTGGCCCCAAGGAACATTAGGGTGA ACTGCCTAGCACCTGGACTTATCAAGACTAGCTTCAGCAGGATGCTCTGGATGGACA AGGAAAAAGAGGAAAGCATGAAAGAAACCCTGCGGATAAGAAGGTTAGGCGAGCC AGAGGATTGTGCTGGCATCGTGTCTTTCCTGTGCTCTGAAGATGCCAGCTACATCAC TGGGGAAACAGTGGTGGTGGGTGGAGGAACCCCGTCCCGCCTCTGAGGACCGGGAG ACAGCCCACAGGCCAGAGTTGGGCTCTAGCTCCTGGTGCTGTTCCCGCATTCACCCA CTGGCCTTTCCCACCTCTGCTCACCTTACTGTTCACCTCATCAAATCAGTTCTGCCCT GTGAAAAGATCCAGCCTTCCCTGCCGTCAAGGTGGCGTCTTACTCGGGATTTCTGCT GTTGTTGTGGCCTTGGGTAAAGGCCTCCCCTGAGAACACAGGACAGGCCTGCTGACA AGGCTGAGTCTACCTTGGCAAAGACCAAGATATTTTTTCCCGGGCCACTGGGGAATC TGAGGGGTGATGGGAGAGAAGGAACCTGGAGTGGAAGGAGCAGAGTTGCAAATTA ACAACTTGCAAATGAGGTGCAAATAAAATGCAGATGATTGCGCGGCTTTGAATCCA AAAAAAAAAAAAAAAAA MICAL1 (SEQ ID NO: 13; NM_022765.3). CCCAAGACTGTCCCCGCTGGAGGCGGTAGAGGGATCCAGAAGTAATGAGATGCTAA TGAGTCGCGAATAAAGCCCGGGCGGCGCCCCGCGCCCCTCGCGGAAGCCCACACTC CGCGCGACTCCAGGCGCACGCCCCGGGCCGCCCCGCATCCCAGCATCCCCGCCCGA TCTCGGCGTTTCCGCCCCCGCCCCCGCCCCCGCCCTCCCACCCGCTCAGACCTGGTTG CCAGCCCAACAGGAAGCGGCCCCTCCCGGCTTCGGAGCCGCCGCCACTCATCTCTGC CCAGCTGCTGCCCTCCCCAGGAGGCCTCCATGGCTTCACCTACCTCCACCAACCCAG CGCATGCCCACTTTGAGAGCTTCCTGCAGGCCCAGCTGTGCCAGGACGTGCTGAGCA GCTTCCAGGAGCTGTGTGGGGCCCTGGGGCTGGAACCCGGTGGGGGGCTGCCCCAG TACCACAAGATCAAGGACCAGCTCAACTACTGGAGCGCCAAGTCACTGTGGACCAA GCTGGACAAGCGAGCAGGCCAGCCTGTCTACCAGCAGGGCCGGGCCTGCACCAGCA CCAAGTGCCTGGTGGTGGGTGCTGGACCTTGCGGGCTGCGGGTCGCTGTGGAGCTGG CGCTGCTGGGGGCCCGAGTGGTGCTGGTGGAAAAGCGCACCAAGTTCTCTCGCCAC AACGTGCTCCACCTCTGGCCCTTCACCATCCACGACCTGCGGGCACTCGGTGCTAAG AAGTTCTACGGGCGCTTCTGCACCGGCACCCTGGACCACATCAGCATCAGGCAGCTC CAGCTGCTTCTGCTGAAGGTAGCATTGCTGCTGGGGGTGGAAATTCACTGGGGTGTC ACTTTCACTGGCCTCCAGCCCCCTCCTAGGAAGGGGAGTGGCTGGCGTGCCCAGCTC CAACCCAACCCCCCTGCCCAGCTGGCCAACTATGAATTTGACGTCCTTATCTCGGCT GCAGGAGGTAAATTCGTCCCTGAAGGCTTCAAAGTTCGAGAAATGCGAGGCAAACT GGCCATTGGCATCACAGCCAACTTTGTGAATGGACGCACCGTGGAGGAGACACAGG TGCCGGAGATCAGTGGTGTAGCCAGGATCTACAACCAGAGCTTCTTCCAGAGCCTTC TCAAAGCCACAGGCATTGATCTGGAGAACATTGTGTACTACAAGGACGACACCCAC TACTTTGTGATGACAGCCAAGAAGCAGTGCCTGCTGCGGCTGGGGGTGCTGCGCCA GGACTGGCCAGACACCAATCGGCTGCTGGGCAGTGCCAATGTGGTGCCCGAGGCTC TGCAGCGCTTTACCCGGGCAGCTGCTGACTTTGCCACCCATGGCAAGCTCGGGAAAC TAGAGTTTGCCCAGGATGCCCATGGGCAGCCTGATGTCTCTGCCTTTGACTTCACGA GCATGATGCGGGCAGAGAGTTCTGCTCGTGTGCAAGAGAAGCATGGCGCCCGCCTG CTGCTGGGACTGGTGGGGGACTGCCTGGTGGAGCCCTTCTGGCCCCTGGGCACTGGA GTGGCACGGGGCTTCCTGGCAGCCTTTGATGCAGCCTGGATGGTGAAGCGGTGGGC AGAGGGCGCTGAGTCCCTAGAGGTGTTGGCTGAGCGTGAGAGCCTGTACCAGCTTCT GTCACAGACATCCCCAGAAAACATGCATCGCAATGTGGCCCAGTATGGGCTGGACC CAGCCACCCGCTACCCCAACCTGAACCTCCGGGCAGTGACCCCCAATCAGGTACGA GACCTGTATGATGTGCTAGCCAAGGAGCCTGTGCAGAGGAACAACGACAAGACAGA TACAGGGATGCCAGCCACCGGGTCGGCAGGCACCCAGGAGGAGCTGCTACGCTGGT GCCAGGAGCAGACAGCTGGGTACCCGGGAGTCCACGTCTCCGATTTGTCTTCCTCCT GGGCTGATGGGCTAGCTCTGTGTGCCCTGGTGTACCGGCTGCAGCCTGGCCTGCTGG AACCCTCAGAGCTGCAGGGGCTGGGAGCTCTGGAAGCAACTGCTTGGGCACTAAAG GTGGCAGAGAATGAGCTGGGCATCACACCGGTGGTGTCTGCACAGGCCGTGGTAGC AGGGAGTGACCCACTGGGCCTCATTGCCTACCTCAGCCACTTCCACAGTGCCTTCAA GAGCATGGCCCACAGCCCAGGCCCTGTCAGCCAGGCCTCCCCAGGGACCTCCAGTG CTGTATTATTCCTTAGTAAACTTCAGAGGACCCTGCAGCGATCCCGGGCCAAGGAAA ATGCAGAGGATGCTGGTGGCAAGAAGCTGCGCTTGGAGATGGAGGCCGAGACCCCA AGTACTGAGGTGCCACCTGACCCAGAGCCTGGTGTACCCCTGACACCCCCATCCCAA CACCAGGAGGCCGGTGCTGGGGACCTGTGTGCACTTTGTGGGGAACACCTCTATGTC CTGGAACGCCTCTGTGTCAACGGCCATTTCTTCCACCGGAGCTGCTTCCGCTGCCAT ACCTGTGAGGCCACACTGTGGCCAGGTGGCTACGAGCAGCACCCAGGAGATGGACA TTTCTACTGCCTCCAGCACCTGCCCCAGACAGACCACAAAGCGGAAGGCAGCGATA GAGGCCCTGAGAGTCCGGAGCTCCCCACACCAAGTGAGAATAGCATGCCACCAGGC CTCTCAACTCCCACAGCCTCGCAGGAGGGGGCCGGTCCTGTTCCAGATCCCAGCCAG CCCACCCGTCGGCAGATCCGCCTCTCCAGCCCGGAGCGCCAGCGGTTGTCCTCCCTT AACCTTACCCCTGACCCGGAAATGGAGCCTCCACCCAAGCCTCCCCGCAGCTGCTCC GCCTTGGCCCGCCACGCCCTGGAGAGCAGCTTTGTGGGCTGGGGCCTGCCAGTCCAG AGCCCTCAAGCTCTTGTGGCCATGGAGAAGGAGGAAAAAGAGAGTCCCTTCTCCAG TGAAGAGGAAGAAGAAGATGTGCCTTTGGACTCAGATGTGGAACAGGCCCTGCAGA CCTTTGCCAAGACCTCAGGCACCATGAATAACTACCCAACATGGCGTCGGACTCTGC TGCGCCGTGCGAAGGAGGAGGAGATGAAGAGGTTCTGCAAGGCCCAGACCATCCAA CGGCGACTAAATGAGATTGAGGCTGCCTTGAGGGAGCTAGAGGCCGAGGGCGTGAA GCTGGAGCTGGCCTTGAGGCGCCAGAGCAGTTCCCCAGAACAGCAAAAGAAACTAT GGGTAGGACAGCTGCTACAGCTCGTTGACAAGAAAAACAGCCTGGTGGCTGAGGAG GCCGAGCTCATGATCACGGTGCAGGAATTGAATCTGGAGGAGAAACAGTGGCAGCT GGACCAGGAGCTACGAGGCTACATGAACCGGGAAGAAAACCTAAAGACAGCTGCT GATCGGCAGGCTGAGGACCAGGTCCTGAGGAAGCTGGTGGATTTGGTCAACCAGAG AGATGCCCTCATCCGCTTCCAGGAGGAGCGCAGGCTCAGCGAGCTGGCCTTGGGGA CAGGGGCCCAGGGCTAGACGAGGGTGGGCCGTCTGCTTTCGTTCCCACAAAGAAAG CACCTCACCCCAGCACAGTGCCACCCCTGTTCATCTGGGCTGCCTGGCAGAGAGCCT TGCTGTTTACAATTAAAATGTTTCTGCCACAAAAAAAAAAAAAAAAAAA MOB3B (SEQ ID NO: 14; AJ580636.1). ATGTCCATAGCCCTGAAGCAGGTATTCAACAAGGACAAGACCTTCCGACCCAAGAG GAAATTTGAACCTGGCACACAGAGGTTTGAGCTGCACAAACGGGCTCAGGCATCCC TCAACTCGGGTGTGGACCTGAAGGCGGCTGTGCAGTTGCCCAGTGGGGAGGACCAG AATGACTGGGTGGCAGTACATGTGGTGGACTTCTTCAATCGGATCAACCTCATCTAT GGCACCATCTGTGAGTTCTGCACCGAGCGGACCTGTCCTGTGATGTCAGGGGGCCCC AAATATGAGTATCGGTGGCAGGATGATCTCAAGTATAAGAAGCCAACAGCGCTGCC AGCTCCCCAGTACATGAACCTTCTTATGGATTGGATTGAGGTTCAGATCAACAACGA GGAAATATTTCCAACATGCGTGGGTGTTCCCTTCCCAAAGAACTTCCTTCAGATCTG CAAGAAGATCCTGTGCCGCCTTTTCCGGGTCTTTGTCCACGTCTATATCCACCACTTC GACCGGGTCATTGTGATGGGTGCAGAGGCCCATGTCAACACCTGCTACAAACACTTC TATTACTTTGTCACAGAGATGAACCTCATAGACCGCAAGGAGCTAGAGCCTTTGAAA GAAATGACGAGCAGGATGTGTCACTAA NUSAP1 (SEQ ID NO: 15; NM_016359.4). GCGTTACAGGCCCTTTGGCGCCTGCGTATTCGTGAAGTGTGAAAAAAGCGCGCCTCT GTTGGGACGGGAAATCAGCCTTTCTATTGGTCAGGGTTAGAAACCCCGCCTTTGAGG CATTTTCAACCAATGGAAGCGCGGCATTCTTCATTTAAACTGTCTATAAATTTCTGCC TAGTCAAAGTTAAGAGTGGCGCCAGGGATTTGAACCGCGCTGACGAAGTTTGGTGA TCCATCTTCCGAGTATCGCCGGGATTTCGAATCGCGATGATCATCCCCTCTCTAGAG GAGCTGGACTCCCTCAAGTACAGTGACCTGCAGAACTTAGCCAAGAGTCTGGGTCTC CGGGCCAACCTGAGGGCAACCAAGTTGTTAAAAGCCTTGAAAGGCTACATTAAACA TGAGGCAAGAAAAGGAAATGAGAATCAGGATGAAAGTCAAACTTCTGCATCCTCTT GTGATGAGACTGAGATACAGATCAGCAACCAGGAAGAAGCTGAGAGACAGCCACTT GGCCATGTCACCAAAACAAGGAGAAGGTGCAAGACTGTCCGTGTGGACCCTGACTC ACAGCAGAATCATTCAGAGATAAAAATAAGTAATCCCACTGAATTCCAGAATCATG AAAAGCAGGAAAGCCAGGATCTCAGAGCTACTGCAAAAGTTCCTTCTCCACCAGAC GAGCACCAAGAAGCTGAGAATGCTGTTTCCTCAGGTAACAGAGATTCAAAGGTACC TTCAGAAGGAAAGAAATCTCTCTACACAGATGAGTCATCCAAACCTGGAAAAAATA AAAGAACTGCAATCACTACTCCAAACTTTAAGAAGCTTCATGAAGCTCATTTTAAGG AAATGGAGTCCATTGATCAATATATTGAGAGAAAAAAGAAACATTTTGAAGAACAC AATTCCATGAATGAACTGAAGCAGCAGCCCATCAATAAGGGAGGGGTCAGGACTCC AGTACCTCCAAGAGGAAGACTCTCTGTGGCTTCTACTCCCATCAGCCAACGACGCTC GCAAGGCCGGTCTTGTGGCCCTGCAAGTCAGAGTACCTTGGGTCTGAAGGGGTCACT CAAGCGCTCTGCTATCTCTGCAGCTAAAACGGGTGTCAGGTTTTCAGCTGCTACTAA AGATAATGAGCATAAGCGTTCACTGACCAAGACTCCAGCCAGAAAGTCTGCACATG TGACCGTGTCTGGGGGCACCCCAAAAGGCGAGGCTGTGCTTGGGACACACAAATTA AAGACCATCACGGGGAATTCTGCTGCTGTTATTACCCCATTCAAGTTGACAACTGAG GCAACGCAGACTCCAGTCTCCAATAAGAAACCAGTGTTTGATCTTAAAGCAAGTTTG TCTCGTCCCCTCAACTATGAACCACACAAAGGAAAGCTAAAACCATGGGGGCAATC TAAAGAAAATAATTATCTAAATCAACATGTCAACAGAATTAACTTCTACAAGAAAA CTTACAAACAACCCCATCTCCAGACAAAGGAAGAGCAACGGAAGAAACGCGAGCA AGAACGAAAGGAGAAGAAAGCAAAGGTTTTGGGAATGCGAAGGGGCCTCATTTTGG CTGAAGATTAATAATTTTTTAACATCTTGTAAATATTCCTGTATTCTCAACTTTTTTCC TTTTGTAAATTTTTTTTTTTTGCTGTCATCCCCACTTTAGTCACGAGATCTTTTTCTGC TAACTGTTCATAGTCTGTGTAGTGTCCATGGGTTCTTCATGTGCTATGATCTCTGAAA AGACGTTATCACCTTAAAGCTCAAATTCTTTGGGATGGTTTTTACTTAAGTCCATTAA CAATTCAGGTTTCTAACGAGACCCATCCTAAAATTCTGTTTCTAGATTTTTAATGTCA AGTTCCCAAGTTCCCCCTGCTGGTTCTAATATTAACAGAACTGCAGTCTTCTGCTAGC CAATAGCATTTACCTGATGGCAGCTAGTTATGCAAGCTTCAGGAGAATTTGAACAAT AACAAGAATAGGGTAAGCTGGGATAGAAAGGCCACCTCTTCACTCTCTATAGAATA TAGTAACCTTTATGAAACGGGGCCATATAGTTTGGTTATGACATCAATATTTTACCT AGGTGAAATTGTTTAGGCTTATGTACCTTCGTTCAAATATCCTCATGTAATTGCCATC TGTCACTCACTATATTCACAAAAATAAAACTCTACAACTCATTCTAACATTGCTTACT TAAAAGCTACATAGCCCTATCGAAATGCGAGGATTAATGCTTTAATGCTTTTAGAGA CAGGGTCTCACTGTGTTGCCCAGGCTGGTCTCAAACTCCACCAAATGTACTTCTTATT CATTTTATGGAAAAGACTAGGCTTTGCTTAGTATCATGTCCATGTTTCCTTCACCTCA GTGGAGCTTCTGAGTTTTATACTGCTCAAGATCGTCATAAATAAAATTTTTTCTCATT GTCATAGAAAAAAAAAAAAAAAAAA IL27RA (SEQ ID NO: 16; NM_004843.3). GCGGAGGCGGCCTGCCGGGGTGGTTCGGCTTCCCGTTGCCGCCTCGGGCGCTGTACC CAGAGCTCGAAGAGGAGCAGCGCGGCCGCGCGGACCCGGCAAGGCTGGGCCGGAC TCGGGGCTCCCGAGGGACGCCATGCGGGGAGGCAGGGGCGCCCCTTTCTGGCTGTG GCCGCTGCCCAAGCTGGCGCTGCTGCCTCTGTTGTGGGTGCTTTTCCAGCGGACGCG TCCCCAGGGCAGCGCCGGGCCACTGCAGTGCTACGGAGTTGGACCCTTGGGCGACT TGAACTGCTCGTGGGAGCCTCTTGGGGACCTGGGAGCCCCCTCCGAGTTACACCTCC AGAGCCAAAAGTACCGTTCCAACAAAACCCAGACTGTGGCAGTGGCAGCCGGACGG AGCTGGGTGGCCATTCCTCGGGAACAGCTCACCATGTCTGACAAACTCCTTGTCTGG GGCACTAAGGCAGGCCAGCCTCTCTGGCCCCCCGTCTTCGTGAACCTAGAAACCCAA ATGAAGCCAAACGCCCCCCGGCTGGGCCCTGACGTGGACTTTTCCGAGGATGACCC CCTGGAGGCCACTGTCCATTGGGCCCCACCTACATGGCCATCTCATAAAGTTCTGAT CTGCCAGTTCCACTACCGAAGATGTCAGGAGGCGGCCTGGACCCTGCTGGAACCGG AGCTGAAGACCATACCCCTGACCCCTGTTGAGATCCAAGATTTGGAGCTAGCCACTG GCTACAAAGTGTATGGCCGCTGCCGGATGGAGAAAGAAGAGGATTTGTGGGGCGAG TGGAGCCCCATTTTGTCCTTCCAGACACCGCCTTCTGCTCCAAAAGATGTGTGGGTA TCAGGGAACCTCTGTGGGACGCCTGGAGGAGAGGAACCTTTGCTTCTATGGAAGGC CCCAGGGCCCTGTGTGCAGGTGAGCTACAAAGTCTGGTTCTGGGTTGGAGGTCGTGA GCTGAGTCCAGAAGGAATTACCTGCTGCTGCTCCCTAATTCCCAGTGGGGCGGAGTG GGCCAGGGTGTCCGCTGTCAACGCCACAAGCTGGGAGCCTCTCACCAACCTCTCTTT GGTCTGCTTGGATTCAGCCTCTGCCCCCCGTAGCGTGGCAGTCAGCAGCATCGCTGG GAGCACGGAGCTACTGGTGACCTGGCAACCGGGGCCTGGGGAACCACTGGAGCATG TAGTGGACTGGGCTCGAGATGGGGACCCCCTGGAGAAACTCAACTGGGTCCGGCTT CCCCCTGGGAACCTCAGTGCTCTGTTACCAGGGAATTTCACTGTCGGGGTCCCCTAT CGAATCACTGTGACCGCAGTCTCTGCTTCAGGCTTGGCCTCTGCATCCTCCGTCTGG GGGTTCAGGGAGGAATTAGCACCCCTAGTGGGGCCAACGCTTTGGCGACTCCAAGA TGCCCCTCCAGGGACCCCCGCCATAGCGTGGGGAGAGGTCCCAAGGCACCAGCTTC GAGGCCACCTCACCCACTACACCTTGTGTGCACAGAGTGGAACCAGCCCCTCCGTCT GCATGAATGTGAGTGGCAACACACAGAGTGTCACCCTGCCTGACCTTCCTTGGGGTC CCTGTGAGCTGTGGGTGACAGCATCTACCATCGCTGGACAGGGCCCTCCTGGTCCCA TCCTCCGGCTTCATCTACCAGATAACACCCTGAGGTGGAAAGTTCTGCCGGGCATCC TATTCTTGTGGGGCTTGTTCCTGTTGGGGTGTGGCCTGAGCCTGGCCACCTCTGGAA GGTGCTACCACCTAAGGCACAAAGTGCTGCCCCGCTGGGTCTGGGAGAAAGTTCCT GATCCTGCCAACAGCAGTTCAGGCCAGCCCCACATGGAGCAAGTACCTGAGGCCCA GCCCCTTGGGGACTTGCCCATCCTGGAAGTGGAGGAGATGGAGCCCCCGCCGGTTA TGGAGTCCTCCCAGCCCGCCCAGGCCACCGCCCCGCTTGACTCTGGGTATGAGAAGC ACTTCCTGCCCACACCTGAGGAGCTGGGCCTTCTGGGGCCCCCCAGGCCACAGGTTC TGGCCTGAACCACACGTCTGGCTGGGGGCTGCCAGCCAGGCTAGAGGGATGCTCAT GCAGGTTGCACCCCAGTCCTGGATTAGCCCTCTTGATGGATGAAGACACTGAGGACT CAGAGAGGCTGAGTCACTTACCTGAGGACACCCAGCCAGGCAGAGCTGGGATTGAA GGACCCCTATAGAGAAGGGCTTGGCCCCCATGGGGAAGACACGGATGGAAGGTGGA GCAAAGGAAAATACATGAAATTGAGAGTGGCAGCTGCCTGCCAAAATCTGTTCCGC TGTAACAGAACTGAATTTGGACCCCAGCACAGTGGCTCACGCCTGTAATCCCAGCAC TTTGGCAGGCCAAGGTGGAAGGATCACTTAGAGCTAGGAGTTTGAGACCAGCCTGG GCAATATAGCAAGACCCCTCACTACAAAAATAAAACATCAAAAACAAAAACAATTA GCTGGGCATGATGGCACACACCTGTAGTCCGAGCCACTTGGGAGGCTGAGGTGGGA GGATCGGTTGAGCCCAGGAGTTCGAAGCTGCAGGGACCTCTGATTGCACCACTGCA CTCCAGGCTGGGTAACAGAATGAGACCTTATCTCAAAAATAAACAAACTAATAAAA AGCAAAAAAAAAAAAAAAAAAAAAAAAAAAA HBA2 (SEQ ID NO: 17; NM_000517.4). CATAAACCCTGGCGCGCTCGCGGGCCGGCACTCTTCTGGTCCCCACAGACTCAGAGA GAACCCACCATGGTGCTGTCTCCTGCCGACAAGACCAACGTCAAGGCCGCCTGGGG TAAGGTCGGCGCGCACGCTGGCGAGTATGGTGCGGAGGCCCTGGAGAGGATGTTCC TGTCCTTCCCCACCACCAAGACCTACTTCCCGCACTTCGACCTGAGCCACGGCTCTG CCCAGGTTAAGGGCCACGGCAAGAAGGTGGCCGACGCGCTGACCAACGCCGTGGCG CACGTGGACGACATGCCCAACGCGCTGTCCGCCCTGAGCGACCTGCACGCGCACAA GCTTCGGGTGGACCCGGTCAACTTCAAGCTCCTAAGCCACTGCCTGCTGGTGACCCT GGCCGCCCACCTCCCCGCCGAGTTCACCCCTGCGGTGCACGCCTCCCTGGACAAGTT CCTGGCTTCTGTGAGCACCGTGCTGACCTCCAAATACCGTTAAGCTGGAGCCTCGGT AGCCGTTCCTCCTGCCCGCTGGGCCTCCCAACGGGCCCTCCTCCCCTCCTTGCACCG GCCCTTCCTGGTCTTTGAATAAAGTCTGAGTGGGCAGCAAAAAAAAAAAAAAAAAA PPM1F (SEQ ID NO: 18; NM_014634). AGGGACGGGAAGTGGGCGGGGCCGGCCGGCAGCAGCTTGCGGGACACGGAGCCGC GAGGAGACAGCTGAGGCCCGCGGAGACCAGGGGGTGAAGCCTGGAGACCCTCTTGC CCTGGCCTAGCTGCAGGCCCCCGGGATGCTTTGGGCATGTCCTCTGGAGCCCCACAG AAGAGCAGCCCAATGGCCAGTGGAGCTGAGGAGACCCCAGGCTTCCTGGACACGCT CCTGCAAGACTTCCCAGCCCTGCTGAACCCAGAGGACCCTCTGCCATGGAAGGCCCC AGGGACGGTGCTCAGCCAGGAGGAGGTGGAGGGCGAGCTGGCTGAGCTGGCCATG GGCTTTCTGGGCAGCAGGAAGGCCCCGCCACCACTTGCTGCTGCTCTGGCCCACGAA GCAGTTTCACAGCTGCTACAGACAGACCTTTCCGAATTCAGGAAGTTGCCCAGGGAG GAAGAAGAAGAGGAGGAGGACGATGACGAGGAGGAAAAGGCCCCTGTGACCTTGC TGGATGCCCAAAGCCTGGCACAGAGTTTCTTTAACCGCCTTTGGGAAGTCGCCGGCC AGTGGCAGAAGCAGGTGCCATTGGCTGCCCGGGCCTCACAGCGGCAGTGGCTGGTC TCCATCCACGCCATCCGGAACACTCGCCGCAAGATGGAGGACCGGCACGTGTCCCT CCCTTCCTTCAACCAGCTCTTCGGCTTGTCTGACCCTGTGAACCGCGCCTACTTTGCT GTGTTTGATGGTCACGGAGGCGTGGATGCTGCGAGGTACGCCGCTGTCCACGTGCAC ACCAACGCTGCCCGCCAGCCAGAGCTGCCCACAGACCCTGAGGGAGCCCTCAGAGA AGCCTTCCGGCGCACCGACCAGATGTTTCTCAGGAAAGCCAAGCGAGAGCGGCTGC AGAGCGGCACCACAGGTGTGTGTGCGCTCATTGCAGGAGCGACCCTGCACGTCGCC TGGCTCGGGGATTCCCAGGTCATTTTGGTACAGCAGGGACAGGTGGTGAAGCTGAT GGAGCCACACAGACCAGAACGGCAGGATGAGAAGGCGCGCATTGAAGCATTGGGT GGCTTTGTGTCTCACATGGACTGCTGGAGAGTCAACGGGACCCTGGCCGTCTCCAGA GCCATCGGGGATGTCTTCCAGAAGCCCTACGTGTCTGGGGAGGCCGATGCAGCTTCC CGGGCGCTGACGGGCTCCGAGGACTACCTGCTGCTTGCCTGTGATGGCTTCTTTGAC GTCGTACCCCACCAGGAAGTTGTTGGCCTGGTCCAGAGCCACCTGACCAGGCAGCA GGGCAGCGGGCTCCGTGTCGCCGAGGAGCTGGTGGCTGCGGCCCGGGAGCGGGGCT CCCACGACAACATCACGGTCATGGTGGTCTTCCTCAGGGACCCCCAAGAGCTGCTGG AGGGCGGGAACCAGGGAGAAGGGGACCCCCAGGCAGAAGGGAGGAGGCAGGACTT GCCCTCCAGCCTTCCAGAACCTGAGACCCAGGCTCCACCAAGAAGCTAGGTGGTTTC CAGGCCCCTGCCCTCCCCTTCCTCCCATCCTTGTCCTTCTCTCCCTCAGAAGCCTCAG GACCCAACAGGTGGCAGGCAGTGGACAGGGTGCCCGCCCCACAGTGCTTTCCCCAG CACCCCAGAGCCAGTCGGGACACCCCCCGCAGCCCGTCCTGGTGGCTGTGGAACTG CACTGGGTGGCGGGCAGATGGTGGAAGGCAGCTTAGGAGACCTCACCAAAGAGAA GATGGACCGGCTCTTGCTCCCAGCTCCTATTAGGCCCGGGGTGGGACCAGAGGTCAT AGGTGCCCAACGGCAGCCAAACCAAAGACACTGGTGTGCATGGGGCAGCATGGTTG TGCACGTGGGACCCTGGGGCGGACCCAGGAGCCAAACTCTTGAAGCACCCCCTGGG TCAGGCCCAGCAGCGGAGTGGCCAGCCCCAGTTTCCCATTGCTCCTCTCTGCGGCCA GGGCCAGGTGGGTTCATATTTACAGATATGCCCAGCCAGTCCTGGTCGGCCACACCA GTGTCCCAAAGAGGAGAGCGCAGCAGAGCCAGGGGTCTGTTCTGTAGCAGCCACCC CCCTGCCCCCACTCCAGGGCAGCCATGATGTGCTTGGGCCCACCAGGGCCTTCCGGG CTGCTCTCTTCCCTGAGCCCGGAACCGGCGACGCACATGTGTCTTTTGTTGGTGTGTT TGTTTTTTTCCAGGGAGGTCTAATTCCGAAGCAGTATTCCAGGTTTTCTCTTTGTTTT ATCAGTGCCAAGATGACCTGTTGTGTCATATAATTTAAGCAGAGCTTAGCATTTATT TTATTCTTTAGAAAACTTAAGTATTTACTTTTTTAAAGCTATTTTTCAAGGAACCTTTT TTTGCAGTATTATTGAATTTATTTTCTAAATCAGGATTGAAACAGGAACTTTTCCAGG TGGTGTTAATAAGCCATTCAAGTGCCTTACACAGCTTTGAAGAAACTAGGACTGCAG TGGGCTCGGATAGGCCCATTGAGGTTTTTAGAAAAGCAGGATTTGTTTTGTTAGGGA GGCATGATTTTGGTGAGATCTTTCTGGAAGAGTTTTCCGCCTCTTTGTGATGCTGAAC ACCCCCAAGGTTCTCCCCTCCCCCCGCTGCCCAGGTGACTGGCAGGAGCTGCGACTG CCACGTAGTGGTGCCTGGGCCCGACAGCGGGGCTCTGGGCATCCCGGGTGACCTTG GCCCATCTGCCTGCATTCCCACCCCCTTGGGCCTGGCTGGATCCCAGGCAGAGGGAC CTTGCTGCTGTGTGATTGGAACATTCCCAAATATCTTGTGAATTTGTAATCAAATTGG TCTCATTGGGAAAGACTCTTAATTAAGAGGCTCAGGCAAGCACAGAGGCAGCCCGT GGGTCTCTGTCTCAGTCTGGAGGCAGCAGGGATGCTGCTGGGAGTCCATGGCACAG GCCACAGCCCCTCACCTTGCCGCGGTGGCTGGCAGCACGCCTGCCTTGCTCTGCCCC ATGCCCTGAACAGGCATGAGAGCTCCACGTCCCCTAGTGCACCCTGAGAGGGGGCT CACAAGTGACCGATCCTGGGTGCCTCAGGGAGCTCACTGAGGGCGTGCAAAGTTGA AAGTGGCAAGGCTGGGGGAGGGTGTCGGGTAGAGGGAAGAGGGCAGGGGGCTAGG GGAGGACTCAGAGGCCATCTGCAGGGCCAAGCCACAGGAAGGGCTGAGCTGGAGG TGGGCAGGGCTGCTCCAGGCAGGTCAGAGCAGTGCAGGGGGAGGAGAGGAGAAAG GGAGGAAGCTGGGCTGTGTGGTCCCCATGAAGGCATTCAGAGTCCACCTGCAGACA GCGAGAGCCCCAGGAAGGTTTGCACAGCTGTGCCCCAAGCACCTTGGCCTCCTCTCA GCTCGCCGAGGAGGCACGCTAGAGCCGCCTTCCCGGTGGGAGCCCTCTGTCCCACA GGGAGCGGGGAGCCAGCTTTGCTGGGGCCCTACCTGCATGCCCAGCCTTACCCCTCA TTCTCACAGCACAGATGAGGTTGAGACCATGCAGTCAATGCATTGCTTAAGGTCTCT TATTTACAAAAAAAAACCTTAAACATAGTCGCTGTCATTCAGACATTCAGAGAATGG TTGGCCACAAACAATGACCAAGTATTGCTTGGCTTAACTTGAAGGCCTGCTGTCTCC TTCTGGGGGTCAGGGACGCAGCTCCACCCTCACCACTAGCCCACCCTGCCCGTGGGC ATAACCTTGACGAAGAGAGAGAATGATTGGCATCTGCTTTTCTCTTTTCTTTGCTAAT AATTCTGTTCCTGGCTGCCGAGAGTGAAGTTTCACCATGTGGAGGTTTGGCTCCTAT CACCTGGTGGTCTGATTCATACCCTAGCCTGAGGCTCCACTGGAAGATCTCGCAGCC TCAGTGTATGGGAAACCCTTTCCCCAGGCTTGTCCCAGCACTGCCGCTCCCCACCCC TGAGCCAGGACCCCAGAGGATGGCCATGCCCCGTGCCTGGCAGAGGTCTGGTGCCA GCACTGGGAGCTGCTCCGCCCTTGCCTTGGGGCCGAGGGAGCCCTCGTCCACCCCTG CACAGCAGCTGGGCACAGAGGAGCGCTCTTCCATCTTGACCAGGACTGCACCAAGA AGCACCAGGTGTCTTCAGCCTCCAACCTCCGGGGCGACCTTCTCTTCCAGCCACAGT CCCATGAGGGCCCCTAGCCAGGGACACTGGTCTGTAAATTGTAATCCTTTCTCCAGC CCAGCTCTCCACTTGTTCCTTGTGTGAGCTGAGCAGGCAGTGCACCTCTGAGTGTCC CTTTTGTAAGGCCCAGGGGTTGCACTGAGTCTGCAGAGGCCGCGACCTCCTAGAACG CTGTGGGTGCAGGTGAGCCGGCGTGTCCTGGGGAGATGCTGCCAGCACACAGGGGC CCTCCTGCTGCCAGCAGGTTGGGGTGGTTAAGTCTTATTAGTGTCTATTCTTAAAATT AAGTGGGCTGGAGAAGAATGGAGCTCCACATGCCAGCACCGTATATGGAATACAAA AGCTGGGGAAGCAGGGCCTGCCTTACAGGTGTGGCTGACTCTGAGCCCAGGCCTGC AGGGGTGGAGGGCAGTCCCTCAGAATCCCAGAGGCAGTCCCAGCCTCAGAACCCAG GATAGGAAATGGGTGTGTTTAGTGGGGAAAGGGACGGGGTGCAGACGGCAGGGCC AGTATGGGGCCCCCTCCCTCTCCTCTCCTCTCCTATGGTGAGCCCAGCGTGGGCACC GGGCCGTCTCAGCCGTGTTCCCAGGGCTGGGAGGACAGCTCTGGCCCTTCTTAGGCC TAGCCTCGTCCCAAGCTAAATGTAAGCCAGTTGGGCTGTGTTAAAGGAAGCAGTGTT TTTGGTTCGATTCTGCCTCTGTAGCTCAAGGGGGGCAGCCCCCAGAGTCCTGTGCAT TCTGCCAAGGCTCCATAGCTTTGCCAAATGCACGGAGCTCTGCCATTCCGGTGCAGT GCAGGCCTTGCGAAGGGTTTATCTGCGTTCGTCTCGGTGGGCTTCTCCTGCATGGGA GTTGTGTTCCTGTGCAAGGGGGAGCTTTGCTCCAGGACAGGATGACTGTCTTCCCTA TTCTTAGGGACAAGTCCCAAGATGCCAGAAAGGCAGTCTCCCAAGGACCCACCATG CAGAAGTGTCAATAAACCACAAGTTCTGAACTCTGTAAAAAAAAAAAAAA PPP2R1A (SEQ ID NO: 19; CR450340.1). ATGGCGGCGGCCGACGGCGACGACTCGCTGTACCCCATCGCGGTGCTCATAGACGA ACTCCGCAATGAGGACGTTCAGCTTCGCCTCAACAGCATCAAGAAGCTGTCCACCAT CGCCTTGGCCCTTGGGGTTGAAAGGACCCGAAGTGAGCTTCTGCCTTTCCTTACAGA TACCATCTATGATGAAGATGAGGTCCTCCTGGCCCTGGCAGAACAGCTGGGAACCTT CACTACCCTGGTGGGAGGCCCAGAGTACGTGCACTGCCTGCTGCCACCGCTGGAGTC GCTGGCCACAGTGGAGGAGACAGTGGTGCGGGACAAGGCAGTGGAGTCCTTACGGG CCATCTCACACGAGCACTCGCCCTCTGACCTGGAGGCGCACTTTGTGCCGCTAGTGA AGCGGCTGGCGGGCGGCGACTGGTTCACCTCCCGCACCTCGGCCTGCGGCCTCTTCT CCGTCTGCTACCCCCGAGTGTCCAGTGCTGTGAAGGCGGAACTTCGACAGTACTTCC GGAACCTGTGCTCAGATGACACCCCCATGGTGCGGCGGGCCGCAGCCTCCAAGCTG GGGGAGTTTGCCAAGGTGCTGGAGCTGGACAACGTCAAGAGTGAGATCATCCCCAT GTTCTCCAACCTGGCCTCTGACGAGCAGGACTCGGTGCGGCTGCTGGCGGTGGAGG CGTGCGTGAACATCGCCCAGCTTCTGCCCCAGGAGGATCTGGAGGCCCTGGTGATGC CCACTCTGCGCCAGGCCGCTGAAGACAAGTCCTGGCGCGTCCGCTACATGGTGGCTG ACAAGTTCACAGAGCTCCAGAAAGCAGTGGGGCCTGAGATCACCAAGACAGACCTG GTCCCTGCCTTCCAGAACCTGATGAAAGACTGTGAGGCCGAGGTGAGGGCCGCAGC CTCCCACAAGGTCAAAGAGTTCTGTGAAAACCTCTCAGCTGACTGTCGGGAGAATGT GATCATGTCCCAGATCTTGCCCTGCATCAAGGAGCTGGTGTCCGATGCCAACCAACA TGTCAAGTCTGCCCTGGCCTCAGTCATCATGGGTCTCTCTCCCATCTTGGGCAAAGA CAACACCATCGAGCACCTCTTGCCCCTCTTCCTGGCTCAGCTGAAGGATGAGTGCCC TGAGGTACGGCTGAACATCATCTCTAACCTGGACTGTGTGAACGAGGTGATTGGCAT CCGGCAGCTGTCCCAGTCCCTGCTCCCTGCCATTGTGGAGCTGGCTGAGGACGCCAA GTGGCGGGTGCGGCTGGCCATCATTGAGTACATGCCCCTCCTGGCTGGACAGCTGGG AGTGGAGTTCTTTGATGAGAAACTTAACTCCTTGTGCATGGCCTGGCTTGTGGATCA TGTATATGCCATCCGCGAGGCAGCCACCAGCAACCTGAAGAAGCTAGTGGAAAAGT TTGGGAAGGAGTGGGCCCATGCCACAATCATCCCCAAGGTCTTGGCCATGTCCGGA GACCCCAACTACCTGCACCGCATGACTACGCTCTTCTGCATCAATGTGCTGTCTGAG GTCTGTGGGCAGGACATCACCACCAAGCACATGCTACCCACGGTTCTGCGCATGGCT GGGGACCCGGTTGCCAATGTCCGCTTCAATGTGGCCAAGTCTCTGCAGAAGATAGG GCCCATCCCGGACAACAGCACCTTGCAGAGTGAAGTCAAGCCCATCCTAGAGAAGC TGACCCAGGACCAGGATGTGGACGTCAAATACTTTGCCCAGGAGGCTCTGACTGTTC TGTCTCTCGCC CFLAR (SEQ ID NO: 20; NM_003879.5). ATACTCAGTCACACAAGCCATAGCAGGAAACAGCGAGCTTGCAGCCTCACCGACGA GTCTCAACTAAAAGGGACTCCCGGAGCTAGGGGTGGGGACTCGGCCTCACACAGTG AGTGCCGGCTATTGGACTTTTGTCCAGTGACAGCTGAGACAACAAGGACCACGGGA GGAGGTGTAGGAGAGAAGCGCCGCGAACAGCGATCGCCCAGCACCAAGTCCGCTTC CAGGCTTTCGGTTTCTTTGCCTCCATCTTGGGTGCGCCTTCCCGGCGTCTAGGGGAGC GAAGGCTGAGGTGGCAGCGGCAGGAGAGTCCGGCCGCGACAGGACGAACTCCCCC ACTGGAAAGGATTCTGAAAGAAATGAAGTCAGCCCTCAGAAATGAAGTTGACTGCC TGCTGGCTTTCTGTTGACTGGCCCGGAGCTGTACTGCAAGACCCTTGTGAGCTTCCCT AGTCTAAGAGTAGGATGTCTGCTGAAGTCATCCATCAGGTTGAAGAAGCACTTGATA CAGATGAGAAGGAGATGCTGCTCTTTTTGTGCCGGGATGTTGCTATAGATGTGGTTC CACCTAATGTCAGGGACCTTCTGGATATTTTACGGGAAAGAGGTAAGCTGTCTGTCG GGGACTTGGCTGAACTGCTCTACAGAGTGAGGCGATTTGACCTGCTCAAACGTATCT TGAAGATGGACAGAAAAGCTGTGGAGACCCACCTGCTCAGGAACCCTCACCTTGTTT CGGACTATAGAGTGCTGATGGCAGAGATTGGTGAGGATTTGGATAAATCTGATGTGT CCTCATTAATTTTCCTCATGAAGGATTACATGGGCCGAGGCAAGATAAGCAAGGAG AAGAGTTTCTTGGACCTTGTGGTTGAGTTGGAGAAACTAAATCTGGTTGCCCCAGAT CAACTGGATTTATTAGAAAAATGCCTAAAGAACATCCACAGAATAGACCTGAAGAC AAAAATCCAGAAGTACAAGCAGTCTGTTCAAGGAGCAGGGACAAGTTACAGGAATG TTCTCCAAGCAGCAATCCAAAAGAGTCTCAAGGATCCTTCAAATAACTTCAGGCTCC ATAATGGGAGAAGTAAAGAACAAAGACTTAAGGAACAGCTTGGCGCTCAACAAGA ACCAGTGAAGAAATCCATTCAGGAATCAGAAGCTTTTTTGCCTCAGAGCATACCTGA AGAGAGATACAAGATGAAGAGCAAGCCCCTAGGAATCTGCCTGATAATCGATTGCA TTGGCAATGAGACAGAGCTTCTTCGAGACACCTTCACTTCCCTGGGCTATGAAGTCC AGAAATTCTTGCATCTCAGTATGCATGGTATATCCCAGATTCTTGGCCAATTTGCCTG TATGCCCGAGCACCGAGACTACGACAGCTTTGTGTGTGTCCTGGTGAGCCGAGGAG GCTCCCAGAGTGTGTATGGTGTGGATCAGACTCACTCAGGGCTCCCCCTGCATCACA TCAGGAGGATGTTCATGGGAGATTCATGCCCTTATCTAGCAGGGAAGCCAAAGATG TTTTTTATTCAGAACTATGTGGTGTCAGAGGGCCAGCTGGAGGACAGCAGCCTCTTG GAGGTGGATGGGCCAGCGATGAAGAATGTGGAATTCAAGGCTCAGAAGCGAGGGCT GTGCACAGTTCACCGAGAAGCTGACTTCTTCTGGAGCCTGTGTACTGCGGACATGTC CCTGCTGGAGCAGTCTCACAGCTCACCATCCCTGTACCTGCAGTGCCTCTCCCAGAA ACTGAGACAAGAAAGAAAACGCCCACTCCTGGATCTTCACATTGAACTCAATGGCT ACATGTATGATTGGAACAGCAGAGTTTCTGCCAAGGAGAAATATTATGTCTGGCTGC AGCACACTCTGAGAAAGAAACTTATCCTCTCCTACACATAAGAAACCAAAAGGCTG GGCGTAGTGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCCAAGGAGGGCAGAT CACTTCAGGTCAGGAGTTCGAGACCAGCCTGGCCAACATGGTAAACGCTGTCCCTA GTAAAAATACAAAAATTAGCTGGGTGTGGGTGTGGGTACCTGTATTCCCAGTTACTT GGGAGGCTGAGGTGGGAGGATCTTTTGAACCCAGGAGTTCAGGGTCATAGCATGCT GTGATTGTGCCTACGAATAGCCACTGCATACCAACCTGGGCAATATAGCAAGATCCC ATCTCTTTAAAAAAAAAAAAAAAGGACAGGAACTATCTTACTCAATGTATTAGTCAT GTTTCTCTAGAGGGACAGAACTAATAGGATACATGTATATAAAAAGGGGAGTTTATT AAGGAGTATTGACTCACATGATCACAGGGTTAGGTCCCACAATAGGTCATCTGCAA GCAAGGAAGCCAATTCAAGTCCCAAAGCTGAAGAACTTGGAGTCCAATGTTTGAGG GCAGGAAGCATTCAGCATGAGAGAAAGATGGAGGCCAGAAGACTACACCAGTCTA GTCTTTCCATGTTTTGCCTGCTTTTATTCTGGCAGTGCTGGCAGCTGATTAGATGGTG CCCACCCAGATTGAGGATGGTCTGCCTTTCCCAGTCCACTGACTCAAATGTTAAATC TCCTTTGGCAGCACCCTCACAGATGTACCCGGGAACACTTTGCATCCTTCTATTCAAT CAAGTTGATACTCAGTATTAACCATCACAGTCCATTTGGGCAACTATACCAAATTAC CATAGACCAGGTGACTTAAACAGCAGTTATTTCTCACAGTTCCGGAGGCTGGGAAAT CCAACATCTAAGTGGTAGCATATCTGGTGTCTGGTAAGGCATGCTTCCAGATCTTAC CAGATGTCAGTCTTTTGATGTTCTCACATGGCAGAAAAAGAGGATGCAAACTCTCAA GTATATCTTTAAGGGCACAAATTCCATTCATGAGGGCTCTACCCTCATCACCTAATT ACCTCCCAAAGGCCCCACCTTCTGATACTGTCACTTTGGGGATACTGTCTCCCCTTTG AATTCTGGGGGGAATACAAACATTCAGTTTGTAACAATAGCCTTATGATTTAGAGGT TACTTGTTCATTCACCTAGACCTCAAATTGCATTTTACAGCTAGTCAAGTATATCTTT CTCTGATTTGATAGTGTGACCTAAAAGGGGACCATTGTTTGAAATATCATTAGAGTT GCTTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTGAGACAGAGT TTCATTCTGCTGCCCAGGCTGGAGTGCAGTGGCATCATCTTGGCTCATTGCAACCTCT GCCTTCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGATTACAG GCTCCTGCCACCACACCCGGCTAATTTTTGTATTTTTAGTGGAGACAGGGTTTCCACC ATGTTGGCCAGCGTGGTCTTGAACTCCTGACCTCAGGTGATTCACCAGCCTCGGCCT CCCAAAGTGCTGGGATTACAGGTGTGAGCCACTGCACCTGGCCTATTATTATTTTTA AATTTTTTTTTTTTAATTGATCATTCTTGGGTGTTTCTCACAGAGGGTGATTTGGCAG GGTCACAGGACAATAGTGGAGGGAAGGTCAGCAGATAAACAAGTGAACAAAGGTC TCTGGTTTTCCTAGGCAGAGGACCCTGCGGCCTTCCGCAGTGTTTGTGTCCCTGGGTA CTTGAGATTAGGGAGTGGTGATGACTCTTAAGGAGCATGCTGCCTTCAAGCATCTGT TTAACAAAGCACATCTTGCACTGCCCTTAATCCATTTAACCCTGAGTGGACACAGCA CATGTTTCAGAGAGCACAGGGTTGGGGGTAAGGTCATAGATCAACAGCATCCTAAG GCAGAAGAATTTTTCTTAGTACAGAACAAAATGAAGTCTCCCATGTCTACTTCTTTCT ACACAGACACAGCAACAATCTGATTTCTCTATCTTTTCCCCACCTTTCCCCCTTTTCT ATTCCACAAAACCGCCATCGTCATCATGGCCTGTTCTCAATGAGCTGTTGGGTACAC CTCCCAGACGGGGTGGCGGCTGGGCAGAGGGGCTCCTCACTTCCCAGATGGGGCGG CCAGGCGGACGCGCCCCCCACCTCCCTCCCGGACGGGATAGCTGGCCGGGCGGGGG CTGACCCCCCACCTCCCTCCCCGACGGGGCGGCTGGCCGGGCGGGGGCTGACCCCC ACGCCTCCCTCCCGGACGGGGCGGCTGCCAGGCGGAGGGGCTCCTCACTTCTCAGA CGGGGTGGCTGCTGGGCGGAGACGCTCCTCACTTCCCAGACAGGGTGGCTGTCGGG CGGAGGGGCTCCTCACTTCTCAGACGGGGCAGCTGCGGGCGGAGGGGCTCCTCACT TCTCAGACGGGGTGGCCGGGCAGAGAAGCTCCTCACATCCCAGACGGGGGGGCGGG GCAGAGGCGCTCCCCACATCTCAGACGATGGGCGGCCGGGCAGAGACGCTCCTCAC TTCATCCCAGACGGGGTGGCGGCCGGGCAGAAGCTGTAATCTCGGCACCCTGGGGG GCCAAGGCAGGCGGCTGGGAGGCGGAGGCCGTAGCCAGCTGAGATCACACCACTGC ACTCCAGCCTGGGCAACATTGAGCACTGAGTGGACGAGACTCTGCCCGCAATCCCG GCACCTCGGGAGGCCGAGGCTGGCAGATCACTCGCAGTCAGGAGCTGGAGACCAGC CCGGCCAACACAGTGAAACCCTGTCTCCACCAAAAAAATACGAAAACCAGTCAGGC GTGGCGGCGCCCGCAATGGCAGGCACGCGGCAGGCCGAGGCGGGAGAATCAGGCA GGGAGGCTGCAGTGAGCCGAGATGGCAGCAGTACAGTCCAGCTTCGGCTCGGCATC AGAGGGAGACCGTGGGGAGAGGGAGAAGAGAGGGAGGGGGAGAGGGCTATTTTTA AAATTTTTTAAAATTGCTGAACAGGGGTACCTCTGGGCAGTGTGTCAGAATACCACT TTTTAAATATTTTATGATTTATTTATTTTTCTATTTCTTGAGGTTTTAACTGATGTGTA TCTGTATGTCTATTTGTGTATATTTTGTCATGATCATGTAACAGAGTCTGAAAAGTGT CGAAGAGACAGTTTTCAGGAACAACAAGCAATTATTCCTACTTTCCAAGTTATTTTG ATGCCATGGTGGCTCATACCTATAATCTGAGTACTTTGGGAGGCTGAGGTGGACTGA TCACTTGAGCCCAGGAGTTTGAGACCAGCCTGGGCAACATAGCAAGACTCCATCTCT ACAAAAAAAGACAAAATTTAGCTGAGCGTGGTGGCGTGTTCCTGTAGTCCCAGCTA CTTGGGAGGCTGAAGTGAGTGGATCCCCTGAGCCCAGAGAGGTCAAGGTTGTGATG AGCTGTGATCACACCACTGCACTTCAGCATGGGAGACAGAGTGAGACCCTGTTTCAG AAAAAATAAATAAATAAAACCACCAGCACCACAAACAACAACAAAAAGTTATTTTG TACTTGTTTTGAGCACAGGACTCCTGAGGGTATCTTTGCATTTAATATTACATAGGG GTGCCAGTGGGAAGTAATGTGTATGCTTGGCCTCATGAGCTAAAACCCTGTGTTAAT TATGACAGAAGGAAAGTGTGTGAGAGAGATCTTAACTACCTAGCAGCTCTAGCTGC CATCTTGAACCATGAAGATACGGGCCACACGTAGGGGTAGCTGGGTAGTGAGCAGC AAGAAGCCTTGTTGGATGAGGGCACGAAGGAGCAGAATCACTGGAATCACTGTGTC AGCCCTAATTACCTACCTCTGGACTTTTATGTGAGGGGAAAAAAAATTGACAGTTTA TATTTATCTCAACCTAGTTAACCCAAGTGATGCATTGTTATGAGATTAAAATGTTTGG AGGCCGGGTGCGGTGGCTCACGCCTATAATCCCAGCCCTTTGGGAGGCCAAGGCGG GCGGATCACGAGGTCAGGAGATCAAGACCATCCTGGCTAACATGTAAAACCCCGTC TCTACTAAAAATACAAAAAATTAGCCAGGCGTTGTGGCGGTCGCCTGTAGTCCCTGC TATTTGGGAGGCCGAGGCAAGAGAACGGCATGAACCTGGGAGGTGGAGCTTGCAGC GAGCTGAGATCTTGCCACTGCACTCCAGCCTGGGCGACAGTGCGAGACTCTGTCTCA AAAATAAATAAATAAATAAATAATAAATAAAATGTTTGGAATGTTGGCTTCATCCCT GGGATGCAAGGCTGGTTCAACATACGCAAATCAAGAAACATAATTCATCACATAAA CAGAACTAAAGACAAAAACCACATGATTATCTCAATAGATACAGAAAAGGCCTTCA ATAAAATTCAACGTTGCTTCATGTTAAAAACTCTCAATAAACTAGGTATTGATGGAA AATATCTCAAAATAATAACCATTTATGACAAACCCACAGCCATTATCATACTGAATG GGCAAAAGCTGGAAGCATTCCCCTTGAAAACTGGCACAAGACAGGGATGCCGTCTC ACCACTCCTATTTAACATAGTATTGGAAGTTCTGGCCAAGAAAATCAGGCAAGAGA AACAAATAAGGGGTATTCAAATAGGAAAAGAGGAAGTAAAACTGTGTTTGCAGATG ACATGATACTATATCTAGAAAACCCCATTATCTCCACCCAAAAGTTCCTTAAGCTGA TAAGCAACTTCAGCAAAGTCTCAGGATACAAAATCAATGTGCAGAAATCACAAGCA TTCTATACACCAACAATACACAAGCAGAGAGCCAAATCATGAATGAACTCCCATTC ACAGTTGCTAGAAAGAGAATAAAATACCTAGGAATACAGCTAATAAGATGTGAAGG ATCTCTTCAAGGAGAACTACAAACCACTGCTCAAGGAAATAAGAGAGGACACAAAT GAAAAAACATTCCATTCTCGTGGATAGGAAGAATCAATATCATGAAAATGGCCATA CTACCCAAAGTAATTTATAGGTTCATTGCTATTCCCATTAAACTACTATTGACATTCT TCACAGAATTAGAAAAAAACTACTTTAAAATTCAAATGGAACCAAAAAAGAGCCCG TATAACCAAGACAACAATAAGCAAAAAGAACAAAGCTGGAAGCATCACACTACCC AACTTCAAAGTATACTGCAAGGCTACAGTAGCCAAAATGGCATGGTACTGGTACAA AAACAGACACATAGACCAATGGAACAGAATAGAGACCAGAGAAAGAAGACCACAC ATCTACAGCCATCTGATCATCGACAAACCTGACAAAAACAAGCAATGGGGAAAAGA TTCCCTATTTAATAAATGGTGCTGGGAAAACTGGCTAGCCATATGCAGAAAATTGAA ACTGACCCCTTCCTTACACCTTATACAAAAATTAACTCAAGATTAAAGACTTAATGT AAAACCTAAAACTATAAAAACCCTAGAAGAAAATCTATTTAATACCATTCAAGACA TAGGCACAAGCAAAGGTTTCATGACAAAAACATCAAAAGCAATTGCAACAAAAGCA AAAATTACAAATGGGATCTAATTAAACTAAAGAGCTCCTGCACAGCAAAAGAAACT ATCATTAGAGTGAACAGGCAACCTACAGAATGGGAGAACATTTTTGCAATCTATCCA TCTGACAAAGGTCTAATATCCAGAACCTACAAGGAACTTAAAACAAATTTACAAGG AAAAAAACAACCCCATCAAAAAGTGGACAAAGGACATGAACAGACACTTCTCAAA AGAAGACATTTATGTGGCCAACAAACATATAAAAAAAAGCTCAACCTTACTGATCA TTAGAGAAATGCAAAGGAGAACCACAATGAGATACCATCTCATGCCGGTCAGAATG GTGATTATTAAAAAGTCAAAAAACAACAGATGCTGGCGAGGCTGTGGAGAAGTAGG AACACTTTTACATTGTTGGTGGGAATGTAAATTAGTTCAACCGTTGTGGAAGTGTGT GTGGCTATTCCTCAAAGATCTAGAACTAGAAATACTATTTGTCCCAGCAATCCCATT ACTGGGTATATACCCAAAGGAATATAAACCATTTTATTATAAAGATACATGCACATT TTTGTTCATTGCAGCACTCTTCACAATAGCAAAGACACAATAGCAAATGCCCATCAA AGATAGACTGGATAAAGAAAATGTGGTACATATACACCATGGAATACTGTGCAGTG CAGCCATTACAGCTTTTGGTGATACAGTGAATCAGATTTTTCATTAATTCTTTTAATT GGTTATTACTGAACGTGAAAAAGTAATGTTTGTATTGAAATCTTGAGTCTGGCCATG TTTCTATTTTAAATTCATAAAGAATTCTAACAAGAGGAATTCCAAGAATGTCATAAA TGGATGTTTCTCCATGGATGAAGGAACTGTTTTATTCACTTGCTGATAATTCAGCCTA ATCCAGTTTGACATCATATAGATAAGTAGTTGAATTATGGATTTAAAATACATATCA TTTTCTAACTCCAAAGGTAATACTTATTTAAATGGTTTTGAAAATATAGAAAGGCAC AATTTCTTTTTAAATCTGTTATTCTCCACCACCACTCAATCTGTCTATCATCTATCTCT CCATTCATTCTTCCATTTGTTTATATCTGTTAATCTTTGTATGTGTTCATGTATAGCTT TTACATGATTGGAATCATAATGCATATTCCATTTTGAAGTCTGCTTTTTTTTACACAA AAATATGTTGTGAATATTTTCCTATATTATGAAATATCATTAGCTGAGCTTTTAGAAT TGACTGCATGTTTTGGTACCATTTAGATATAGTTTAAGATACTTAGAAGTTATGTGGC TTTGCCACTATGGATGAATCTTATTTACTCAATATTAATTACTTACAAATAACCTCAC CTAAACACTACTCAGCCATAAAAAGGAATGAATTAATGACATTCACAGCAACCTGG AGACTATTACTCTAAAGGAAGTAACTGAGGAATGGAAAACCAAACATTGTATGTTC TCACTCATAAGTGGGAGATAAGCTATGAGGATGCAAAGGCATAAGAAGGATACAAT GGACTTTGGGGACTTAGGGGAAAGGGTGGGAGGGGGGTGAAGGATAAAAGAATAC AAATTGGGTTCAGTGTATACTGCTCAGGTGATGGGTGCACCAGAATCTCACAAGTAA CCACTTAATTACTTACGCATGTAACCAGATACCACCTGTTCCCCAAACACCTATGGA AATAATTTTGTTTTTTTTTTTAAAAAAGGAATGAGATCATGTCCTTTGCAGGGACATG GATGAAGCTGGAAGCCATTATCCTCAGCAAACTAACAGAGGAGCAGGAAACCAAAC ACCACATGTTCTCACTTGTAAGCGGAAGCTGAACAATGAGAACACACGGACACAGG GATGAGATCAACACACACTGGGGCCTGATGCAGGGGCCGTAGCGGGGAGAGCATCA GGATAACTAGCTAATGCATGTGGGGCTTAATACCTAGGTGATAGGTTGATAGGTGCA GCAAACCACCATGGGACACGTTTACCTATGTAACAAACCCGCACATCCTGCACTTGT ATCCAGAACTTAAAATATTTTAAAAATCTTTAGAGAATACAAAAAAAAAAAAAAAG ATTCTTCAATGCATACACAATAAAATTGCAGTTCAGTCAAACATTGGAAGTCTTTCT CTGACTGTCTAGTTGGTATCTTCATTTTCAGCTTCTTCAAGATCCCACTCCAAACACT GTTAGCTCAGCCAAATTGAACAGCTCATATCTCCTACCTCTGGATCTTTGGTTCTGGT GATTGTATATTTCTGGACCATCTGGAACCCCAGCATATCACCCTACCCCACATCTCC ACATCCCCAAAATATAACCATACTTCAAGGGCAGTTCAAATACCATCTCCTTCTATC CTCCATGAAGTCAGTTATCTCTTCCATTGGAATTATCGCCCCCTCTCCTGAACAGTAC TATTTCGTGTGAATCTCCTCCAAGCCTTCTTTTCATTTTATATCTCATGCTGTAATTCT TGGAAAGTATGCTGTAGCTCAAGTGCAGAATTCTCATCAGTTTTATCTTTATATCTCT CCTAAACACTTTACCTGATGAAGAGCCTGGCATACACATAAATATATATTGAATGAA TCAGTGATGGATTGAAAAGAGAAATGATGGATCTCCTAAATTTTAACTTTTATAAAA TATTTTGATACATTCATGACCTTACTTTAGCAAGCAATGAACGTGATGTAAACTATT GTTGATATAGTTTTTATATTGGAAGTGTAAGTAGTTTGTGGCATGGGATTGTGACAT ATCCTAGGTTTCCTCATCTTCTTTTTATTGAAATGTAATTCACAAGCCATAAAATTTG CCCCTTTAAAGTAAATGATGCAGTGGATTTTAGTATATTTACAGAGTTGTGCAATCA TCACCACTATCTAATTCCAGAACATTTCCATCTACCTAGAAACTCCATACCAGTGAG CTGCCACTCTAATCCTCCTCTTCCCCCAGCCTCTAGAAACAATAATCCATTTTCTGTC TCTATGATTTGCCTGTTCTAGATATTTTATAAAAATAAACATGTGGCCTTTCGTGTCT GACTTCCTTCACTTAAAAAAAAAAAAAAAAAA DHRS13 (SEQ ID NO: 21; NM_144683.3). CGCCTCCGCCTTCGGAGGCTGACGCGCCCGGGCGCCGTTCCAGGCCTGTGCAGGGC GGATCGGCAGCCGCCTGGCGGCGATCCAGGGCGGTGCGGGGCCTGGGCGGGAGCCG GGAGGCGCGGCCGGCATGGAGGCGCTGCTGCTGGGCGCGGGGTTGCTGCTGGGCGC TTACGTGCTTGTCTACTACAACCTGGTGAAGGCCCCGCCGTGCGGCGGCATGGGCAA CCTGCGGGGCCGCACGGCCGTGGTCACGGGCGCCAACAGCGGCATCGGAAAGATGA CGGCGCTGGAGCTGGCGCGCCGGGGAGCGCGCGTGGTGCTGGCCTGCCGCAGCCAG GAGCGCGGGGAGGCGGCTGCCTTCGACCTCCGCCAGGAGAGTGGGAACAATGAGGT CATCTTCATGGCCTTGGACTTGGCCAGTCTGGCCTCGGTGCGGGCCTTTGCCACTGC CTTTCTGAGCTCTGAGCCACGGTTGGACATCCTCATCCACAATGCCGGTATCAGTTC CTGTGGCCGGACCCGTGAGGCGTTTAACCTGCTGCTTCGGGTGAACCATATCGGTCC CTTTCTGCTGACACATCTGCTGCTGCCTTGCCTGAAGGCATGTGCCCCTAGCCGCGT GGTGGTGGTAGCCTCAGCTGCCCACTGTCGGGGACGTCTTGACTTCAAACGCCTGGA CCGCCCAGTGGTGGGCTGGCGGCAGGAGCTGCGGGCATATGCTGACACTAAGCTGG CTAATGTACTGTTTGCCCGGGAGCTCGCCAACCAGCTTGAGGCCACTGGCGTCACCT GCTATGCAGCCCACCCAGGGCCTGTGAACTCGGAGCTGTTCCTGCGCCATGTTCCTG GATGGCTGCGCCCACTTTTGCGCCCATTGGCTTGGCTGGTGCTCCGGGCACCAAGAG GGGGTGCCCAGACACCCCTGTATTGTGCTCTACAAGAGGGCATCGAGCCCCTCAGTG GGAGATATTTTGCCAACTGCCATGTGGAAGAGGTGCCTCCAGCTGCCCGAGACGAC CGGGCAGCCCATCGGCTATGGGAGGCCAGCAAGAGGCTGGCAGGGCTTGGGCCTGG GGAGGATGCTGAACCCGATGAAGACCCCCAGTCTGAGGACTCAGAGGCCCCATCTT CTCTAAGCACCCCCCACCCTGAGGAGCCCACAGTTTCTCAACCTTACCCCAGCCCTC AGAGCTCACCAGATTTGTCTAAGATGACGCACCGAATTCAGGCTAAAGTTGAGCCTG AGATCCAGCTCTCCTAACCCTCAGGCCAGGATGCTTGCCATGGCACTTCATGGTCCT TGAAAACCTCGGATGTGTGCGAGGCCATGCCCTGGACACTGACGGGTTTGTGATCTT GACCTCCGTGGTTACTTTCTGGGGCCCCAAGCTGTGCCCTGGACATCTCTTTTCCTGG TTGAAGGAATAATGGGTGATTATTTCTTCCTGAGAGTGACAGTAACCCCAGATGGAG AGATAGGGGTATGCTAGACACTGTGCTTCTCGGAAATTTGGATGTAGTATTTTCAGG CCCCACCCTTATTGATTCTGATCAGCTCTGGAGCAGAGGCAGGGAGTTTGCAATGTG ATGCACTGCCAACATTGAGAATTAGTGAACTGATCCCTTTGCAACCGTCTAGCTAGG TAGTTAAATTACCCCCATGTTAATGAAGCGGAATTAGGCTCCCGAGCTAAGGGACTC GCCTAGGGTCTCACAGTGAGTAGGAGGAGGGCCTGGGATCTGAACCCAAGGGTCTG AGGCCAGGGCCGACTGCCGTAAGATGGGTGCTGAGAAGTGAGTCAGGGCAGGGCA GCTGGTATCGAGGTGCCCCATGGGAGTAAGGGGACGCCTTCCGGGCGGATGCAGGG CTGGGGTCATCTGTATCTGAAGCCCCTCGGAATAAAGCGCGTTGACCGCCGAAAAA AAAAAAAAAAAAAAA ACAA1 (SEQ ID NO: 22; NM_001607.3). GGGTTCCCAGGCCGACTCTCCTTGTGGTTGGCTGAGGCTGGAGGTGGACGGGACTTT TGGAGGGTCGCTCGCGTCTGTTCGCAGAGCTGTGGGCGGAGTTGAGGCCTTGGAGG CTGAGATGTGGTTCTGCGCGTGTGCGGACGGCTGTCTGTTAACTCCGCGGTCAGTTC CCGGACTGGTGGCTGGTCTGCAGGGTTGACCTGCGCAATGCAGAGGCTGCAGGTAG TGCTGGGCCACCTGAGGGGTCCGGCCGATTCCGGCTGGATGCCGCAGGCCGCGCCTT GCCTGAGCGGTGCCCCGCAGGCCTCGGCCGCGGACGTGGTGGTGGTGCACGGGCGG CGCACGGCCATCTGCCGGGCGGGCCGCGGCGGCTTCAAGGACACCACCCCCGACGA GCTTCTCTCGGCAGTCATGACCGCGGTTCTCAAGGACGTGAATCTGAGGCCGGAACA GCTGGGGGACATCTGTGTCGGAAATGTGCTGCAGCCTGGGGCCGGGGCAATCATGG CCCGAATCGCCCAGTTTCTGAGTGACATCCCGGAGACTGTGCCTTTGTCCACTGTCA ATAGACAGTGTTCGTCGGGGCTACAGGCAGTGGCCAGCATAGCAGGTGGCATCAGA AATGGGTCTTATGACATTGGCATGGCCTGTGGGGTGGAGTCCATGTCCCTGGCTGAC AGAGGGAACCCTGGAAATATTACTTCGCGCTTGATGGAGAAGGAGAAGGCCAGAGA TTGCCTGATTCCTATGGGGATAACCTCTGAGAATGTGGCTGAGCGGTTTGGCATTTC ACGGGAGAAGCAGGATACCTTTGCCCTGGCTTCCCAGCAGAAGGCAGCAAGAGCCC AGAGCAAGGGCTGTTTCCAAGCTGAGATTGTGCCTGTGACCACCACGGTCCATGATG ACAAGGGCACCAAGAGGAGCATCACTGTGACCCAGGATGAGGGTATCCGCCCCAGC ACCACCATGGAGGGCCTGGCCAAACTGAAGCCTGCCTTCAAGAAAGATGGTTCTAC CACAGCTGGAAACTCTAGCCAGGTGAGTGATGGGGCAGCTGCCATCCTGCTGGCCC GGAGGTCCAAGGCAGAAGAGTTGGGCCTTCCCATCCTTGGGGTCCTGAGGTCTTATG CAGTGGTTGGGGTCCCACCTGACATCATGGGCATTGGACCTGCCTATGCCATCCCAG TAGCTTTGCAAAAAGCAGGGCTGACAGTGAGTGACGTGGACATCTTCGAGATCAAT GAGGCCTTTGCAAGCCAGGCTGCCTACTGTGTGGAGAAGCTACGACTCCCCCCTGAG AAGGTGAACCCCCTGGGGGGTGCAGTGGCCTTAGGGCACCCACTGGGCTGCACTGG GGCACGACAGGTCATCACGCTGCTCAATGAGCTGAAGCGCCGTGGGAAGAGGGCAT ACGGAGTGGTGTCCATGTGCATCGGGACTGGAATGGGAGCCGCTGCCGTCTTTGAAT ACCCTGGGAACTGAGTGAGGTCCCAGGCTGGAGGCGCTACGCAGACAGTCCTGCTG CTCTAGCAGCAAGGCAGTAACACCACAAAAGCAAAACCACATGGGAAAACTCAGC ACTGGTGGTGGTGGCAGTGGACAGATCAAGGCACTTCAACTCATTTGGAAAATGTG AACACTGATGACATGGTATAGGAGTGGGTGGGGTGTTGAGCCACCCATCAGACCCT CTTTAGCTGTGCAAGATAAAAGCAGCCTGGGTCACCCAGGCCACAAGGCCATGGTT AATTCTTAAGGCAAGGCAAATCCATGGATGAGAAGTGCAATGGGCATAGTAAAAGT GCATGAATTTATCTTAAAAAAAAAAAAAAAAAAAAAA INPP5J (SEQ ID NO: 23; NM_001284285.1). CAGGTTGAAATGGCTGATGACATCACTGGTTCCCGGGAGCGGTAGAGCTGGAGCCG GAGCCAAGGGAGTCCAGGCTGCCGGGGGCTGCAGACATGGAGGGCCAGAGCAGCA GGGGCAGCAGGAGGCCAGGGACCCGGGCTGGCCTGGGTTCCCTGCCCATGCCCCAG GGTGTTGCCCAAACTGGGGCACCCTCCAAGGTGGACTCAAGTTTTCAGCTCCCAGCA AAGAAGAACGCAGCCCTAGGACCCTCGGAACCAAGGTTGGCTCTGGCACCTGTAGG GCCACGGGCAGCTATGTCAGCTTCCTCGGAAGGACCGAGGCTGGCTCTGGCATCTCC CCGACCAATCCTGGCTCCACTGTGTACCCCTGAAGGGCAGAAAACAGCTACTGCCC ACCGCAGCTCCAGCCTGGCCCCAACATCTGTGGGCCAGCTGGTGATGTCTGCCTCAG CTGGACCAAAGCCTCCCCCAGCGACCACAGGCTCAGTTCTGGCTCCGACGTCCCTGG GGCTGGTGATGCCTGCCTCAGCAGGGCCAAGATCTCCCCCAGTCACCCTGGGGCCCA ATCTGGCCCCAACCTCCAGAGACCAGAAGCAGGAGCCACCTGCCTCCGTGGGACCC AAGCCAACACTGGCAGCCTCTGGCCTGAGCCTGGCCCTGGCTTCTGAGGAGCAGCC CCCAGAACTCCCCTCCACCCCTTCCCCGGTGCCCAGTCCAGTTCTGTCTCCAACTCAG GAACAGGCCCTGGCTCCAGCATCCACGGCATCAGGCGCAGCCTCTGTGGGACAGAC ATCAGCTAGAAAGAGGGATGCCCCAGCCCCTAGACCTCTCCCTGCTTCTGAGGGGC ATCTCCAGCCTCCAGCTCAGACATCTGGTCCTACAGGCTCCCCACCCTGCATCCAAA CCTCCCCAGACCCTCGGCTCTCCCCCTCCTTCCGAGCCCGGCCTGAGGCCCTCCACA GCAGCCCTGAGGATCCTGTTTTGCCACGGCCACCCCAGACCTTGCCCTTGGATGTGG GCCAGGGTCCTTCAGAGCCTGGCACTCACTCCCCTGGACTTCTGTCCCCCACCTTCC GGCCTGGGGCCCCCTCAGGCCAGACTGTGCCCCCACCTCTGCCCAAGCCACCCCGAT CACCCAGCCGTTCCCCAAGCCACTCCCCGAATCGCTCTCCCTGTGTTCCCCCAGCCC CTGACATGGCCCTCCCAAGGCTTGGCACACAGAGTACAGGGCCTGGCAGGTGCCTG AGCCCCAACCTTCAGGCCCAAGAAGCCCCAGCCCCAGTCACCACCTCCTCTTCTACA TCCACCCTGTCATCCTCCCCTTGGTCAGCTCAGCCTACCTGGAAGAGCGACCCCGGC TTCCGGATCACTGTGGTCACATGGAACGTGGGCACTGCCATGCCCCCAGACGATGTC ACATCCCTCCTCCACCTGGGCGGTGGTGACGACAGCGACGGCGCAGACATGATCGC CATAGGGTTGCAGGAAGTGAACTCCATGCTCAACAAGCGACTCAAGGACGCCCTCT TCACGGACCAGTGGAGTGAGCTGTTCATGGATGCGCTAGGGCCCTTCAACTTCGTGC TGGTGAGTTCGGTGAGGATGCAGGGTGTCATCCTGCTGCTGTTCGCCAAGTACTACC ACCTGCCCTTCCTGCGAGACGTGCAGACCGACTGCACGCGCACTGGCCTGGGCGGCT ACTGGGGTAACAAGGGTGGCGTGAGCGTGCGCCTGGCGGCCTTCGGGCACATGCTC TGCTTCCTGAACTGCCACTTGCCTGCGCATATGGACAAGGCGGAGCAGCGCAAAGA CAACTTCCAGACCATCCTCAGCCTCCAGCAGTTCCAAGGGCCGGGCGCACAGGGCA TCCTGGATCATGACCTCGTGTTCTGGTTCGGGGACCTGAACTTCCGCATTGAGAGCT ATGACCTGCACTTTGTCAAGTTTGCCATCGACAGTGACCAGCTCCATCAGCTCTGGG AGAAGGACCAGCTCAACATGGCCAAGAACACCTGGCCCATTCTGAAGGGCTTTCAG GAGGGGCCCCTCAACTTCGCTCCCACCTTCAAGTTTGATGTGGGTACCAACAAATAC GATACCAGTGCCAAGAAACGGAAGCCAGCTTGGACAGACCGTATCCTATGGAAGGT CAAGGCTCCAGGTGGGGGTCCCAGCCCCTCAGGACGGAAGAGCCACCGACTCCAGG TGACGCAGCACAGCTACCGCAGCCACATGGAATACACAGTCAGCGACCACAAGCCT GTGGCTGCCCAGTTCCTCCTGCAGTTTGCCTTCAGGGACGACATGCCACTGGTGCGG CTGGAGGTGGCAGATGAGTGGGTGCGGCCCGAGCAGGCGGTGGTGAGGTACCGCAT GGAAACAGTGTTCGCCCGCAGCTCCTGGGACTGGATCGGCTTATACCGGGTGGGTTT CCGCCATTGCAAGGACTATGTGGCTTATGTCTGGGCCAAACATGAAGATGTGGATGG GAATACCTACCAGGTAACATTCAGTGAGGAATCACTGCCCAAGGGCCATGGAGACT TCATCCTGGGCTACTATAGTCACAACCACAGCATCCTCATCGGCATCACTGAACCCT TCCAGATCTCGCTGCCTTCCTCGGAGTTGGCCAGCAGCAGCACAGACAGCTCAGGCA CCAGCTCAGAGGGAGAGGATGACAGCACACTGGAGCTCCTTGCACCCAAGTCCCGC AGCCCCAGTCCTGGCAAGTCCAAGCGACACCGCAGCCGCAGCCCGGGACTGGCCAG GTTCCCTGGGCTTGCCCTACGGCCCTCATCCCGTGAACGCCGTGGTGCCAGCCGTAG CCCCTCACCCCAGAGCCGCCGCCTGTCCCGAGTGGCTCCTGACAGGAGCAGTAATG GCAGCAGCCGGGGCAGTAGTGAAGAGGGGCCCTCTGGGTTGCCTGGCCCCTGGGCC TTCCCACCAGCTGTGCCTCGAAGCCTGGGCCTGTTGCCCGCCTTGCGCCTAGAGACT GTAGACCCTGGTGGTGGTGGCTCCTGGGGACCTGATCGGGAGGCCCTGGCGCCCAA CAGCCTGTCTCCTAGTCCCCAGGGCCATCGGGGGCTGGAGGAAGGGGGCCTGGGGC CCTGAGGGTGGGGTAGGCAGATGGGCCAAGGTGACCACCATTCTGCCTCAATCTTTT GCAAGCCCACCTGCCTCTCTCCTGCTGCTCCTCCAGCTGTATCTGCACCTGCCTCTCT GTCCTGGCCAGGGGTGGACAACTGGGGTCCCCCAAAACTCAGTCCTGGCACCTCAA CTGTGACAATCAGCAAAGCCCCACCCAGGCCCCCATCTGGGATGATGGGAGAGCTC TGGCAGATGTCCCAATCCTGGAGGTCATCCATTAGGAATTAAATTCTCCAGCCTCAA AAAAAAAAAAAAAAA OAZ1 (SEQ ID NO: 24; NM_004152.2). TTTTGCGAACGGCGAGCAGCGGCGGCGGCGCGGAGAGACGCAGCGGAGGTTTTCCT GGTTTCGGACCCCAGCGGCCGGATGGTGAAATCCTCCCTGCAGCGGATCCTCAATAG CCACTGCTTCGCCAGAGAGAAGGAAGGGGATAAACCCAGCGCCACCATCCACGCCA GCCGCACCATGCCGCTCCTAAGCCTGCACAGCCGCGGCGGCAGCAGCAGTGAGAGT TCCAGGGTCTCCCTCCACTGCTGTAGTAACCCGGGTCCGGGGCCTCGGTGGTGCTCC TGATGCCCCTCACCCACCCCTGAAGATCCCAGGTGGGCGAGGGAATAGTCAGAGGG ATCACAATCTTTCAGCTAACTTATTCTACTCCGATGATCGGCTGAATGTAACAGAGG AACTAACGTCCAACGACAAGACGAGGATTCTCAACGTCCAGTCCAGGCTCACAGAC GCCAAACGCATTAACTGGCGAACAGTGCTGAGTGGCGGCAGCCTCTACATCGAGAT CCCGGGCGGCGCGCTGCCCGAGGGGAGCAAGGACAGCTTTGCAGTTCTCCTGGAGT TCGCTGAGGAGCAGCTGCGAGCCGACCATGTCTTCATTTGCTTCCACAAGAACCGCG AGGACAGAGCCGCCTTGCTCCGAACCTTCAGCTTTTTGGGCTTTGAGATTGTGAGAC CGGGGCATCCCCTTGTCCCCAAGAGACCCGACGCTTGCTTCATGGCCTACACGTTCG AGAGAGAGTCTTCGGGAGAGGAGGAGGAGTAGGGCCGCCTCGGGGCTGGGCATCC GGCCCCTGGGGCCACCCCTTGTCAGCCGGGTGGGTAGGAACCGTAGACTCGCTCATC TCGCCTGGGTTTGTCCGCATGTTGTAATCGTGCAAATAAACGCTCACTCCGAATTAG CGGTGTATTTCTTGAAGTTTAATATTGTGTTTGTGATACTGAAGTATTTGCTTTAATT CTAAATAAAAATTTATATTTTACTTTTTTATTGCTGGTTTAAGATGATTCAGATTATC CTTGTACTTTGAGGAGAAGTTTCTTATTTGGAGTCTTTTGGAAACAGTCTTAGTCTTT TAACTTGGAAAGATGAGGTATTAATCCCCTCCATTGCTCTCCAAAAGCCAATAAAGT GATTACACCCGA PNOC (SEQ ID NO: 25; NM_006228). GCCAGGAAGGCTTGCAGGTTCTGCTGTTTGGTTGCTGAAGGGGGTCAGTGTGTGTAT GTGTCATGGAGGTGGGCAGGGAAGGGGAGGGCTGTGCGTGGGGGAGAGGATATAT ATGCTGGTGTGGCTGAGAAAGCGGAACCGAGCCTCGCATCCATCGGAGGGAGCCGG GGACTGACAGCTCTCAGCACCTGCTTCCTGCTCCTGCACCATGAAAGTCCTGCTTTG TGACCTGCTGCTGCTCAGTCTCTTCTCCAGTGTGTTCAGCAGTTGTCAGAGGGACTGT CTCACATGCCAGGAGAAGCTCCACCCAGCCCTGGACAGCTTCGACCTGGAGGTGTG CATCCTCGAGTGTGAAGAGAAGGTCTTCCCCAGCCCCCTCTGGACTCCATGCACCAA GGTCATGGCCAGGAGCTCTTGGCAGCTCAGCCCTGCCGCCCCAGAGCATGTGGCGG CTGCTCTCTACCAGCCGAGAGCTTCGGAGATGCAGCATCTGCGGCGAATGCCCCGA GTCCGGAGCTTGTTCCAGGAGCAGGAAGAGCCCGAGCCTGGCATGGAGGAGGCTGG TGAGATGGAGCAGAAGCAGCTGCAGAAGAGATTTGGGGGCTTCACCGGGGCCCGGA AGTCGGCCAGGAAGTTGGCCAATCAGAAGCGGTTCAGTGAGTTTATGAGGCAATAC TTGGTCCTGAGCATGCAGTCCAGCCAGCGCCGGCGCACCCTGCACCAGAATGGTAA TGTGTAGCCGGAAGGGGCGCTCCTCCCAGCTGTACCGGCCACTGCAACCCATGAGC GTCCAGGTGATCCCCCAAACAGCATGTGCTCAGCCCCAGACCTGCCGCCTGGGAATC AGGATTCCTTCTTCCCCAAGGCACTGAGCGCCTGCAGATCCCGCAGGCTTCGTTTGC CTCCAGAACCTTCCCGTCTGATTGTTCCTCCCCAGCCCCCTGGCATGTTTCACCACAA CCCTGTTGCTACATCAGAGTGTATTTTTGTAATTCCTCTAGCTACCATTTCAATAGCC CCATCTCTCCTGCTCACCCGCCTCTTGCCCCTTCTAGGGGCAGGTGAAAGGAATAGG AAATTGAACCTGGGGTTTTGACTTGCCACTGCCATAACTTGTTTGTAAAAGAGCTGT TCTTTTTGACTGATTGTTTTAAACAACGATTTCTCCATTAAACTTCTACTGAGCAAAT GGTTAATAAAAAAAAAAAAAAAAAA PDE4B (SEQ ID NO: 26; NM_002600). AGAGCGCTGCGGCCGCGGCGGTGCAGCAGAGGCGCCTCGGGCAGGAGGAGGGCGG CTTCTGCGAGGGCAGCCTGAGGTATTAAAAAGTGTCAGCAAACTGCATTGAATAAC AGACATCCTAAGAGGGGATATTTTCCACCTCTATAATGAAGAAAAGCAGGAGTGTG ATGACGGTGATGGCTGATGATAATGTTAAAGATTATTTTGAATGTAGCTTGAGTAAA TCCTACAGTTCTTCCAGTAACACACTTGGGATCGACCTCTGGAGAGGGAGAAGGTGT TGCTCAGGAAACTTACAGTTACCACCACTGTCTCAAAGACAGAGTGAAAGGGCAAG GACTCCTGAGGGAGATGGTATTTCCAGGCCGACCACACTGCCTTTGACAACGCTTCC AAGCATTGCTATTACAACTGTAAGCCAGGAGTGCTTTGATGTGGAAAATGGCCCTTC CCCAGGTCGGAGTCCACTGGATCCCCAGGCCAGCTCTTCCGCTGGGCTGGTACTTCA CGCCACCTTTCCTGGGCACAGCCAGCGCAGAGAGTCATTTCTCTACAGATCAGACAG CGACTATGACTTGTCACCAAAGGCGATGTCGAGAAACTCTTCTCTTCCAAGCGAGCA ACACGGCGATGACTTGATTGTAACTCCTTTTGCCCAGGTCCTTGCCAGCTTGCGAAG TGTGAGAAACAACTTCACTATACTGACAAACCTTCATGGTACATCTAACAAGAGGTC CCCAGCTGCTAGTCAGCCTCCTGTCTCCAGAGTCAACCCACAAGAAGAATCTTATCA AAAATTAGCAATGGAAACGCTGGAGGAATTAGACTGGTGTTTAGACCAGCTAGAGA CCATACAGACCTACCGGTCTGTCAGTGAGATGGCTTCTAACAAGTTCAAAAGAATGC TGAACCGGGAGCTGACACACCTCTCAGAGATGAGCCGATCAGGGAACCAGGTGTCT GAATACATTTCAAATACTTTCTTAGACAAGCAGAATGATGTGGAGATCCCATCTCCT ACCCAGAAAGACAGGGAGAAAAAGAAAAAGCAGCAGCTCATGACCCAGATAAGTG GAGTGAAGAAATTAATGCATAGTTCAAGCCTAAACAATACAAGCATCTCACGCTTTG GAGTCAACACTGAAAATGAAGATCACCTGGCCAAGGAGCTGGAAGACCTGAACAAA TGGGGTCTTAACATCTTTAATGTGGCTGGATATTCTCACAATAGACCCCTAACATGC ATCATGTATGCTATATTCCAGGAAAGAGACCTCCTAAAGACATTCAGAATCTCATCT GACACATTTATAACCTACATGATGACTTTAGAAGACCATTACCATTCTGACGTGGCA TATCACAACAGCCTGCACGCTGCTGATGTAGCCCAGTCGACCCATGTTCTCCTTTCT ACACCAGCATTAGACGCTGTCTTCACAGATTTGGAGATCCTGGCTGCCATTTTTGCA GCTGCCATCCATGACGTTGATCATCCTGGAGTCTCCAATCAGTTTCTCATCAACACA AATTCAGAACTTGCTTTGATGTATAATGATGAATCTGTGTTGGAAAATCATCACCTT GCTGTGGGTTTCAAACTGCTGCAAGAAGAACACTGTGACATCTTCATGAATCTCACC AAGAAGCAGCGTCAGACACTCAGGAAGATGGTTATTGACATGGTGTTAGCAACTGA TATGTCTAAACATATGAGCCTGCTGGCAGACCTGAAGACAATGGTAGAAACGAAGA AAGTTACAAGTTCAGGCGTTCTTCTCCTAGACAACTATACCGATCGCATTCAGGTCC TTCGCAACATGGTACACTGTGCAGACCTGAGCAACCCCACCAAGTCCTTGGAATTGT ATCGGCAATGGACAGACCGCATCATGGAGGAATTTTTCCAGCAGGGAGACAAAGAG CGGGAGAGGGGAATGGAAATTAGCCCAATGTGTGATAAACACACAGCTTCTGTGGA AAAATCCCAGGTTGGTTTCATCGACTACATTGTCCATCCATTGTGGGAGACATGGGC AGATTTGGTACAGCCTGATGCTCAGGACATTCTCGATACCTTAGAAGATAACAGGAA CTGGTATCAGAGCATGATACCTCAAAGTCCCTCACCACCACTGGACGAGCAGAACA GGGACTGCCAGGGTCTGATGGAGAAGTTTCAGTTTGAACTGACTCTCGATGAGGAA GATTCTGAAGGACCTGAGAAGGAGGGAGAGGGACACAGCTATTTCAGCAGCACAAA GACGCTTTGTGTGATTGATCCAGAAAACAGAGATTCCCTGGGAGAGACTGACATAG ACATTGCAACAGAAGACAAGTCCCCCGTGGATACATAATCCCCCTCTCCCTGTGGAG ATGAACATTCTATCCTTGATGAGCATGCCAGCTATGTGGTAGGGCCAGCCCACCATG GGGGCCAAGACCTGCACAGGACAAGGGCCACCTGGCCTTTCAGTTACTTGAGTTTGG AGTCAGAAAGCAAGACCAGGAAGCAAATAGCAGCTCAGGAAATCCCACGGTTGACT TGCCTTGATGGCAAGCTTGGTGGAGAGGGCTGAAGCTGTTGCTGGGGGCCGATTCTG ATCAAGACACATGGCTTGAAAATGGAAGACACAAAACTGAGAGATCATTCTGCACT AAGTTTCGGGAACTTATCCCCGACAGTGACTGAACTCACTGACTAATAACTTCATTT ATGAATCTTCTCACTTGTCCCTTTGTCTGCCAACCTGTGTGCCTTTTTTGTAAAACATT TTCATGTCTTTAAAATGCCTGTTGAATACCTGGAGTTTAGTATCAACTTCTACACAGA TAAGCTTTCAAAGTTGACAAACTTTTTTGACTCTTTCTGGAAAAGGGAAAGAAAATA GTCTTCCTTCTTTCTTGGGCAATATCCTTCACTTTACTACAGTTACTTTTGCAAACAG ACAGAAAGGATACACTTCTAACCACATTTTACTTCCTTCCCCTGTTGTCCAGTCCAAC TCCACAGTCACTCTTAAAACTTCTCTCTGTTTGCCTGCCTCCAACAGTACTTTTAACT TTTTGCTGTAAACAGAATAAAATTGAACAAATTAGGGGGTAGAAAGGAGCAGTGGT GTCGTTCACCGTGAGAGTCTGCATAGAACTCAGCAGTGTGCCCTGCTGTGTCTTGGA CCCTGCCCCCCACAGGAGTTGTACAGTCCCTGGCCCTGTTCCCTACCTCCTCTCTTCA CCCCGTTAGGCTGTTTTCAATGTAATGCTGCCGTCCTTCTCTTGCACTGCCTTCTGCG CTAACACCTCCATTCCTGTTTATAACCGTGTATTTATTACTTAATGTATATAATGTAA TGTTTTGTAAGTTATTAATTTATATATCTAACATTGCCTGCCAATGGTGGTGTTAAAT TTGTGTAGAAAACTCTGCCTAAGAGTTACGACTTTTTCTTGTAATGTTTTGTATTGTG TATTATATAACCCAAACGTCACTTAGTAGAGACATATGGCCCCCTTGGCAGAGAGGA CAGGGGTGGGCTTTTGTTCAAAGGGTCTGCCCTTTCCCTGCCTGAGTTGCTACTTCTG CACAACCCCTTTATGAACCAGTTTTGGAAACAATATTCTCACATTAGATACTAAATG GTTTATACTGAGCTTTTACTTTTGTATAGCTTGATAGGGGCAGGGGGCAATGGGATG TAGTTTTTACCCAGGTTCTATCCAAATCTATGTGGGCATGAGTTGGGTTATAACTGG ATCCTACTATCATTGTGGCTTTGGTTCAAAAGGAAACACTACATTTGCTCACAGATG ATTCTTCTGAATGCTCCCGAACTACTGACTTTGAAGAGGTAGCCTCCTGCCTGCCATT AAGCAGGAATGTCATGTTCCAGTTCATTACAAAAGAAAACAATAAAACAATGTGAA TTTTTATAATAAAATGTGAACTGATGTAGCAAATTACGCAAATGTGAAGCCTCTTCT GATAACACTTGTTAGGCCTCTTACTGATGTCAGTTTCAGTTTGTAAAATATGTTTCAT GCTTTCAGTTCAGCATTGTGACTCAGTAATTACAGAAAATGGCACAAATGTGCATGA CCAATGTATGTCTATGAACACTGCATTGTTTCAGGTGGACATTTTATCATTTTCAAAT GTTTCTCACAATGTATGTTATAGTATTATTATTATATATTGTGTTCAAATGCATTCTA AAGAGACTTTTATATGAGGTGAATAAAGAAAAGCATGATTAGATTAAAAAAA SCARB1 (SEQ ID NO: 27; NM_005505.4). GCTCAGGCCCCGCCCCTGCCGCCGGAATCCTGAAGCCCAAGGCTGCCCGGGGGCGG TCCGGCGGCGCCGGCGATGGGGCATAAAACCACTGGCCACCTGCCGGGCTGCTCCT GCGTGCGCTGCCGTCCCGGATCCACCGTGCCTCTGCGGCCTGCGTGCCCGGAGTCCC CGCCTGTGTCGTCTCTGTCGCCGTCCCCGTCTCCTGCCAGGCGCGGAGCCCTGCGAG CCGCGGGTGGGCCCCAGGCGCGCAGACATGGGCTGCTCCGCCAAAGCGCGCTGGGC TGCCGGGGCGCTGGGCGTCGCGGGGCTACTGTGCGCTGTGCTGGGCGCTGTCATGAT CGTGATGGTGCCGTCGCTCATCAAGCAGCAGGTCCTTAAGAACGTGCGCATCGACCC CAGTAGCCTGTCCTTCAACATGTGGAAGGAGATCCCTATCCCCTTCTATCTCTCCGTC TACTTCTTTGACGTCATGAACCCCAGCGAGATCCTGAAGGGCGAGAAGCCGCAGGT GCGGGAGCGCGGGCCCTACGTGTACAGGGAGTTCAGGCACAAAAGCAACATCACCT TCAACAACAACGACACCGTGTCCTTCCTCGAGTACCGCACCTTCCAGTTCCAGCCCT CCAAGTCCCACGGCTCGGAGAGCGACTACATCGTCATGCCCAACATCCTGGTCTTGG GTGCGGCGGTGATGATGGAGAATAAGCCCATGACCCTGAAGCTCATCATGACCTTG GCATTCACCACCCTCGGCGAACGTGCCTTCATGAACCGCACTGTGGGTGAGATCATG TGGGGCTACAAGGACCCCCTTGTGAATCTCATCAACAAGTACTTTCCAGGCATGTTC CCCTTCAAGGACAAGTTCGGATTATTTGCTGAGCTCAACAACTCCGACTCTGGGCTC TTCACGGTGTTCACGGGGGTCCAGAACATCAGCAGGATCCACCTCGTGGACAAGTG GAACGGGCTGAGCAAGGTTGACTTCTGGCATTCCGATCAGTGCAACATGATCAATG GAACTTCTGGGCAAATGTGGCCGCCCTTCATGACTCCTGAGTCCTCGCTGGAGTTCT ACAGCCCGGAGGCCTGCCGATCCATGAAGCTAATGTACAAGGAGTCAGGGGTGTTT GAAGGCATCCCCACCTATCGCTTCGTGGCTCCCAAAACCCTGTTTGCCAACGGGTCC ATCTACCCACCCAACGAAGGCTTCTGCCCGTGCCTGGAGTCTGGAATTCAGAACGTC AGCACCTGCAGGTTCAGTGCCCCCTTGTTTCTCTCCCATCCTCACTTCCTCAACGCTG ACCCGGTTCTGGCAGAAGCGGTGACTGGCCTGCACCCTAACCAGGAGGCACACTCC TTGTTCCTGGACATCCACCCGGTCACGGGAATCCCCATGAACTGCTCTGTGAAACTG CAGCTGAGCCTCTACATGAAATCTGTCGCAGGCATTGGACAAACTGGGAAGATTGA GCCTGTGGTCCTGCCGCTGCTCTGGTTTGCAGAGAGCGGGGCCATGGAGGGGGAGA CTCTTCACACATTCTACACTCAGCTGGTGTTGATGCCCAAGGTGATGCACTATGCCC AGTACGTCCTCCTGGCGCTGGGCTGCGTCCTGCTGCTGGTCCCTGTCATCTGCCAAA TCCGGAGCCAAGAGAAATGCTATTTATTTTGGAGTAGTAGTAAAAAGGGCTCAAAG GATAAGGAGGCCATTCAGGCCTATTCTGAATCCCTGATGACATCAGCTCCCAAGGGC TCTGTGCTGCAGGAAGCAAAACTGTAGGGTCCTGAGGACACCGTGAGCCAGCCAGG CCTGGCCGCTGGGCCTGACCGGCCCCCCAGCCCCTACACCCCGCTTCTCCCGGACTC TCCCAGCGGACAGCCCCCCAGCCCCACAGCCTGAGCCTCCCAGCTGCCATGTGCCTG TTGCACACCTGCACACACGCCCTGGCACACATACACACATGCGTGCAGGCTTGTGCA GACACTCAGGGATGGAGCTGCTGCTGAAGGGACTTGTAGGGAGAGGCTCGTCAACA AGCACTGTTCTGGAACCTTCTCTCCACGTGGCCCACAGGCCTGACCACAGGGGCTGT GGGTCCTGCGTCCCCTTCCTCGGGTGAGCCTGGCCTGTCCCGTTCAGCCGTTGGGCC CAGGCTTCCTCCCCTCCAAGGTGAAACACTGCAGTCCCGGTGTGGTGGCTCCCCATG CAGGACGGGCCAGGCTGGGAGTGCCGCCTTCCTGTGCCAAATTCAGTGGGGACTCA GTGCCCAGGCCCTGGCCACGAGCTTTGGCCTTGGTCTACCTGCCAGGCCAGGCAAAG CGCCTTTACACAGGCCTCGGAAAACAATGGAGTGAGCACAAGATGCCCTGTGCAGC TGCCCGAGGGTCTCCGCCCACCCCGGCCGGACTTTGATCCCCCCGAAGTCTTCACAG GCACTGCATCGGGTTGTCTGGCGCCCTTTTCCTCCAGCCTAAACTGACATCATCCTAT GGACTGAGCCGGCCACTCTCTGGCCGAAGTGGCCGCAGGCTGTGCCCCCGAGCTGC CCCCACCCCCTCACAGGGTCCCTCAGATTATAGGTGCCCAGGCTGAGGTGAAGAGG CCTGGGGGCCCTGCCTTCCGGGCGCTCCTGGACCCTGGGGCAAACCTGTGACCCTTT TCTACTGGAATAGAAATGAGTTTTATCATCTTTGAAAAATAATTCACTCTTGAAGTA ATAAACGTTTAAAAAAATGGGAAAAAAAAAAAAAAAAAA TMEM9B (SEQ ID NO: 28; NM_020644.2). GTGCGCGAACGGCTCCGGCCCGCACGGGTCGCCAGAGGCGACTGTGTGACACTCGG AGTTTGCTGGGGTCTCCGTGGGCGGGAGGACTTTCCAGCGCAATGGCGACTCCCTAA GCCCCGCAGCTTCTGCGCCCGGGAAAGATATCCAAGAGATGCAAAGCTCTACTGGG CCCAGGCTGCCACCCCAGAGGCCCCCTTCCGTCCCGGGGCCGGGGCTAGGCCAAGG CGGGCACCAGGACTGCCCAGCCTCCCGGCCCTTCGCACTGGTAACCGGTTCCGGGGC GGATGCTTTTTGCATCTGACCCGGCGCGCCCGGTGACGCCTTCGCGTCCAGACGGAA GTGCGGGCGGAGGATCCCCAGCCGGGTCCCAAGCCTGTGCCTGAGCCTGAGCCTGA GCCTGAGCCCGAGCCGGGAGCCGGTCGCGGGGGCTCCGGGCTGTGGGACCGCTGGG CCCCCAGCGATGGCGACCCTGTGGGGAGGCCTTCTTCGGCTTGGCTCCTTGCTCAGC CTGTCGTGCCTGGCGCTTTCCGTGCTGCTGCTGGCGCAGCTGTCAGACGCCGCCAAG AATTTCGAGGATGTCAGATGTAAATGTATCTGCCCTCCCTATAAAGAAAATTCTGGG CATATTTATAATAAGAACATATCTCAGAAAGATTGTGATTGCCTTCATGTTGTGGAG CCCATGCCTGTGCGGGGGCCTGATGTAGAAGCATACTGTCTACGCTGTGAATGCAAA TATGAAGAAAGAAGCTCTGTCACAATCAAGGTTACCATTATAATTTATCTCTCCATT TTGGGCCTTCTACTTCTGTACATGGTATATCTTACTCTGGTTGAGCCCATACTGAAGA GGCGCCTCTTTGGACATGCACAGTTGATACAGAGTGATGATGATATTGGGGATCACC AGCCTTTTGCAAATGCACACGATGTGCTAGCCCGCTCCCGCAGTCGAGCCAACGTGC TGAACAAGGTAGAATATGCACAGCAGCGCTGGAAGCTTCAAGTCCAAGAGCAGCGA AAGTCTGTCTTTGACCGGCATGTTGTCCTCAGCTAATTGGGAATTGAATTCAAGGTG ACTAGAAAGAAACAGGCAGACAACTGGAAAGAACTGACTGGGTTTTGCTGGGTTTC ATTTTAATACCTTGTTGATTTCACCAACTGTTGCTGGAAGATTCAAAACTGGAAGCA AAAACTTGCTTGATTTTTTTTTCTTGTTAACGTAATAATAGAGACATTTTTAAAAGCA CACAGCTCAAAGTCAGCCAATAAGTCTTTTCCTATTTGTGACTTTTACTAATAAAAAT AAATCTGCCTGTAAATTATCTTGAAGTCCTTTACCTGGAACAAGCACTCTCTTTTTCA CCACATAGTTTTAACTTGACTTTCAAGATAATTTTCAGGGTTTTTGTTGTTGTTGTTTT TTGTTTGTTTGTTTTGGTGGGAGAGGGGAGGGATGCCTGGGAAGTGGTTAACAACTT TTTTCAAGTCACTTTACTAAACAAACTTTTGTAAATAGACCTTACCTTCTATTTTCGA GTTTCATTTATATTTTGCAGTGTAGCCAGCCTCATCAAAGAGCTGACTTACTCATTTG ACTTTTGCACTGACTGTATTATCTGGGTATCTGCTGTGTCTGCACTTCATGGTAAACG GGATCTAAAATGCCTGGTGGCTTTTCACAAAAAGCAGATTTTCTTCATGTACTGTGA TGTCTGATGCAATGCATCCTAGAACAAACTGGCCATTTGCTAGTTTACTCTAAAGAC TAAACATAGTCTTGGTGTGTGTGGTCTTACTCATCTTCTAGTACCTTTAAGGACAAAT CCTAAGGACTTGGACACTTGCAATAAAGAAATTTTATTTTAAACCCAAGCCTCCCTG GATTGATAATATATACACATTTGTCAGCATTTCCGGTCGTGGTGAGAGGCAGCTGTT TGAGCTCCAATGTGTGCAGCTTTGAACTAGGGCTGGGGTTGTGGGTGCCTCTTCTGA AAGGTCTAACCATTATTGGATAACTGGCTTTTTTCTTCCTATGTCCTCTTTGGAATGT AACAATAAAAATAATTTTTGAAACATCCATCAGTGTATCTATCTATGTCTCCTAGTTT TTTCCTCCTCCCTCTTTTGCTGTATAATGAGATTGAAGATATAAAGACATTTTGTACC CTGTAAAAAAAA PPP6R3 (SEQ ID NO: 29; XM_005274081). AACTCAAGGCCTGCTTGATACGTCCGCCATTTTGGGCGCTTCGCTGATGGTGTCGGT GAGCGCGTTTCCCGCCTGAGCGCAACTAGCGGCGGGTCGTGGGCACCTCCAGGAGA GCTTGTTTCATATCCATATCCCACTGTATTCCTGCTAATCTGCTAATGCAGTAAATTG GAGGAAAACTGTTACCAGGATAACCTGTAATGGGCAAGGAGCCACAAAGAAGAAA ACATTTCTTTTAATTTTTAAACTTGGTTTGAAAGACCAGCATGTTTTGGAAATTTGAT CTTCACTCATCATCCCACATAGACACACTTCTAGAAAGAGAAGATGTAACACTGAAG GAGTTAATGGATGAGGAAGATGTTTTACAGGAATGTAAAGCTCAGAACCGCAAACT TATAGAGTTTCTGTTAAAAGCAGAATGTCTCGAAGATTTAGTCTCATTCATTATAGA AGAACCACCTCAAGACATGGATGAAAAGATCAGATACAAGTATCCAAATATATCTT GTGAGTTGCTCACTTCTGATGTCTCCCAGATGAATGATAGACTGGGAGAAGATGAAT CCTTGCTAATGAAATTATATAGCTTCCTCCTAAACGATTCCCCTTTGAATCCACTACT TGCCAGTTTCTTCAGCAAGGTGCTAAGTATTCTTATCAGCAGAAAACCAGAACAGAT TGTGGATTTCTTAAAGAAGAAGCATGATTTTGTAGACCTTATTATAAAGCACATAGG AACTTCTGCTATCATGGATTTGTTGCTCAGGCTCCTGACGTGTATCGAACCTCCACAG CCCAGGCAAGATGTGCTGAATTGGTTAAATGAGGAGAAAATTATCCAGAGGCTTGT GGAAATAGTTCATCCATCGCAAGAAGAAGATCGACATTCAAATGCATCACAATCAC TTTGTGAAATTGTTCGCCTGAGCAGAGACCAGATGTTACAAATTCAGAACAGTACAG AGCCCGACCCCCTGCTTGCCACTCTAGAAAAGCAAGAAATTATAGAGCAGCTTCTAT CAAATATTTTCCACAAGGAGAAAAATGAGTCAGCCATAGTCAGTGCAATCCAGATA TTGCTGACTTTACTTGAGACACGACGACCAACATTTGAAGGCCATATAGAGATCTGC CCACCAGGCATGAGCCATTCAGCTTGTTCAGTAAACAAGAGTGTTCTAGAAGCCATC AGAGGAAGACTTGGATCTTTTCATGAACTCCTGCTGGAGCCACCCAAGAAAAGTGT GATGAAGACCACATGGGGTGTGCTGGATCCTCCTGTGGGGAATACCCGGTTGAATGT CATTAGGTTGATATCCAGCCTGCTTCAAACCAATACCAGCAGTATAAATGGGGACCT TATGGAGCTGAATAGCATTGGAGTCATATTGAACATGTTCTTCAAGTATACATGGAA TAACTTTTTGCATACACAAGTGGAAATTTGTATTGCACTGATTCTTGCAAGTCCTTTT GAAAACACAGAAAATGCCACAATTACCGATCAAGACTCCACTGGTGATAATTTGTT ATTAAAACATCTTTTCCAAAAATGTCAATTAATAGAACGAATACTTGAAGCCTGGGA AATGAATGAGAAGAAACAGGCTGAGGGAGGAAGACGGCATGGTTACATGGGACAC CTAACGAGGATAGCTAACTGTATCGTGCACAGCACTGACAAGGGCCCCAACAGTGC ATTAGTGCAGCAGCTTATCAAAGATCTTCCCGACGAAGTCAGGGAACGATGGGAGA CGTTCTGCACAAGCTCCTTAGGAGAAACTAACAAGAGGAACACGGTAGATCTAGTT ACAACCTGCCATATTCATTCATCCAGTGATGATGAAATTGACTTTAAAGAAACGGGT TTCTCACAGGATTCTTCTTTGCAGCAAGCCTTTTCTGATTATCAGATGCAACAAATGA CGTCCAATTTTATTGACCAGTTTGGCTTCAACGATGAGAAGTTTGCAGATCAAGATG ACATTGGCAATGTTTCTTTTGATCGAGTATCAGACATCAACTTTACTCTCAATACAAA TGAAAGTGGAAATATTGCCTTGTTTGAAGCATGTTGTAAGGAAAGAATACAACAGTT TGATGATGGTGGCTCTGATGAGGAAGATATATGGGAGGAAAAGCACATCGCATTCA CACCAGAATCCCAAAGACGATCCAGCTCGGGGAGTACAGACAGTGAGGAAAGTAC AGACTCTGAAGAAGAAGATGGAGCAAAGCAAGACTTGTTTGAACCCAGCAGTGCCA ACACGGAGGATAAAATGGAGGTGGACCTGAGTGAACCACCCAACTGGTCAGCTAAC TTTGATGTCCCAATGGAAACAACCCACGGTGCTCCATTGGATTCTGTGGGATCTGAT GTCTGGAGCACAGAGGAGCCGATGCCAACTAAAGAGACGGGCTGGGCTTCTTTTTC AGAGTTCACGTCTTCCCTGAGCACAAAAGATTCTTTAAGGAGTAATTCTCCAGTGGA AATGGAAACCAGCACTGAACCCATGGACCCTCTGACTCCCAGTGCGGCTGCCCTGG CAGTGCAGCCAGAAGCGGCAGGCAGTGTGGCCATGGAAGCCAGCTCTGACGGAGA GGAGGATGCAGAAAGTACAGACAAGGTAACTGAGACAGTGATGAATGGCGGCATG AAGGAAACGCTCAGCCTCACTGTAGATGCCAAGACAGAGACTGCGGTCTTCAAAAG TGAGGAAGGGAAACTGTCTACCTCTCAAGATGCTGCTTGTAAAGACGCAGAGGAGT GTCCCGAGACTGCAGAGGCGAAGTGCGCGGCGCCCAGGCCTCCCAGCAGCAGTCCC GAGCAGAGTGCCTCCGATGCCTGTCTGTTGCTCCTTAGGACTGGCCAACCAAGCGCA CCAGGTGACACTTCAGTGAATGGCCCTGTATGACGGGTGACGTCTGCTGCTGCTGAC TGAGGACTGCAGACCGCCACCACTCAGGGGCTCTGGAGGGGTCAGCTGGAGCCCAC CAAGCTGTCACTGCTGCACTCACTCTGCAAGGGATCAGGACCAGCAACCTTTATATT CTAGATTCTAAGACATTGTACAGAGAAATTCAGAAGTGTAAAAATATTGCACATTGA CAAATACCAAGAATTTTTGCGTATGTTTATATTGTATTGTTCTAAATAATGGGTAGCC TGTGAAATAAGATCTTGCCACCCATGTAATAATAGTAGTAATACTATAGTTAAAATG GCTGTAAGAATAGTTTTATAAAAGTGAATACACAGATCTATTGTATTTGAAACATAA CTTTGACAATTATTAGTGTGACCAAAGTATTAGGCGGTTTTCATACATTTTTCACCTT GTACAAAATTATGAATTCATTTTTCCTCCAGGCCGACAAGGAGTTGTAGAATGAAAA TGCCCTCTAAGTGTTATTTTGGTTGTTCTAACTTACAAAAGTGATTTTGAATAAGAAA TATTTGGTGTTCTTTTTATAACCAGTTTTTGATTGGTAATTGTTTTCTGTATTGTTTAA AACGGATCAAAAATGTAAGTCTATTGGTAGAGATTAAGTAAAGTATTTATTGCTACA TCATAGTTGATAAATTGATGTTATCGTAAAGCCATATGTTCTGTTCAAGTCTTGTTTG CTTGAAATGATTATTCCTACAAGTGAAACACTAGACTATTTGGAGTGTATATGGCTT GTGTTTTGGGATTTTTTTTTTTTTTTTTTGGCTTTTGTTTTTGTTTGTTTTTTTGTTTCAT TTGGTAGTTCATCTGCCTTTTAACCCATTCACCAAAATTTACCTTGTTAACAAGCATC ACCAATGAACATTTCAGAGCAATCTGCATATTTAACAGACCTAAAATAAATCCTATT AGGCAAGTCAGTTGAAAATGCTCGTGCTGCTAATGGAATTAGAGTGCGTTCATTTTA CAGGCTAGTATTTTAAAAGTAGAAATCAAAATCTGGCACCGAAGCATGCTAATTGTT TACTGTACCTTGTGAGGTTTTCACTCATAAATTTAAACCAGTGTATTTTTTTAGAACT GGTTTGTGTATATATATAGTGATTATGGATACTAATTCAATGTAATTTATAATTTTCT ATGTCAATACAAAAATACATCACAGCCTTCTCAAACAGCTCAAGCAATATATTGTAT ATTGCCATATCGTCTGGTGAAAGGGTTAAATTACTTCACCTCTTGCACTTTTAGATGC AAATCAGTTTTTCATTTCTGTAATAGAAAATTATTCACGTATTTTTACATCATTTGTTT TTCCTGACCAGTATTTAAAACCAAAAGGATATTCTGAAAAATGGCCAACAATTTTTT TAGAAGTAGCATCCCAAGCAGCGTGCCTAAACATTACATTGCATATGGAAATAAAA GAATCAAACGTCTAATGCCTTATTATTTCTGATTTCCTTTTTCATTTTAAGTGGTGTG GAGATTCCAGCACTCCCAGGACAGTGGAGTCAGCAGTAAGCCCTGGGACAGGTGGC AAGGGTGGGTCCCTTGACCTTTGCACGCCTCCTCAGGAACCCCCTTTCCCGGGTGAG CCCCTCTCTGAAGAGACTGTCCTTGGGCCTCCTCTGGAAGCAGCACCCCCAGAGGAC AGGGCTCCTCCTGCTTGCCTCAGGGCTGCCTGACTTGAATGGCGTTGGACCTCGGGG ATTACTGGTAGATAATATGCTCTGGTCTCGCCTGGTGGTGAGTTTTGCCAGCCATGG CCAGGGTTTGGCTCCACTGGTGGCACACGTGGCCTCCGTGGTATGGACCTGGTGGCT TCTCCATCCCACTGTGGCCTCTGTGGTATGGACCTGGTGGCTTCTCCATCCTACCCAA GGTAACAGTGTCTTGCTTCATCCCACTGACTGCTGGGAGAGAGCCTCTGGGACTTTT CTTTGGGGCATCATTTTGTTTTGTCTTTCGTAGCAGGGAAAGGATATGACAATGGGG AGGACAGTTCTTTTGGAGGTTGGAGGGGCCAAGCCAAGGACAGGAGCAAGTGTGCC CTCATTTTGTTTCTACTTTTAATTTCTGTGTGTTGGCCATACTGAATTATGAGACTAA CAGATGTCTACAATACAATACCTGTATTCAAAATAACAAAAATAAAGCCTGATTCTT TGTTTCTAGAAA 

1. A radiation biodosimetry assay system, comprising a plurality of in vitro nucleic acid amplification reaction mixtures, each amplification reaction mixture comprising: (a) a probe of at least 10 nucleotides directed to at least one of SEQ ID NOs: 1-39, or the complementary sequences thereof, labeled with a fluorescent dye and a quencher; and (b) one or more primer pairs, each primer pair comprising primers of at least 10 nucleotides directed to at least one of SEQ ID NOs: 1-39, or a complementary sequence thereof.
 2. The radiation biodosimetry assay system of claim 1, wherein the system comprises primers of at least 10 nucleotides and probes of at least 10 nucleotides directed to at least two of SEQ ID NOs: 1-39.
 3. The radiation biodosimetry assay system of claim 2, wherein the system comprises primers of at least 10 nucleotides and probes of at least 10 nucleotides directed to at least three of SEQ ID NOs: 1-39.
 4. The radiation biodosimetry assay system of claim 1, wherein the radiation biodosimetry assay system additionally comprises mRNA, or cDNA derived therefrom, from a subject exposed to ionizing radiation before the mRNA was obtained.
 5. The radiation biodosimetry assay system of claim 1, wherein the in vitro nucleic acid amplification reaction mixtures are provided in a multi-well plate.
 6. The radiation biodosimetry assay system of claim 5, wherein at least two nucleic acid probes directed to at least two different nucleic acid targets are in the same wells of the multi-well plate.
 7. A radiation biomarker assay kit, comprising a nucleic acid probe set comprising a plurality of nucleic acid probes of at least 10 nucleotides each that are directed to at least three of SEQ ID NOs: 1-39 or the complementary sequences thereof, the nucleic acid probe set further comprising a probe detectably labeled with a fluorescent dye and a quencher and configured for PCR amplification, a set of primer pairs comprising a plurality of primer pairs each comprising primers of at least 10 nucleotides that are directed to at least three of SEQ ID NOs: 1-39 or the complementary sequences thereof, and instructions for calculating an estimate of absorbed radiation dose from a fluorescence value obtained by contacting in vitro an mRNA sample from a human subject suspected of suffering from radiation exposure or cDNA derived therefrom to the nucleic acid probe set and a thermostable polymerase under PCR conditions.
 8. The radiation biomarker assay kit of claim 7, wherein the nucleic acid probe set comprises probes of at least 10 nucleotides directed to at least four of SEQ ID NOs: 1-39.
 9. The radiation biomarker assay kit of claim 7, wherein the nucleic acid probe set comprises probes of at least 10 nucleotides directed to at least five of SEQ ID NOs: 1-39.
 10. The radiation biomarker assay kit of claim 7, further comprising radiation exposure positive and negative control mRNA samples or cDNAs thereof.
 11. The radiation biomarker assay kit of claim 7, wherein the nucleic acid probes are provided in a multi-well plate.
 12. A method for estimating absorbed dose of ionizing radiation exposure received by a subject, comprising (i) determining the mRNA expression levels of mRNAs comprising at least one of SEQ ID NOs: 1-39 in a stabilized blood sample comprising mRNA from the subject to obtain an expression profile; and (ii) transforming the gene expression profile into an estimate of absorbed radiation dose for the subject based on a mathematical algorithm.
 13. (canceled)
 14. (canceled)
 15. The method of claim 12, wherein transforming in step (ii) comprises calculating an estimate of absorbed radiation dose from a fluorescence value obtained by contacting in vitro an mRNA sample from a human subject suspected of suffering from radiation exposure or cDNA derived therefrom to a nucleic acid probe set and a thermostable polymerase under PCR conditions.
 16. The method of claim 15, wherein the nucleic acid probe set comprises a plurality of nucleic acid probes of at least 10 nucleotides each that are directed to at least three of SEQ ID NOs: 1-39 or the complementary sequences thereof, the nucleic acid probe set further comprising a probe detectably labeled with a fluorescent dye and a quencher and configured for PCR amplification.
 17. The method of claim 15, wherein the mRNA sample from a human subject or cDNA derived therefrom is further contacted to a set of primer pairs comprising a plurality of primer pairs each comprising primers of at least 10 nucleotides that are directed to at least three of SEQ ID NOs: 1-39 or the complementary sequences thereof.
 18. A method for radiation treatment triage of a subject in need thereof comprising: (i) determining the mRNA expression levels of mRNAs comprising at least one of SEQ ID NOs: 1-39 in a stabilized blood sample comprising mRNA from the subject to obtain a gene expression profile; and (ii) providing a suitable treatment for radiation exposure to the subject based on the expression levels of the genes.
 19. (canceled)
 20. (canceled)
 21. The method of claim 18, further comprising transforming the gene expression profile into an estimate of absorbed radiation dose for the subject.
 22. The method of claim 21, wherein transforming comprises calculating an estimate of absorbed radiation dose from a fluorescence value obtained by contacting in vitro an mRNA sample from a human subject suspected of suffering from radiation exposure or cDNA derived therefrom to a nucleic acid probe set and a thermostable polymerase under PCR conditions suitable for amplification of the mRNA or cDNA.
 23. The method of claim 22, wherein the nucleic acid probe set comprises a plurality of nucleic acid probes of at least 10 nucleotides each that are directed to at least three of SEQ ID NOs: 1-39 or the complementary sequences thereof, the nucleic acid probe set further comprising a probe detectably labeled with a fluorescent dye and a quencher and configured for PCR amplification.
 24. The method of claim 22, wherein the mRNA sample from a human subject or cDNA derived therefrom is further contacted to a set of primer pairs comprising a plurality of primer pairs each comprising primers of at least 10 nucleotides that are directed to at least three of SEQ ID NOs: 1-39 or the complementary sequences thereof. 